{
    "paper_id": "99983516d02863474096c63a11a61d6d1abc007b",
    "metadata": {
        "title": "Supplementary webappendix SUPPLEMENTARY APPENDIX: Safety and Immunogenicity of an anti-Middle East Respiratory Syndrome Coronavirus DNA Vaccine: an Open-Label, Dose-Ranging Phase 1 Clinical Trial",
        "authors": [
            {
                "first": "Kayvon",
                "middle": [],
                "last": "Modjarrad",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Christine",
                "middle": [
                    "C"
                ],
                "last": "Roberts",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Kristin",
                "middle": [
                    "T"
                ],
                "last": "Mills",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Amy",
                "middle": [
                    "R"
                ],
                "last": "Castellano",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "L",
                "middle": [
                    "P N"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "C",
                "middle": [
                    "C R C"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Kristopher",
                "middle": [],
                "last": "Paolino",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Kar",
                "middle": [],
                "last": "Muthumani",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Emma",
                "middle": [
                    "L"
                ],
                "last": "Reuschel",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Merlin",
                "middle": [
                    "L"
                ],
                "last": "Robb",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Trina",
                "middle": [],
                "last": "Racine",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Myoung-Don",
                "middle": [],
                "last": "Oh",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Claude",
                "middle": [],
                "last": "Lamarre",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "I",
                "middle": [],
                "last": "Zaidi",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Jean",
                "middle": [],
                "last": "Boyer",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Sagar",
                "middle": [
                    "B"
                ],
                "last": "Kudchodkar",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Moonsup",
                "middle": [],
                "last": "Jeong",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Janice",
                "middle": [
                    "M"
                ],
                "last": "Darden",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Young",
                "middle": [
                    "K"
                ],
                "last": "Park",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "J",
                "middle": [
                    "D"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Paul",
                "middle": [
                    "T"
                ],
                "last": "Scott",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Celine",
                "middle": [],
                "last": "Remigio",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "D",
                "middle": [
                    "P T"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "R",
                "middle": [
                    "N"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Ajay",
                "middle": [
                    "P"
                ],
                "last": "Parikh",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Megan",
                "middle": [
                    "C"
                ],
                "last": "Wise",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Ami",
                "middle": [],
                "last": "Patel",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Elizabeth",
                "middle": [
                    "K"
                ],
                "last": "Duperret",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Kevin",
                "middle": [
                    "Y"
                ],
                "last": "Kim",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Hyeree",
                "middle": [],
                "last": "Choi",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "B",
                "middle": [
                    "S"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Scott",
                "middle": [],
                "last": "White",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Mark",
                "middle": [],
                "last": "Bagarazzi",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Jeanine",
                "middle": [
                    "M"
                ],
                "last": "May",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Deborah",
                "middle": [],
                "last": "Kane",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Hoijin",
                "middle": [],
                "last": "Lee",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Gary",
                "middle": [],
                "last": "Kobinger",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Nelson",
                "middle": [
                    "L"
                ],
                "last": "Michael",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "David",
                "middle": [
                    "B"
                ],
                "last": "Weiner",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Stephen",
                "middle": [
                    "J"
                ],
                "last": "Thomas",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            },
            {
                "first": "Joel",
                "middle": [
                    "N"
                ],
                "last": "Maslow",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Institutional Review Boards WRAIR Institutional Review Board (IRB) Walter Reed Army Institute of Research",
                    "institution": "",
                    "location": {
                        "addrLine": "Group III Day 0 0\u00b70 0\u00b70 0\u00b70 NC NC NC Week 1 4\u00b70 32\u00b70 28\u00b70 0\u00b70232, 0\u00b7999 0\u00b70488 Week 2 23\u00b71 33\u00b73 12\u00b75 0\u00b76728 0\u00b76027, 0\u00b7999 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341 Week 4 50\u00b70, 0\u00b7999 0\u00b76943 Week 14, 0\u00b7999 Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085 Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853 Week 60, 377.5 95% CI 123.4, 1155.3 170.7, 886.7 152.1, 937.0 Week 6 N 23 23 24 GMT 1917.1 3398.8 1848.6 95% CI 558.5, 6580.4 1429.0, 8083.8 573.3, 5960.2 Week 12 N 22 23 24 GMT 3200.0 3398.8 2769.7 95% CI 946.4, 10820.3 1329.2, 8690.7 942.5, 8139.1 Week 14 N 22 20 21 GMT 8770.2 8742.7 20318.7 95% CI 2433.5, 31608.0 3285.3, 23265.1 6532.9, 63195.6 Week 24 N 22 20 23 GMT 5822.8 6625.7 14881.7 95% CI 1841.8, 18408.9 3283.9, 13368.0 6168.6, 35902.0 Week 36 N 21 23 22 GMT 2377.6 2228.9 5467.2 95% CI 832.7, 6788.7 950.8, 5225.1 2366.7, 12629.3 Week 60 N 21 23 22 GMT 1312.5 1081.4, 503 Robert Grant Avenue Silver Spring",
                        "postBox": "72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351 Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400 Week 12",
                        "postCode": "81\u00b78 87\u00b70 87\u00b75 0\u00b76995, 90\u00b79 95\u00b70 95\u00b72, 0\u00b7999 > 0\u00b7999, 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806, 20910-7500",
                        "settlement": "Maryland"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Modjarrad K, Roberts CC, Mills KT, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 2019; published online July 24. http://dx.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Methods and interpretation S1-ELISA Recombinant MERS-CoV Spike glycoprotein S1 (amino acids 1-725) portion (Sino Biological) was bound to solid phase 96-well microtiter plates overnight. Plates were washed and blocked then sequentially incubated with (1) four-fold serial dilutions of serum from participants starting at 1:100, in duplicate and (2) horseradish peroxidase enzyme-conjugated anti-human IgG secondary reagent. ABTS\u00ae Peroxidase Substrate (Mandel Scientific) was added to plates and optical density at 405 nm was measured on a standard microplate reader. Serum from a MERS-CoV infected rhesus macaque from pre-clinical testing served as a positive control in the assay. The endpoint titer of anti-S1-specific antibody in serum was defined as the reciprocal of the highest serum dilution with measured optical density that is above 0\u00b71 and greater than the plate cut-off value. Positives were defined as endpoint titer \u2265100; negatives were reported as 50.",
            "cite_spans": [
                {
                    "start": 251,
                    "end": 254,
                    "text": "(1)",
                    "ref_id": null
                },
                {
                    "start": 345,
                    "end": 348,
                    "text": "(2)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "fl-S-ELISA Same as S1-ELISA except plates were coated with recombinant full-length MERS-CoV S protein (Sino Biological) and the dilution series of participant serum was five-fold starting at 1:5. Positives were defined as endpoint titer \u22655; negatives were reported as 1.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Participant serum was serially diluted two-fold,in triplicate starting at 1:10, mixed with 100 plaque forming units of MERS-CoV EMC-2012 strain and incubated to allow for serum antibody and virus interaction. The serum/virus/medium mixtures were added to monolayers of Vero cells. Following incubation, light microscopy was used to evaluate cytopathic effects in wells. Neutralization in this assay was defined as a \u2265 50% reduction of virus-induced cytopathic effects per well (NT50). The titer value for each replicate was defined as the reciprocal of the highest serum dilution at which a 50% reduction in cytopathic effects was observed and results were reported as the GMT of the triplicate NT50 measures. Positives were defined as endpoint GMT \u22657\u00b79 (two of three replicates positive); negatives were reported as 6\u00b73 (one of three replicates positive) or 5 (no replicates positive).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MERS EMC-2012/ Vero cell neutralization assay"
        },
        {
            "text": "IFN\u03b3-ELISPOT Human IFN\u03b3 ELISpotPRO kits (Mabtech) were used as directed. Briefly, frozen participant PBMCs were thawed and rested overnight. Plates pre-coated with IFN-\u03b3 specific capture antibody were washed and blocked with media containing 10% FBS. Cells were stimulated for 24 hours with each of five pools (custom synthesis by GenScript; each pool contained 44-45 peptides) of 15-mer peptides, overlapping by 11 amino acids, spanning the entire MERS-CoV S-glycoprotein. Secreted IFN\u03b3 was detected with an alkaline phosphatase conjugated antibody and signal was developed using a BCIP/NBT-plus substrate. Spots were counted using a CTL ImmunoSpot plate reader and software. Spot counts for each peptide pool were calculated as background-subtracted SFU/million PBMCs. The total SFU/million PBMC count for 5 peptide pools was reported. Positives were defined as SFU/million PBMCs \u2265141, two times the mean total spot counts of all baseline samples. Screening laboratory abnormality greater than or equal to Grade 2 20 Able and willing to comply with all study procedures 12 Screening BMI greater than or equal to 35 6 PI decision related to illness or condition that may interfere with study requirements 4",
            "cite_spans": [
                {
                    "start": 1008,
                    "end": 1018,
                    "text": "Grade 2 20",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "MERS EMC-2012/ Vero cell neutralization assay"
        },
        {
            "text": "Active drug or alcohol use that may affect study requirements 1 Week 3 16\u00b77 61\u00b75 41\u00b72 0\u00b70414 0\u00b74621 0\u00b72341",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Multi"
        },
        {
            "text": "Week 4 50\u00b70 72\u00b70 75\u00b70 0\u00b71482 1\u00b70000 0\u00b71351",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Multi"
        },
        {
            "text": "Week 6 73\u00b79 87\u00b70 79\u00b72 0\u00b74591 0\u00b77008 0\u00b77400",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Multi"
        },
        {
            "text": "Week 12 81\u00b78 87\u00b70 87\u00b75 0\u00b76995 > 0\u00b7999 0\u00b76943",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Multi"
        },
        {
            "text": "Week 14 90\u00b79 95\u00b70 95\u00b72 > 0\u00b7999 > 0\u00b7999 > 0\u00b7999",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Multi"
        },
        {
            "text": "Week 24 86\u00b74 95\u00b70 100\u00b70 0\u00b76079 0\u00b74651 0\u00b71085",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Multi"
        },
        {
            "text": "Week 36 81\u00b70 87\u00b70 95\u00b75 0\u00b76927 0\u00b76078 0\u00b71853",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Multi"
        },
        {
            "text": "Week 60 71\u00b74 78\u00b73 86\u00b74 0\u00b77322 0\u00b76995 0\u00b72806",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Multi"
        },
        {
            "text": "N=Number of participants in the mITT population. NC=not calculable; because of lack of response across all groups, p-value is not calculable. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Multi"
        },
        {
            "text": "Day 0 > 0\u00b7999",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "Week 1 0\u00b7032",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "Week 2-3 0\u00b711",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "Week 4 0\u00b7758",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "Week 6 0\u00b7831",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "Week 12 0\u00b7886",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "Week 14 0\u00b7337",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "Week 24 0\u00b7153",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "Week 36 0\u00b7320",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "Week 60 0\u00b7416 *All p-values are nominal (not pre-specified for inference and not adjusted for multiplicity)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "Supplementary Appendix Safety and Immunogenicity of GLS-5300 MERS DNA Vaccine Page 15 Date:13Nov2017 v10.0 -3-PROTOCOL ACKNOWLEDGEMENT I have read this Protocol and agree that it contains all necessary details for carrying out the study described. I understand that it must be reviewed by the Institutional Review Board or Independent Ethics Committee overseeing the conduct of the study and receive approval or a favorable opinion before implementation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "The signature of the Principal Investigator and Sponsor Medical Monitor below constitute their approval of this protocol and provide the necessary assurances that this study will be conducted according to the Declaration of Helsinki, GCP, ICH guidelines, local legal and regulatory regulations as well as to all stipulations of the protocol in both the clinical and administrative sections, including statements regarding confidentiality. Research Hypothesis: GLS-5300 administered by intramuscular (IM) injection followed by electroporation (EP) will be well-tolerated and immunogenic.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Time Point P-value*, Kruskal-Wallis Test"
        },
        {
            "text": "This is a Phase I open-label dose ranging study to evaluate the safety, tolerability, and immunogenicity of GLS-5300. GLS-5300 contains plasmid pGX9101 that encodes for a consensus sequence of the spike (S) protein of the Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Design:"
        },
        {
            "text": "Currently there are no approved treatments or prophylactic vaccines for MERS CoV, although a number of products are poised to be advanced into human trials.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Design:"
        },
        {
            "text": "This clinical trial will evaluate whether GLS-5300 administered via intramuscular (IM) injection and followed by EP is able to generate protective immunity against MERS CoV and whether there is an immune reactivity follows a pattern of vaccine dose response. Injections will be given in the deltoid or lateral quadriceps muscle followed immediately by EP with the CELLECTRA \u00ae -5P device.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Design:"
        },
        {
            "text": "Participants (n=25 per group) will be administered GLS-5300 at one of three dose levels: 0.67 mg, 2 mg, or 6 mg DNA/dose. These doses will be administered as 1 ml IM injections followed by EP with the CELLECTRA \u00ae -5P device. Participants will receive a 3-dose series with immunizations occurring at 0, 4 and 12 weeks (0-4-12 week schedule).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evaluation of IM administration of GLS-5300:"
        },
        {
            "text": "It is estimated that approximately 225 participants will need to be screened to fill the desired enrollment of 75 participants. Date:13Nov2017 v 10.0 -10-Safety assessment: Participants will be monitored for adverse events utilizing the \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (Appendix B)\". Pain will be assessed at a minimum of 30 minutes post vaccination according to an AE grading scale (Appendix B). Laboratory safety assessments will be obtained at screening, 1 week following the 1 st vaccination, and 2 weeks following the 2 nd and 3 rd vaccinations. Adverse events will be monitored from the time of informed consent to study discharge by telephone on day 1 post vaccination and again at weeks 8 and 16 and during on-site visits at weeks 1, 2 or 3, 4, and 12, and 3, 6, and 12 months after the final vaccination. Injection Site Reactions will be monitored up to approximately 1 month following the each vaccination.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Estimated Number of Participants Screened"
        },
        {
            "text": "In the event that a stopping criterion is reached (Section 7.5), the study will not continue until a full discussion has been conducted with the DoD Research Monitor, Medical Monitor, Principal Investigator, and IRB (if applicable).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Estimated Number of Participants Screened"
        },
        {
            "text": "Immunogenicity assessment: Blood will be obtained for antibody and T-cell responses at baseline and then at weeks 1 and 2 or 3 and 4; at 2 weeks following each vaccination; and at 3, 6, and 12 months following the final vaccination. Serum will be separated and sent for analysis for humoral responses (neutralizing and binding antibody titers) to the laboratory of Dr. Gary Kobinger at the National Microbiology Laboratory in Quebec,Canada. Whole blood will be processed to obtain peripheral blood mononuclear cells (PBMCs) for determination of cell mediated immune responses (CD4 and CD8 T-cell responsiveness to MERS CoV peptides).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Estimated Number of Participants Screened"
        },
        {
            "text": "Inclusion Criteria:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Population:"
        },
        {
            "text": "a. Age 18-50 years; military, civilian, male and female b. Able to provide consent to participate and having signed an Informed Consent Form (ICF);",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Population:"
        },
        {
            "text": "c. Able and willing to comply with all study procedures; d. Women of childbearing potential agree to either remain sexually abstinent, use medically effective contraception (oral contraception, barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 3 months following the last injection, or have a partner who is unable to induce pregnancy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Population:"
        },
        {
            "text": "e. Sexually active men who are considered sexually fertile must agree to use either a barrier method of contraception during the study, and agree to continue the use for at least 3 months following the last injection, or have a partner who is permanently sterile or unable to become pregnant.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Population:"
        },
        {
            "text": "\u2022 All information about the volunteer's medical history and that of his or her sexual partner will be based on self-report. Only the female volunteer's current pregnancy status will be verified with either a urine or serum pregnancy test.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Population:"
        },
        {
            "text": "f. Normal screening ECG or screening ECG with no clinically significant findings; g. Screening laboratory must be within normal limits or have Grade 0-1 findings (Appendix B);",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Population:"
        },
        {
            "text": "h. No history of clinically significant immunosuppressive or autoimmune disease.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Population:"
        },
        {
            "text": "i. Not currently or within the previous 4 weeks taking immunosuppressive agents (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose less than 20 mg/day). c. Previous infection with MERS CoV; as assessed by self report and solicited exposure history d. Administration of any vaccine within 4 weeks of first dose; e. A BMI greater than or equal to 35; f. Administration of any monoclonal or polyclonal antibody product within 4 weeks of the first dose g. Administration of any blood product within 3 months of first dose; h. Pregnancy or breast feeding or have plans to become pregnant during the course of the study; i. History of positive serologic test for HIV, hepatitis B surface antigen (HBsAg) or any potentially communicable infectious disease as determined by the Principal Investigator or Medical Monitor; j. Positive serologic test for hepatitis C (exception: successful treatment with confirmation of sustained virologic response); k. Baseline evidence of kidney disease as measured by creatinine greater than 1.5 (CKD Stage II or greater); l. Baseline screening lab(s) with Grade 2 or higher abnormality (Appendix B); m. Chronic liver disease or cirrhosis; n. Immunosuppressive illness including hematologic malignancy, history of solid organ or bone marrow transplantation; o. Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose less than 20 mg/day); p. Current or anticipated treatment with TNF-\u03b1 inhibitors, e.g. infliximab, adalimumab, etanercept; q. Prior major surgery or any radiation therapy within 4 weeks of group assignment; r. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome; s. Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator (AICD); t. Metal implants within 20 cm of the planned site(s) of injection; u. Presence of keloid scar formation or hypertrophic scar as a clinically significant medical condition at the planned site(s) of injection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Population:"
        },
        {
            "text": "v. Prisoner or participants who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness; w. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or INTRODUCTION",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Population:"
        },
        {
            "text": "In 2012 a participant presented to a hospital in Jeddah, Saudi Arabia with a progressive respiratory illness and renal failure, from whom viral culture yielded a novel coronavirus (Zaki 2012 NEJM). Subsequent cases were identified among those living in or travelers to Saudi Arabia and the Arabian Peninsula. The new virus was subsequently renamed as the Middle East respiratory syndrome coronavirus (MERS CoV) and the disease referred to simply as MERS. Genetic sequence analysis of human coronaviruses has divided the coronaviruses into three distinct phylogenetic groups (\u03b1, \u03b2, and \u03b3). Both MERS CoV and the Severe Acute Respiratory Syndrome coronavirus (SARS CoV) are \u03b2 coronaviruses; however, SARS CoV maps to subgroup 2b, whereas MERS CoV maps to subgroup 2c (Agnihothram 2014 JID, Chan 2012 J Infect).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MERS CoV Epidemiology and Clinical Illness"
        },
        {
            "text": "MERS typically presents as an upper respiratory tract infection. It is not uncommon, however, for the disease to progress to acute respiratory distress syndrome (ARDS) and multi-organ failure (Arabi 2014 AIM). Mortality is highest among the elderly and those with comorbid illness, especially those with underlying lung or cardiac disease (Arabi 2014 AIM, Saad 2014 Int J Infect Dis).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MERS CoV Epidemiology and Clinical Illness"
        },
        {
            "text": "As of 1 November 2015, more than 1600 laboratory-confirmed MERS cases and 580 MERS related deaths, yielding a mortality rate of approximately 35-40% among confirmed cases and as high as 50-60% among the earliest cases in Saudi Arabia. A recent survey of banked sera from Saudi Arabian patients presenting to the hospital or for outpatient care, including some individuals with significant camel exposure, revealed that 15 of 10,009 samples were positive. From these data, the investigators extrapolated that as many as 44,000 individuals country-wide may be seropositive (Muller 2015 Lancet Infect Dis). This suggests that asymptomatic or less severe illness may not be uncommon and that the overall mortality rate may be much lower than reported.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MERS CoV Epidemiology and Clinical Illness"
        },
        {
            "text": "In June 2015 an individual returning to South Korea from a business trip to the Arabian peninsula developed and succumbed to a progressive respiratory illness that was later confirmed to be caused by MERS CoV. Because of delayed diagnosis, coupled with his seeking care at multiple health care facilities, there was consequent widespread transmission resulting in 186 cases and 36 deaths. Although the mortality rate for the Korean outbreak was less than 20%, transmission in the hospital and to family contacts raised alarm for the potential of an even larger outbreak, as transmission in hospital settings has been already common among MERS cases in Saudi Arabia and Europe (Arabi 2014 Ann Int Med, Guery 2013 Lancet). Moreover, the MERS CoV epidemic resulted in a significant negative impact to the Korean economy with GDP slowing to 0.3% growth compared to 0.8% the year prior.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MERS CoV Epidemiology and Clinical Illness"
        },
        {
            "text": "There are no approved therapies or vaccines for MERS CoV infection. Although numerous treatment strategies have been investigated in vitro and in animal models, none have progressed to human evaluation as of November 2015. Vaccine concepts in development include a DNA plasmid-S protein prime followed by S1 protein boost (Wang 2015 The development of vaccine candidates for MERS CoV can be informed by the experiences with SARS CoV. However, only two small Phase I SARS CoV vaccine trials were completed. Two additional Phase I trials were withdrawn prior to enrollment. Martin et al reported a 10-person study (NCT00099463) of a DNA vaccine expressing the S-protein of SARS CoV. Participants were vaccinated with 4 mg/vaccination dose over a 3-dose series (Martin 2008 Vaccine). There were no serious adverse events (SAEs) or Grade 3 or 4 AEs. The most common reaction was mild injection site pain. Neutralizing antibody responses were not detected with a plaque assay, although 8 of 10 participants had detectable neutralizing titers with a lentivirus pseudotype assay. Five individuals had reciprocal titers above 1:40 (range 1:40-1:100) transiently at week 16 that declined to baseline by week 32. ELISpot measurements of T cell responses showed that 4 of 10 achieved CD4 + T cell specific reactions above threshold with two achieving spot counts \u2265 300 versus only 2 who manifested CD8 + T cell responses at any time point, albeit with <150 spots. A second Phase I clinical trial conducted in China (not listed on ClinicalTrials.gov) tested an inactivated SARS CoV virus vaccine administered at two doses without adjuvant (Lin 2007 Vaccine). No SAEs were reported. Antibody titers peaked 2 weeks following the second vaccination and declined thereafter. Seroconversion was documented in 100% of the 36 vaccine recipients on day 42. Antibody titers persisted above threshold in all but one recipient at day 56. Two additional Phase I trials of SARS CoV vaccines were closed prior to enrollment. One was to test a S protein subunit vaccine with an aluminum hydroxide adjuvant (NCT01376765). A second consisted of a wholeinactivated SARS virus given with or without aluminum hydroxide adjuvant (NCT00533741).",
            "cite_spans": [
                {
                    "start": 322,
                    "end": 332,
                    "text": "(Wang 2015",
                    "ref_id": "BIBREF10"
                }
            ],
            "ref_spans": [],
            "section": "Current Treatment"
        },
        {
            "text": "Thus, only two SARS CoV Phase I vaccine trials were completed, though neither yielded any safety concerns. Notably, the DNA plasmid used in the current vaccine trial also targets the coronavirus S protein that mediates viral entry into target cells. However, this plasmid backbone differs from past DNA vaccines in several important ways. The SARS CoV S protein DNA plasmid vaccine used the Vical VR-1012 expression vector that was modified to contain the human T cell leukemia The safety of the GLS-5300 is also be informed from past experience with similar Inovio vaccine candidates that are in, or have completed, human clinical trials. Specific examples include Phase I and 2 trials of INO-3100, the human papilloma virus (HPV) DNA vaccine that incorporates the HPV E6 and E7 proteins of HPV 16 and 18 into a modified pVAX1 backbone and has been administered with or without IL-12 plasmid DNA adjuvant (Bagarazzi 2012 Sci Trans Med, Trimble 2015 Lancet). Current studies include those of a VGX-6150 Hepatitis C vaccine in participants with chronic infection (NCT02027116) and the INO-4212 Ebola virus vaccine (NCT02464670) that use the same plasmid backbone but with different antigen inserts. All of these products to date have been well tolerated and did not elicit any SAEs..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Current Treatment"
        },
        {
            "text": "Emerging and re-emerging infectious diseases pose significant threats to military operations, as they tend to have a high case fatality rate, are often unpredictable in their spread, and occur across areas where service members are deployed. These diseases may arise from within the military community, as spill-over from the surrounding civilian populace or during military operations and deployments. Novel infectious agents pose challenges for early detection and prevention strategies, particularly for military personnel who reside in or are deployed to endemic areas.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Military Relevance"
        },
        {
            "text": "MERS CoV, specifically, is a growing global concern given its airborne route of transmission and high fatality rate and, therefore, may impact military operations or readiness in the Central and ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Military Relevance"
        },
        {
            "text": "The DNA plasmid that is the component of GLS-5300, pGX9101, has been studied as to its immunogenicity in mice, camels, and rhesus macaques and also as part of a challenge model to protect against MERS CoV infection in a non-human primate infection model using rhesus macaques (Muthumani 2015 Sci Transl Med).",
            "cite_spans": [
                {
                    "start": 276,
                    "end": 291,
                    "text": "(Muthumani 2015",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": "Pre-clinical experience with GLS-5300"
        },
        {
            "text": "Following immunization, mice manifested high binding antibody titers (~1:10,000) following two immunizations with pGX9101 and endpoint titers of ~1:50,000 following three immunizations. Neutralizing titers exceeded 1:1,000 following three immunizations. T cell responses in mice against the MERS S protein were broad based with reactive T cells spanning the entire S protein and a magnitude of a cell mediated response as ~2,500 spot forming units per 10 6 PBMCs.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pre-clinical experience with GLS-5300"
        },
        {
            "text": "The ability of pGX9101 to induce a protective immune response was also assessed in camels, the likely intermediate host for MERS. Camels immunized with three injections of pGX9101 at 10 mg per injection, spaced 4 weeks apart were found to develop binding antibodies (3 of 3 animals) with 2 or 3 camels generating detectable neutralizing antibodies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pre-clinical experience with GLS-5300"
        },
        {
            "text": "Finally, non-human primates were immunized with pGX9101 at either low dose (0.5 mg/vaccination) or high dose (2 mg/vaccination) for three vaccinations spaced 3 weeks apart. Notably, after a single vaccination, 2 of 4 animals given a low dose and 4 of 4 macaques given high dose vaccine seroconverted with binding antibody titers of ~1:10,000. After two vaccinations, all animals seroconverted and manifested endpoint binding antibody titers of ~1:50,000. Neutralizing antibody titers after three injections were 1:1,000 without distinction between high or low-dose vaccine. Cytotoxic CD8+ responses were broad based across the MERS S protein, with a dominant response corresponding to the receptor binding region. The magnitude of the response after three vaccinations was approximately 800 SFU/10 6 PBMCs. Importantly, not only was the magnitude of the T cell response significant, but there was breadth of response with almost 20% of cells reactive after immunization.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pre-clinical experience with GLS-5300"
        },
        {
            "text": "Gene expression from plasmid DNA has been used as an efficient means to express target proteins for vaccine related immune responses and to replace or augment naturally occurring proteins and enzymes. DNA plasmids as part of vaccine trials have been developed for a variety of infectious diseases, with a number having been tested as part of Phase I and/or Phase II clinical trials in humans. The results from the first DNA plasmid-based vaccine trial were published in 1998 against HIV (MacGregor 1998 JID) with more than 1200 participants vaccinated ( against H5N1 Avian influenza (NCT01184976) that also employed a non-integrative plasmid based on the pVAX1 expression system. Each of these has an insert comprising a portion of the viral DNA representing a consensus sequence not found in nature to improve the immune response against the viral target and to enhance the breadth of the reaction across different viral strains. These studies along with additional studies sponsored by Inovio Pharmaceuticals (formerly VGX Pharmaceuticals) are enumerated in the table below. In each case, Phase I and II studies have shown no evidence of significant vaccine-associated toxicity, with the primary adverse event reported as transient injection site reactions.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Human experience with DNA plasmids for gene expression"
        },
        {
            "text": "Electroporation (EP) enhances gene expression of plasmid DNA delivered by the intramuscular (IM) or intradermal (ID) routes of administration. Following IM or ID delivery of a DNA vaccine or therapeutic product, EP facilitates entry of the DNA into the target site: muscle or dermal cells. Following cellular uptake, there is efficient and increased production of the proteins encoded by the DNA expression system. The different EP devices, each with varying electrical parameters and protocols, have been reviewed (Prud'homme 2006 Curr Gene Ther). EP has been extensively used in large animal species, such as dogs, pigs, cattle, and NHP, to deliver therapeutic genes that encode for a variety of hormones, cytokines, enzymes or antigens (Prud'homme 2006 Curr Gene Ther) activation of both cellular and humoral responses in animal models (Hirao 2008 Vaccine, Rosati 2008 Vaccine). Importantly, immune responses for DNA vaccines delivered with EP are far superior to vaccination without EP (Rosati 2008 Vaccine) . The IM delivery of DNA with EP is well studied, and optimum conditions for plasmid uptake and expression are described for therapeutic indications, vaccines and tumor animal model systems (Curcio 2008 Cancer Gene Ther, Ugen 2006 Cancer Gene Ther). The Inovio Pharmaceuticals novel constant current IM EP device (Prud'homme 2006 Curr Gene Ther) referred to as the CELLECTRA \u00ae 2000 or CELLECTRA \u00ae device will be used in this clinical trial.",
            "cite_spans": [
                {
                    "start": 990,
                    "end": 1011,
                    "text": "(Rosati 2008 Vaccine)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Administration of similar DNA plasmids by Electroporation (EP)"
        },
        {
            "text": "As of July 31, 2015, more than 650 human subjects have undergone EP with the CELLECTRA \u00ae device in more than 15 different studies. More than 1500 doses of DNA have been administered. The most significant finding has been moderate but self-resolving administration site pain. Evaluation of CPK for muscle damage and ECG for cardiac conduction abnormalities has been unremarkable and no significant EP-related safety issues have been identified. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administration of similar DNA plasmids by Electroporation (EP)"
        },
        {
            "text": "GLS-5300 contains a single plasmid, pGX9001, in sterile water for injection (WFI). Distinguishing name: This is a eukaryotic expression plasmid containing DNA encoding for the full-length MERS CoV S protein. pGX9001 incorporates a consensus sequence of published MERS CoV clinical isolate strains. The S protein DNA sequence has been codon optimized for mammalian expression. The transcription unit is controlled by a synthetic CMV promoter and elements required for replication and selection in E coli, namely a pUC origin of replication (pUC-Ori) and kanamycin resistance gene (KanR), respectively.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "GLS-5300"
        },
        {
            "text": "Because human responses to GLS-5300 are unknown, this study will assess safety, tolerability, and immunogenicity. Based on prior experience with treatment of HIV infection, a dose of 2 mg of GLS-5300 corresponds to a vaccine dose of approximately 30 \u00b5g/kg. Preclinical studies in rhesus macaques assessed high (2 mg/vaccination) and low (0.5 mg/vaccination) doses of pGX9001.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dose and Regimen Rationale"
        },
        {
            "text": "Robust T-cell immune responses in humans were elicited with a dose of 2 mg/vaccination with a similar DNA construct in a Phase I dose-ranging study for the treatment of cervical dysplasia related to HPV cervical infection (Bagarazzi 2012 Sci Transl Med, Trimble 2015 Lancet). Preliminary analysis of the human response to VGX-6150 for the treatment of Hepatitis C shows minimal immunologic benefit since when the dose is increased from 2 mg to 6 mg, there is only a small increase in immune response. Notably, both the HPV product and VGX-6150 are based on the same expression system used to construct GLS-5300. Assessment of antibody and T-cell responses following each vaccination will determine the effectiveness of vaccination. Follow-up will determine the longevity of immunogenicity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dose and Regimen Rationale"
        },
        {
            "text": "In accordance with the International Conference on Harmonisation (ICH), this study has been designed to minimize risk to study participants. Potential risks of study products and administration from studies using similar plasmids with the identical DNA backbone are listed in Table 1 .4. Since the volunteers in this clinical trial are healthy, and this is a first in man study, no direct benefit is expected. The potential side effects of treatment with the investigational products may include discomfort related to the EP technique such as local edema, swelling, or pain. Systemic side effects with vaccines based on the identical backbone have been demonstrated to be generally minimal in more than 650 participants. Since the volunteers in this clinical trial are healthy, no direct benefit is expected. The potential benefit is to determine whether this vaccine will generate protective levels of neutralizing antibodies and cytotoxic T-cells as prophylactic treatment for those at risk for MERS CoV infection.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 276,
                    "end": 283,
                    "text": "Table 1",
                    "ref_id": "TABREF13"
                }
            ],
            "section": "Risks/Benefit Assessment"
        },
        {
            "text": "The principal risk for study personnel is exposure in the clinical setting to infectious pathogens from study participants through various contact mechanisms (e.g., needle stick exposure to blood borne pathogens and exposure to respiratory pathogens from those with upper respiratory tract infection). Adherence to good hygiene practices and standard operating procedures (SOPs) for working with infectious agents and universal precautions will reduce the risk of exposure. There are no known risks to the environment other than those associated with the generation of GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Risks to the Study Personnel and the Environment"
        },
        {
            "text": "Clinical Protocol Date:13Nov2017 v10.0 -21-biohazardous waste attendant to vaccination of humans. All biohazardous waste will be disposed of as stipulated by local, state, and federal regulations and in accordance with study site SOPs.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Risks to the Study Personnel and the Environment"
        },
        {
            "text": "Some discomfort from the needle stick for the blood draw is possible, including swelling or bruising, and there is a very small risk of infection at the site of the needle stick. A few participants may feel light-headed and may develop a rapid heartbeat during blood collection. These symptoms can be stopped by having the participant lie down and/or by stopping the procedure.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Venipuncture"
        },
        {
            "text": "As with any investigational new drug (IND) product, there is the potential risk of a serious, or even life-threatening, allergic reaction the vaccine. To mitigate this risk, potential participants with a history of severe allergic reaction of any kind, or significant allergic reaction to a known component of the experimental products, will be excluded from participation. As the vaccine is formulated only in sterile water, the allergic reaction would most likely be due to the DNA vaccine.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Allergic Reaction"
        },
        {
            "text": "In the event of a severe allergic reaction, the CTC is staffed with trained medical personnel and stocked with appropriate medical emergency equipment to provide acute care for conditions such as anaphylaxis. Further, if required, a formal emergency medical response service (fire department), capable of treating and transferring any life-threatening injuries to a higher level of medical care, is available in close proximity to the trial site.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Allergic Reaction"
        },
        {
            "text": "The EP device delivers three brief (less than 1 second each) electrical impulses to the deltoid (or quadriceps) muscle through 5 electrodes. This results in a brief but intense muscle contractions with each pulse and is associated with local pain/discomfort during the period of EP administration. Additional AEs associated with the procedure has in the past included minor, transient cutaneous bleeding at the sites of electrode and injection needle penetration, and mild to moderate injection site soreness/bruising typically lasting for 24 to 72 hours, but in some instances up to 7 days post administration.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "EP"
        },
        {
            "text": "On one occasion during vaccination in the early phase of another study with a separate EP device the injection needle came in contact with the volunteer's periosteum which created resistance when the vaccinator attempted to withdraw the device. This has never been reported for the CELLECTRA\u00ae EP device. However, to minimize this risk, those volunteers with a body mass index, measured at study baseline, of less than 18 will have a guard used with the device that prevent the electrodes from inserting the full length into the volunteers arm. Additionally, even if the body mass index of the volunteer is greater than 18, the principal investigator or his delegate may still opt use the guard or not vaccinate the volunteer if he or she feels there is not enough muscle mass to accommodate the electrodes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "EP"
        },
        {
            "text": "Pain associated with the EP has been intense but transient and in the experience of this particular device almost all individuals have reported complete disappearance of pain by 5 minutes post EP. Additionally, there is potential for the delivery of excessive electrical energy to the skin and muscle tissue. To prevent this, the device is designed to perform multiple self-monitoring GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "EP"
        },
        {
            "text": "Clinical Protocol Date:13Nov2017 v10.0 -22-functions to identify potentially unsafe operating conditions throughout the vaccination process. Any detected abnormality will result in disconnection and prevention of electrical discharge into the subject. There have been no occurrences of excessive energy delivery in any of the nonclinical and clinical studies conducted with the CELLECTRA \u00ae 2000 device.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "EP"
        },
        {
            "text": "Although the electrocardiogram is safe procedure, a potential harm may come from discovery of a previously known cardiac condition. This information, however, will be kept confidential and only used to refer the participant to appropriate care and treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Electrocardiogram"
        },
        {
            "text": "There is a risk that data collected from participants on results from HIV, Hepatitis B, and Hepatitis C infection could become public and result in social harm. This will be mitigated by following confidentiality procedures as described below.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Testing for Sexually Transmitted Diseases"
        },
        {
            "text": "The leukapheresis procedure will be performed at the same study center as all other study procedures (WRAIR CTC, Robert Grant Ave. Silver Spring, MD). American Red Cross personnel will be responsible for performing the procedure, under contract with the WRAIR. Essentially, plasmapheresis will be performed in which approximately 120ml -150ml of plasma will be removed from the patient over the course of 1.5 -3 hours with a majority fraction of red blood cells (95% -97%) being returned to the volunteer. Because the fraction of plasma of primary interest are peripheral blood mononuclear cells, the procedure will referred to as Leukapheresis throughout this protocol. The procedure, (Leukapheresis) will be offered at the weeks 14 and 24 visits. Only a subset of volunteers will be chosen for this optional procedure that will require additional consent. An interim analysis will be conducted in a subset of volunteers (10 per dose group) at the week 6 visit to determine the five highest immune responders (as measured by neutralization antibody titers). The five individuals will then be recruited for the leukapheresis substudy. The next five highest responders will be recruited if the first five decline. Only a subset of participants are being chosen for this procedure so as to make more efficient use of the leukapheresis by focusing on those who will provide the highest yield of potent neutralizing antibodies. Additionally leukocytes are being collected a later time points when antibody affinity has matured sufficiently.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Leukapheresis"
        },
        {
            "text": "The risks of the leukapheresis procedure include the following: \u2022 blood loss from the inability to return red blood cells during automated plasmapheresis (which may result in the procedure being terminated) \u2022 allergic reactions such as flushing, itching, hives, abdominal cramps, difficulty breathing, which may vary in severity from mild to life-threatening \u2022 vascular injury from the needle used in the procedure. These include bruising or hematoma at the venipuncture site which may present with pain, tingling, or paresthesia \u2022 presyncopal/syncopal episodes during volume removal. These include pallor, weakness, lightheadedness, agitation, sweating, nausea, vomiting, hypotension, tachycardia, bradycardia, fainting, and incontinence. These side effects will be closely monitoring during and immediately after the procedure. The normal saline reinfusion performed in conjunction with plasmapheresis will reduce the likelihood of these reactions. \u2022 reactions to the anticoagulant used during plasmapheresis including any of the following: tingling, paresthesia, muscle cramp, tetany, seizure, and metallic taste in the mouth GLS-5300 GeneOne Life Science, Inc. Clinical Protocol Date:13Nov2017 v10.0 -23-A recent analysis of apheresis procedures (including plasmapheresis) in the US, estimates the risk of these moderate and severe adverse reactions to be 0.37%. Risk is mitigated by limiting volume of plasma removed, careful screening, modern equipment, and experience personnel. The volunteers will be monitored closely by trained American Red Cross medical personnel during the procedure and will wait at the clinic for 15 minutes after the procedure.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Leukapheresis"
        },
        {
            "text": "There is a risk that data collected from participants could be unintentionally released to another party, constituting a breach of confidentiality and potentially causing social harm. This risk is also compounded for military personnel who may have information leaked up the chain of command, although military personnel will not be actively recruited for this study. These risks will be mitigated by the universal practice within the research clinic of complete maintenance of confidentiality among study staff, the limited use of participant identifiers on study materials, and the locking of all print materials related to study participants and password protection of electronic documents related to the study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data Collection"
        },
        {
            "text": "As with all research there is the remote possibility of risks that are unknown or that cannot be foreseen based on available information. This would include late effects that have been seen with some vaccines. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unknown Risks"
        },
        {
            "text": "Hypothesis GLS-5300 administered intramuscularly (IM) followed by EP will be well tolerated and immunogenic.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "HYPOTHESIS AND STUDY OBJECTIVES"
        },
        {
            "text": "\u2022 Evaluate the safety and tolerability of GLS-5300 when administered by IM injection followed by EP in healthy adult participants.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Primary Objectives"
        },
        {
            "text": "\u2022 Incidence of adverse events classified by system organ class (SOC), preferred term (PT) severity, and relationship to study treatment and schedule \u2022 Administration (injection) site reactions (described by frequency and severity grade) and administration site pain \u2022 Changes in safety laboratory parameters described by frequency and severity grade (e.g., liver panel tests, vital signs)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Primary Safety Endpoints"
        },
        {
            "text": "\u2022 Evaluate the cellular and humoral response of GLS-5300 when delivered IM followed by EP \u2022 Evaluate the dose response for cellular and humoral reactivity of GLS-5300 when delivered IM followed by EP",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "\u2022 Quantitative binding antibody titers to the full length MERS CoV Spike (S) glycoprotein \u2022 Qualitative and quantitative levels of neutralizing antibodies against MERS CoV \u2022 Antigen specific cellular immune responses to MERS CoV as determined by:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Immunologic Endpoints"
        },
        {
            "text": "\u2022 Interferon-gamma (IFN-\u03b3) ELISpot \u2022 Intracellular cytokine staining (ICS) (cytotoxic T lymphocyte phenotype, lytic granule loading, granzyme B killing of target cells)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Immunologic Endpoints"
        },
        {
            "text": "\u2022 Explore whether end point antibody titers to MERS CoV S protein are dose related.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "\u2022 Explore the time to onset of antibody production and longevity of serologic response \u2022 Explore if increasing dose levels of GLS-5300 more rapidly induce cellular immunity \u2022 Explore the time to onset of T cell responsiveness and longevity of cell mediated immunity \u2022 Evaluate the kinetics of antigen expression in the peripheral blood compartment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "\u2022 Evaluate host genetics as a potential predictor of vaccine immune response \u2022 Host immune-genotyping as resources are available.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "\u2022 Epitope mapping of CD4+ and CD8+ T lymphocyte responses \u2022 Immunophenotyping and functional characterization of cellular subsets of interest, including natural killer (NK) cells \u2022 Isolate, express and characterize monoclonal antibodies against the MERS CoV S protein and assess their neutralizing and non-neutralizing functional activity. \u2022 Molecular characterization of study vaccine-elicited antibodies may include, but will not be limited to structural biology analysis, Fc analysis, isotype analysis, epitope mapping. \u2022 Correlation of endpoint antibody binding titers across two different ELISA platforms.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "This is a Phase I open-label trial to assess the safety, tolerability, and immunogenicity of GLS-5300 encoding for the S protein of MERS CoV. Eligible participants who consent to participate will be administered GLS-5300 via IM injection followed immediately by EP using the CELLECTRA \u00ae 5P Adaptive Constant Current Electroporation device.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "STUDY DESIGN"
        },
        {
            "text": "Prospective participants who read and sign the informed consent form (ICF) will be screened for eligibility for up to 30 days prior to their first dose. Screening evaluation will consist of a medical history, ECG, and laboratory evaluations. Participants without a history of exclusionary conditions or not clinically significant or normal ECG and Grade 0-1 laboratory values (per the Toxicity Grading Scale for Healthy Adults Appendix B) for CBC, serum chemistry, CPK, will be eligible for participation in the trial. A total of 75 participants divided into 3 groups will be enrolled for this study. It is estimated that approximately 225 participants will need to be screened to fill the desired enrollment of 75 participants.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evaluation of IM Administration of GLS-5300:"
        },
        {
            "text": "Group I Participants (n=25) assigned to receive GLS-5300 will be administered 0.67 mg DNA/dose given as a 1 ml IM injection followed by EP with the CELLECTRA \u00ae -5P device. Participants will receive a 3-dose series with immunizations at 0, 4 and 12 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evaluation of IM Administration of GLS-5300:"
        },
        {
            "text": "Group II Participants (n=25) assigned to receive GLS-5300 will be administered 2 mg DNA/dose given as a 1 ml IM injection followed by EP with the CELLECTRA \u00ae -5P device. Participants will receive a 3-dose series with immunizations at 0, 4 and 12 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evaluation of IM Administration of GLS-5300:"
        },
        {
            "text": "Group III Participants (n=25) assigned to receive GLS-5300 will be administered 6 mg DNA/dose given as a 1 ml IM injection followed by EP with the CELLECTRA \u00ae -5P device. Participants will receive a 3-dose series with immunizations at 0, 4 and 12 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evaluation of IM Administration of GLS-5300:"
        },
        {
            "text": "Participants will be enrolled at the lowest dose (Group I) with continuous enrollment through the 1st week of enrollment. At the start of week 2, clinical laboratory data for the first five participants from Group I will be reviewed as part of the safety review. Once safety labs have been reviewed and cleared for the first five participants in Group 1 , the second dose level will be opened. The next five participants who have met eligibility criteria will then be enrolled into Group II. Then enrollment for Group I will be completed. Once group 1 has completed enrollment of 25 participants, then Group 2 will be populated sequentially. When the first five participants in Group 2 have reached one week post vaccination then safety labs will be reviewed as above. Once this safety assessment is cleared, then Group III will be opened for enrollment of the next five participants. Then enrollment will be completed for Group Table S1 for a summary of study treatments and schedule of dosing.",
            "cite_spans": [
                {
                    "start": 346,
                    "end": 353,
                    "text": "Group 1",
                    "ref_id": null
                },
                {
                    "start": 923,
                    "end": 928,
                    "text": "Group",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 929,
                    "end": 937,
                    "text": "Table S1",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "Evaluation of IM Administration of GLS-5300:"
        },
        {
            "text": "Safety assessments: All participants will be monitored for \uf0d8 Local and systemic adverse events (AE's) at each study visit.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evaluation of IM Administration of GLS-5300:"
        },
        {
            "text": "\uf0d8 Laboratory related AE's following the first, second, and third vaccination.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evaluation of IM Administration of GLS-5300:"
        },
        {
            "text": "Immunogenicity assessments:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evaluation of IM Administration of GLS-5300:"
        },
        {
            "text": "The study will explore humoral and cell mediated immune responses in blood samples collected at the following times: ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evaluation of IM Administration of GLS-5300:"
        },
        {
            "text": "This study will utilize a treatment progression scheme to assess and ensure the safety of each dose level of vaccine as follows.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment Progression Scheme"
        },
        {
            "text": "Participants will be contacted by telephone to assess reactions the day following the 1 st vaccination to assess whether there are any reported AE's or other reactions. If there are no dose-limiting AE's reported for the first 5 participants enrolled, then enrollment can proceed with the remainder of participants at that dose level.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment Progression Scheme"
        },
        {
            "text": "Safety laboratory assessments will be performed 1 week after the 1 st dose of vaccine and 2 weeks after the 2 nd and 3 rd doses for all study participants. If no Grade 3 or Grade 4 AEs or any Serious Adverse Event (SAE) are noted either with clinical assessments or with safety laboratory assessment for the first 5 participants enrolled at a dose level, then enrollment into the next higher dose level can be opened. Labs will be forwarded for review on a monthly basis thereafter until all participants have completed safety lab draws.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment Progression Scheme"
        },
        {
            "text": "Safety Monitoring Committee Safety monitoring will be conducted throughout the study; therefore safety concerns will be identified by continuous review of the data by the PI, clinic staff, clinical monitor, and DoD Research Monitor. As this study represents the first time GLS-5300 is administered to humans, the investigative team will also establish a Safety Monitoring Committee (SMC) to review safety labs and provide oversight of the safe conduct of the study as an additional measure to address and mitigate any risk.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety Monitoring"
        },
        {
            "text": "The SMC will consist of the study PI, the medical monitor and the DoD Research Monitor. Safety reviews will be conducted on a weekly basis either by teleconference or electronically. If there are urgent issues that need to be addressed the SMC will convene ad hoc to address those issues. Enrollment from one dose level to the next will require approval of all review members. A safety GLS-5300 GeneOne Life Science, Inc. Clinical Protocol Date:13Nov2017 v10.0 -28-report summarizing the safety data and SMC protocol considerations for the sentinel group of five volunteers at each dose-level (3 safety reports), including laboratory and monitoring data, the timeframe covered, and an assessment about moving forward will be provided to the Vice Chair and Reviewer with the option to refer to the convened IRB.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety Monitoring"
        },
        {
            "text": "The SMC will review all unanticipated problems involving risk to subjects or others, SAEs, and all subject deaths associated with the protocol and provide an unbiased written report of the event. The SMC will also review any withdrawal or discontinuation of study participation of any volunteer and determine if it was product related. The SMC will also pause the study if the pausing rules are met as outlined in Section 7.5 and notify the IRB immediately of this pause. Reports for events determined by either the investigator or entire SMC to be related or unrelated to participation and reports of events resulting in death will be promptly forwarded to the IRBs.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety Monitoring"
        },
        {
            "text": "The research monitor will function as an independent safety advocate for subjects per AR 70-25 and DoD Instruction 3216.02. An independent research monitor is required to review all unanticipated problems involving risk to subjects or others, SAEs, and all subject deaths associated with the protocol and provide an unbiased written report of the event. At a minimum, the research monitor will comment on the outcomes of the event or problem and, in the case of a SAE or death, comment on the relationship to participation in the study. The research monitor should also indicate whether he/she concurs with the details of the report provided by the study investigator. Reports for events determined by either the investigator or research monitor to be possibly or definitely related to participation and reports of events resulting in death will be forwarded to the WRAIR IRB, ORP HRPO, and USAMRMC CSSD PSSB (sponsor safety office) within 48 hours followed by a written report within 10 working days (as per WRAIR SOP UWZ-C-619.02, Safety Reporting for Clinical Trials).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Monitor"
        },
        {
            "text": "The duties of the research monitor shall be determined on the basis of specific risks or concerns about the research. The research monitor may perform oversight functions if needed (e.g., observe recruitment, enrollment procedures, and the consent process for individuals, groups or units; oversee study interventions and interactions; review monitoring plans and UPIRTSO reports; and oversee data matching, data collection, and analysis) and report their observations and findings to the IRB or a designated official.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Monitor"
        },
        {
            "text": "The research monitor may discuss the research protocol with the investigators, interview human subjects, and consult with others outside of the study about the research. The research monitor shall have authority to stop a research protocol in progress, remove individual human subjects from a research protocol, and take whatever steps are necessary to protect the safety and well-being of human subjects until the IRB can assess the monitor's report. Research monitors shall have the responsibility to promptly report their observations and findings to the IRB or other designated official.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Monitor"
        },
        {
            "text": "Weekly reports will be generated by a contracted statistical support group. These reports will comprise of the frequencies of SAEs and AESI's as well as enrollment status (number of volunteers screened, number of volunteer screening failures, and basic laboratory, ECG, and demographic data for each dosing group in the prior week and as compared to entire study period to date. The SMC will review the summarized safety data and other data as appropriate during weekly meetings to GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data Monitoring"
        },
        {
            "text": "Clinical Protocol Date:13Nov2017 v10.0 -29-inform decisions as described in section 3.3.1. The SMC will be prepared to review any individual event thought to be of major significance and alert the sponsor, IRB and FDA if there are any safety concerns regarding the continuation of the study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data Monitoring"
        },
        {
            "text": "Statistical support for data monitoring efforts will include generation of data safety reports, maintenance of an archive of electronic copies of the datasets statistical programs used to generate reports, and generating and updating and carrying out statistical analysis plan.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data Monitoring"
        },
        {
            "text": "Healthy adult volunteers, male and female, military and civilian, will be recruited by non-coercive means through WRAIR CTC according to applicable U.S. Army regulations.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Recruitment of Participants"
        },
        {
            "text": "Recruitment will be by advertisement in multiple media formats (email, website, social media, newspaper, radio, television) as well as by word of mouth. Recruitment may also include oral presentations and/or distribution of approved recruiting materials at events, meetings, and briefings wherein the desired recruit population might reasonably be expected to attend.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Recruitment of Participants"
        },
        {
            "text": "Recruitment may include referrals of potential participants by individual already screened for the study. Participants will be asked to direct interested persons to contact the CTC. Participants will receive $25 for each referred person who then attends a screening session and meets all inclusion and none of the exclusion criteria. Compensation will be independent of the referred person's decision to enroll. Final authority over dispensation of referral compensation will lie with the CTC Director.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Recruitment of Participants"
        },
        {
            "text": "All advertisements, both general and specific to this study, will have been reviewed and approved by the WRAIR IRB prior to their use. All recruiting methods will direct the volunteer to contact the CTC via e-mail or phone, or the CTC web site where the same contact information will be given.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Recruitment of Participants"
        },
        {
            "text": "Upon calling the recruitment phone number, an IRB approved recruitment script will be used by study personnel to inform potential participants of the details of the study. If the potential participant desires, some basic contact information will be obtained and an appointment for a formal briefing and screening will be made at that time.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Recruitment of Participants"
        },
        {
            "text": "Upon contacting the CTC via e-mail, potential participants will be provided an electronic version of the recruitment script to inform them of the details of the study. If the potential participant desires, some basic contact information will be obtained and an appointment for a formal briefing and screening will then be made (via further e-mail or phone conversations). Volunteers can also be recruited via WRAIR 2038, which is a generic screening protocol managed by the WRAIR CTC. Under this screening protocol, volunteers will undergo a generic screening visit with medical history, exam, vitals, lab tests, along with other potential screening tests. If the volunteer is interested in learning about this clinical trial, they will need to attend a WRAIR 2274 study specific briefing and screening appointment. Then, if the participant remains interested, they will need to sign this study's informed consent form. If the volunteer consents, the screening documentation from WRAIR 2038 can be shared with this study to fulfill the screening requirements, and a copy of said documents can be added to the volunteer's study file for this clinical trial. If military participants are recruited in formation, then the research monitor who will act as the ombudsman for this study, will be present as an independent party. The ombudsman will be available to help answer any questions from an impartial standpoint. Additionally, no senior NCO or officers will be present during the recruitment brief, as to ensure that there is no undue pressure of influence from the soldier's immediate chain of command.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Recruitment of Participants"
        },
        {
            "text": "a. Age 18-50 years; military, civilian, male and female. b. Able to provide consent to participate and having signed an Informed Consent Form.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "c. Able and willing to comply with all study procedures. d. Women of child-bearing potential agree to remain sexually abstinent, use medically effective contraception (oral contraception, barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 3 months following the last injection, or have a partner who is unable to induce pregnancy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "e. Sexually active men who are considered sexually fertile must agree to use either a barrier method of contraception during the study, and agree to continue the use for at least 3 months following the last injection, or have a partner who is permanently sterile or unable to become pregnant;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "f. Normal screening ECG or screening ECG with no clinically significant findings; f. Administration of any monoclonal or polyclonal antibody product within 4 weeks of the first dose; g. Administration of any blood product within 3 months of first dose; h. Pregnancy or breast feeding or have plans to become pregnant during the course of the study; i. History of positive serologic test for HIV, hepatitis B surface antigen (HBsAg); or any potentially communicable infectious disease as determined by the Principal Investigator or Medical Monitor; j. Positive serologic test for hepatitis C (exception: successful treatment with confirmation of sustained virologic response); k. Baseline evidence of kidney disease as measured by creatinine greater than 1.5 (CKD Stage II or greater); GLS-5300 GeneOne Life Science, Inc. Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "Date:13Nov2017 v10.0 -31-l. Baseline screening lab(s) with Grade 2 or higher abnormality; m. Chronic liver disease or cirrhosis; n. Immunosuppressive illness including hematologic malignancy, history of solid organ or bone marrow transplantation; o. Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose less than 20 mg/day); p. Current or anticipated treatment with TNF-\u03b1 inhibitors such as infliximab, adalimumab, etanercept; q. Prior major surgery or any radiation therapy within 4 weeks of group assignment; r. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome; s. Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator (AICD); t. Metal implants within 20 cm of the planned site(s) of injection; u. Presence of keloid scar formation or hypertrophic scar as a clinically significant medical condition at the planned site(s) of injection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "v. Prisoner or participants who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness; w. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "x. Tattoos covering the injection site area h y. Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "A participant will be considered to have completed the study when he/she completes all scheduled study treatments and follow-up visits. If a participant discontinues the study at any time after dosing, the investigator will make every effort to have the participant complete all assessments as indicated in Section 7 -Safety Parameters. The investigator will make every effort to have all scheduled immune assessment blood samples collected as indicated in the Schedule of Events, Table S2 .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 481,
                    "end": 489,
                    "text": "Table S2",
                    "ref_id": "TABREF2"
                }
            ],
            "section": "Discontinuation/Withdrawal of Study Participants"
        },
        {
            "text": "Unless a participant refuses to continue participation, all follow-up visits and procedures should be completed as indicated in the Schedule of Events, Table S2 , following the last dose whether or not the participant has completed all doses.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 152,
                    "end": 160,
                    "text": "Table S2",
                    "ref_id": "TABREF2"
                }
            ],
            "section": "Discontinuation/Withdrawal of Study Participants"
        },
        {
            "text": "All data collected up to the time of withdrawal, including any final evaluation and lab results that may be pending at the time of withdrawal will be reported. Likewise, any specimens collected up to the time of withdrawal, including any blood collected for storage and use in future research, will be kept and utilized as outlined in the protocol and consent form. The study termination eCRF will be completed, with the reason for withdrawal specified.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discontinuation/Withdrawal of Study Participants"
        },
        {
            "text": "The reason for any discontinuation of investigational product will be discussed with the Sponsor's Medical Monitor and indicated on the study forms. The primary reason for a participant discontinuing further dosing or withdrawal from the study itself is to be selected from the following standard categories:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discontinuation/Withdrawal of Study Participants"
        },
        {
            "text": "\u2022 Adverse Event (Adverse Reaction): Clinical or laboratory events occurred that, in the medical judgment of the investigator, are grounds for discontinuation for the best interest of the \u2022 Withdrawal of Consent: The participant desired to withdraw from further participation in the study in the absence of an investigator-determined medical need to withdraw. If the participant gave a reason for withdrawal, it must be recorded on the CRF. This reason does not allow for further data collection or later study related procedures. \u2022 Protocol Violation: The participant failed to meet the protocol entry criteria or failed to adhere to the protocol requirements (e.g., treatment noncompliance, failure to return for defined number of visits). The violation should be discussed with the Sponsor's Medical Monitor prior to discontinuation of either study treatments or study withdrawal. \u2022 Lost to Follow-up: The participant fails to attend study visits and study personnel are unable to contact the participant after repeated attempts including letter sent by certified mail or its equivalent. \u2022 Physician Decision: The participant was terminated for a reason other than those listed above by the physician caring for the participant. \u2022 Incarceration: Participation of prisoners is not planned and any volunteer will be suspended from study visits while incarcerated. The IRB will be notified of the period of incarceration. If possible, site teams will coordinate with correctional authorities to ensure that relevant medical information for the safety and care of the patient is communicated promptly. \u2022 Other: The participant was terminated for a reason other than those listed above, such as termination of study by the Sponsor.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discontinuation/Withdrawal of Study Participants"
        },
        {
            "text": "Investigational Product GLS-5300, the investigational product to be used in this study contains a DNA plasmid encoding for the S protein of MERS CoV. Each product will be provided at a concentration of approximately 6 mg/ml to be diluted and mixed on site to the needed dose such that a standard 1 ml volume will be administered to all study participants. Because of this the concentration of the final plasmid will vary based on the dosage administered. GLS-5300 is a solution in sterile water for injection (sWFI). Therefore, sWFI will be used for dilution of the biologic products during clinical site formulation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "STUDY TREATMENT"
        },
        {
            "text": "The vaccine product will be shipped from manufacturer at VGXI in Houston Texas on dry ice. The lot number for the vaccine to be used is GLS-5300 15L019.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "STUDY TREATMENT"
        },
        {
            "text": "The IP in this study, GLS-5300, completed FDA review on 17 November 2015, with notification that the protocol had no clinical holds was received and that the clinical trial could proceed. There have been no prior FDA submissions for GLS-5300 either alone or in combination with any other product. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "STUDY TREATMENT"
        },
        {
            "text": "The study products will be supplied in a non-blinded fashion indicating the particular component, GLS-5300. Study product will be shipped directly from the manufacturer or its designee to the study site. Each vial will be labeled with a single panel label. Vial labels text may include the following with minimal recoverable volume as indicated. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Packaging and Labeling of GLS-5300"
        },
        {
            "text": "Study product accounting will be performed continuously during the study. Details on study product volume, administration, and accountability are documented in the CRF and on respective pharmacy forms. At completion/termination of the study, all unused and partially used supplies must be returned to GeneOne Life Science, Inc. The investigator, pharmacist/drug administrator and medical monitor must verify that no drug supplies remain at the site at the time of study closeout. Appropriate records will be maintained in the investigator's site file.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Handling of GLS-5300"
        },
        {
            "text": "GeneOne Life Science, Inc. will be responsible for assuring the quality of the investigational product is adequate for the duration of the trial. GLS-5300 will be shipped on dry ice. If there is no dry ice remaining in the frozen shipment container when the shipment is received, the Sponsor must be contacted immediately.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Handling of GLS-5300"
        },
        {
            "text": "The investigational product must be stored in a secure area according to local regulations. All study products must be transferred from the shipping container to the appropriate storage conditions upon arrival. GLS-5300 must be stored frozen in a freezer (NOT frost-free) at or below -15\u00b0C although for long term storage (approximately more than 3 months) it must be stored at -17\u00b0C to -23\u00b0C.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Handling of GLS-5300"
        },
        {
            "text": "Refrigerator/freezer temperature logs must be maintained at the clinical site and temperatures must be recorded and monitored regularly.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Handling of GLS-5300"
        },
        {
            "text": "It is the responsibility of the Investigator to ensure that GLS-5300 is only dispensed to study participants. Authorized personnel at the official study site must be the only ones to dispense the product according to local regulations.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dispensing of GLS-5300"
        },
        {
            "text": "The dosing syringe must be labeled with a four-hour expiration date from the time the vial(s) are removed from storage. The label should also contain the words \"Administer as soon as possible\".",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dispensing of GLS-5300"
        },
        {
            "text": "Detailed instructions on handling and dispensing of Investigational Product are provided below.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dispensing of GLS-5300"
        },
        {
            "text": "A dose of the study product known or suspected to have been taken (accidentally or intentionally) in excess of the dose mandated by the protocol, and any misuse or abuse of study products or any other product taken as a concomitant medication, whether or not associated with an adverse experience, must be reported to GeneOne Life Science within 24 hours. Any clinical sequelae in GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Precautions with Investigational Medicinal Product"
        },
        {
            "text": "Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Precautions with Investigational Medicinal Product"
        },
        {
            "text": "Date:13Nov2017 v10.0 -35-association with the overdose will be reported as an AE or SAE. Details of signs or symptoms, clinical management, and outcome should be reported, if available.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Precautions with Investigational Medicinal Product"
        },
        {
            "text": "GLS-5300 is supplied in single dose 2 mL vials at a concentration of 6 mg/mL at a volume of 0.5 mL minimum recoverable volume.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Preparation of Investigational Product"
        },
        {
            "text": "GLS-5300 will be combined with sWFI to the required volume and concentration by experienced site personnel for IM administration. Detailed instructions for Investigational Product preparation are provided in the Pharmacy Manual.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Preparation of Investigational Product"
        },
        {
            "text": "It is the responsibility of the Investigator to ensure that a current record of investigational product disposition is maintained at each study site where investigational product is inventoried and disposed. Records or logs must comply with applicable regulations and guidelines, and should include:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Records of Investigational Product Disposition at Site"
        },
        {
            "text": "\u2022 Amount received and placed in storage area;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Records of Investigational Product Disposition at Site"
        },
        {
            "text": "\u2022 Amount currently in storage area; \u2022 Label ID number or batch number and use date or expiry date;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Records of Investigational Product Disposition at Site"
        },
        {
            "text": "\u2022 Dates and initials of person responsible for each investigational product inventory entry/movement; \u2022 Amount dispensed to each participant, including unique participant identifiers;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Records of Investigational Product Disposition at Site"
        },
        {
            "text": "\u2022 Amount transferred to another area/site for dispensing or storage;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Records of Investigational Product Disposition at Site"
        },
        {
            "text": "\u2022 Amount returned to Sponsor;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Records of Investigational Product Disposition at Site"
        },
        {
            "text": "\u2022 Amount destroyed at study site, if applicable.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Records of Investigational Product Disposition at Site"
        },
        {
            "text": "Upon completion or termination of the study, all unused and/or partially used investigational product must be returned to GeneOne Life Science, Inc., or its designee, if not authorized by GeneOne Life Science, Inc. to be destroyed at the site.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Return and Destruction of Investigational Product"
        },
        {
            "text": "All investigational products returned to GeneOne Life Science, Inc., or its designee, must be accompanied by the appropriate documentation. Returned supplies should be in the original containers. Empty containers should not be returned to GeneOne Life Science, Inc. It is the Investigator's responsibility to arrange for disposal for all empty containers, provided that procedures for proper disposal have been established according to applicable federal, state, local and institutional guidelines and procedures, and provided that appropriate records of disposal are kept. The return of unused investigational product(s) should be arranged by the responsible Study Monitor.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Return and Destruction of Investigational Product"
        },
        {
            "text": "If investigational products are to be destroyed on site, it is the Investigator's responsibility to ensure that arrangements have been made for the disposal, written authorization has been granted by GeneOne Life Science, Inc., or its designee, procedures for proper disposal have been established according to applicable regulation and guidelines and institutional procedures, and appropriate records of the disposal have been documented. The unused investigational products can only be destroyed after being inspected and reconciled by the responsible GeneOne Life Science, Inc. or designated Study Monitor. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Return and Destruction of Investigational Product"
        },
        {
            "text": "The instructions for use of the CELLECTRA \uf6da device are located in the Operations Manual. Each clinical site will receive training for the use of the CELLECTRA \uf6da device. The following specifications will be used during the study:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Use of CELLECTRA \uf6da Electroporation Device"
        },
        {
            "text": "Number of pulses per treatment = 3 Maximum Current Strength = 0.5 Amperes Voltage Strength = 1 -200 Volts Electroporation pulse duration = 52 milliseconds/pulse Interval separating pulses = 1 second EP needle array length (injection depth) = 12 mm (with array guide in place) = 18 mm (without array guide)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Use of CELLECTRA \uf6da Electroporation Device"
        },
        {
            "text": "The vaccination/electroporation procedure will be performed by qualified personnel. Any licensed healthcare provider designated to perform the procedure must have the appropriate license to administer vaccinations or parenteral drugs to participants (e.g. MD, DO, RN, LPN). Additionally, those administering the vaccination will be trained by the manufacturer in the correct use of the CELLECTRA \u00ae 5P-IM electroporation device. All individuals designated to perform the EP procedure must satisfactorily complete device training from the sponsor or its designee regardless of qualifications. Any deviation from the above procedures must be approved by the sponsor or its designee.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Use of CELLECTRA \uf6da Electroporation Device"
        },
        {
            "text": "Each clinical site is responsible for maintaining investigational device accountability. This includes recording the CELLECTRA \u00ae serial number, applicator serial number, and array lot number used for treatment/ EP of each participant.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Investigational Device Accountability"
        },
        {
            "text": "See Table S2 in the Clinical Protocol Synopsis for Schedule of Events showing study procedures and the times at which they are to be carried out.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 4,
                    "end": 12,
                    "text": "Table S2",
                    "ref_id": "TABREF2"
                }
            ],
            "section": "STUDY PROCEDURES AND TREATMENTS"
        },
        {
            "text": "The assessments during the screening phase will determine the participants' eligibility for the study and also their ability to comply with protocol requirements by completing all screening assessments. The following additional screening evaluations will be performed within 30 days prior to dosing on Day 0. All screening assessment values must be reviewed prior to study treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Screening Evaluations"
        },
        {
            "text": "\u2022 Signed informed consent, which may include consent for photography. If consented, injection sites may be photographed in the event of unusual or high-grade injection site reactions at the investigators discretion. (Section 6.5); \u2022 Review and confirm all inclusion/exclusion criteria (Sections 4.2, 4.3); \u2022 Collect demographics, including gender and ethnic origin;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Screening Evaluations"
        },
        {
            "text": "\u2022 Obtain complete medical history (including procedures history), present conditions and concomitant illnesses (Section 6.1.5); \u2022 Record concomitant medications/treatments at present and in past 8 weeks; GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Screening Evaluations"
        },
        {
            "text": "Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Screening Evaluations"
        },
        {
            "text": "Date:13Nov2017 v10.0 -37-\u2022 Record vital signs including body weight and height, heart rate (HR), blood pressure (BP), respiration rate and oral temperature (Section 6.1.6.3); \u2022 Collect blood for CBC with differential, blood chemistry [Sodium (Na), potassium (K), chloride (Cl), bicarbonate (HCO3), glucose, BUN, creatinine, AST, ALT, CPK (Section 6.1.6.6)]; \u2022 Collect blood for serologic assessment of HIV, Hepatitis B surface antigen (HBsAg), and Hepatitis C antibody (HCV) \u2022 Serum pregnancy test (Section 6.1.6.6); \u2022 12 lead ECG (Section 6.1.6.5); \u2022 Physical Exam (Section 6.1.6.2); and \u2022 Determine proposed site of injection(s) Potential participants will be notified of their eligibility as soon as all lab results are available and an assessment can be made by the investigators. If determined to be eligible, participants will be scheduled for their initial vaccination (Day 0, Visit 1). Regardless of eligibility and enrollment, individuals will be informed at screening and any follow up visits of any significantly abnormal test results in an expeditious manner, via telephone, in person or by written communication. Appropriate counseling will be given regarding necessary medical follow-up. Information on individuals with evidence of reportable infectious diseases (eg, HIV and hepatitis) will be transmitted to the required military and/or civilian public health authorities as applicable. Potential participants will be notified of this possibility during their informed consent process.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Screening Evaluations"
        },
        {
            "text": "The following procedures will be performed at vaccination visits.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vaccine Administration Visits (weeks 0, 4, 12)"
        },
        {
            "text": "The following study evaluations will be performed prior to dosing:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vaccine Administration Visits (weeks 0, 4, 12)"
        },
        {
            "text": "\u2022 Review of medical history from screening \u2022 Concomitant medications/treatments; \u2022 Vital signs \u2022 Urine pregnancy test, if applicable \u2022 Collect whole blood (at week 4 this will only occur for the final 7 participants assigned to each dose group [i.e. 0.67 mg/dose, 2 mg/dose, 6 mg/dose]) and serum (all participants at all visits regardless of dose group) for immune assessment. If PBMCs are to be shipped to Sponsor for processing, then collection should be planned for Monday thru Friday. Blood must be received in PBMC processing lab within 24 hours of collection. (Shipment of samples to Sponsor on a Friday requires prior approval from the Sponsor and PBMC processing lab)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vaccine Administration Visits (weeks 0, 4, 12)"
        },
        {
            "text": "\u2022 Administer study treatment followed by EP",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vaccine Administration Visits (weeks 0, 4, 12)"
        },
        {
            "text": "The following study evaluations will be performed post dose:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vaccine Administration Visits (weeks 0, 4, 12)"
        },
        {
            "text": "\u2022 Pain assessment minimum of 30 minutes after EP;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vaccine Administration Visits (weeks 0, 4, 12)"
        },
        {
            "text": "\u2022 Injection site reaction assessment a minimum of 30 minutes after vaccination;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vaccine Administration Visits (weeks 0, 4, 12)"
        },
        {
            "text": "\u2022 Targeted physical assessment, including vital signs a minimum of 30 minutes after vaccination \u2022 Adverse and Serious adverse event assessment;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vaccine Administration Visits (weeks 0, 4, 12)"
        },
        {
            "text": "\u2022 Distribute Participant Reminder Diary;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vaccine Administration Visits (weeks 0, 4, 12)"
        },
        {
            "text": "\u2022 Download EP data from device within 48 hours following treatment onto a USB storage device and forward to GeneOne Life Science or its designee",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vaccine Administration Visits (weeks 0, 4, 12)"
        },
        {
            "text": "GLS-5300 GeneOne Life Science, Inc. Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Telephone assessment (Day 1 post 1 st vaccination)"
        },
        {
            "text": "The following procedures will be performed the day following the 1 st vaccination:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Telephone assessment (Day 1 post 1 st vaccination)"
        },
        {
            "text": "\u2022 Contact the study participant by phone \u2022 Local and systemic injection site review; \u2022 Adverse and Serious adverse event assessment;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Telephone assessment (Day 1 post 1 st vaccination)"
        },
        {
            "text": "Visits (Week 1)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.3"
        },
        {
            "text": "The following procedures will be performed during the Safety Visit 1 week after the 1 st injection:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.3"
        },
        {
            "text": "\u2022 Concomitant medications/treatments; \u2022 Vital signs; \u2022 Targeted physical assessment;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.3"
        },
        {
            "text": "\u2022 Local and systemic injection site review;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.3"
        },
        {
            "text": "\u2022 Adverse and Serious adverse event assessment;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.3"
        },
        {
            "text": "\u2022 Collect blood for safety laboratory assessment (CBC, serum chemistries, CPK)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.3"
        },
        {
            "text": "\u2022 Collect whole blood (only first 6 participants assigned to each dose group) and serum (all study participants) for immune assessment as indicated; \u2022 Review Participant Reminder Diary.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.3"
        },
        {
            "text": "The following procedures will be performed during the Interval Assessment Visits 2 weeks or 3 weeks following the 1 st vaccination:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Visits (Week 2 or 3)"
        },
        {
            "text": "\u2022 Participants with an EVEN PID# will be assessed at Week 2 post 1 st dose \u2022 Participants with an ODD PID# will be assessed at Week 3 post 1 st dose \u2022 Vital signs; \u2022 Targeted physical assessment;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Visits (Week 2 or 3)"
        },
        {
            "text": "\u2022 Concomitant medications/treatments; \u2022 Local and systemic injection site review;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Visits (Week 2 or 3)"
        },
        {
            "text": "\u2022 Adverse and Serious adverse event assessment;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Visits (Week 2 or 3)"
        },
        {
            "text": "\u2022 Collect whole blood (only the 7 th through 18 th participants in each dose group) and serum (all study participants) for immune assessment as indicated (based on whether the participant is assigned an EVEN or ODD PID as indicated in the first two bullet points of this section).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Visits (Week 2 or 3)"
        },
        {
            "text": "The following procedures will be performed during the Interval Assessment Visits 2 weeks after each injection (weeks 6 and 14) and at 3 and 6 months after the final vaccination (weeks 24 and 36) as below:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Visits (Weeks 6, 14, 24, 36)"
        },
        {
            "text": "\u2022 Concomitant medications/treatments; \u2022 Vital signs;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Visits (Weeks 6, 14, 24, 36)"
        },
        {
            "text": "\u2022 Targeted physical assessment \u2022 Local and systemic injection site review (only at weeks 6 and 14);",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Visits (Weeks 6, 14, 24, 36)"
        },
        {
            "text": "\u2022 Adverse and Serious adverse event assessment;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Visits (Weeks 6, 14, 24, 36)"
        },
        {
            "text": "\u2022 Collect blood for safety laboratory assessment (CBC, serum chemistries, CPK) (weeks 6 and 14 only) \u2022 Collect whole blood and serum for immune assessment as indicated; ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Visits (Weeks 6, 14, 24, 36)"
        },
        {
            "text": "Weeks 8 and 16",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.6"
        },
        {
            "text": "The following procedures will be performed the day following the 1 st vaccination:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.6"
        },
        {
            "text": "\u2022 Contact the study participant (either by phone or in person);",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.6"
        },
        {
            "text": "\u2022 Local and systemic injection site review;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.6"
        },
        {
            "text": "\u2022 Adverse and Serious adverse event assessment;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "6.1.2.6"
        },
        {
            "text": "The following procedures will be performed 12 months after the end of treatment (week 60 visit):",
            "cite_spans": [],
            "ref_spans": [],
            "section": "End of Study Visit (Week 60)"
        },
        {
            "text": "\u2022 Concomitant medications/treatments; \u2022 Vital signs;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "End of Study Visit (Week 60)"
        },
        {
            "text": "\u2022 Targeted physical exam;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "End of Study Visit (Week 60)"
        },
        {
            "text": "\u2022 Urine Pregnancy test, if applicable; \u2022 Adverse event assessment;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "End of Study Visit (Week 60)"
        },
        {
            "text": "\u2022 Collect whole blood and serum for immune assessment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "End of Study Visit (Week 60)"
        },
        {
            "text": "Participants may refuse further vaccinations and/or terminate participation in the study at any time.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Premature Withdrawal"
        },
        {
            "text": "In the event a participant decides to terminate participation prematurely, efforts should be made to perform all study assessments. Participants may also discontinue participation in the study or have their participation discontinued by the principal investigator if safety and/or tolerability issues are considered intolerable and/or not manageable with symptomatic treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Premature Withdrawal"
        },
        {
            "text": "At a minimum, all assessments from the Week 14 visit should be performed prior to withdrawal if not already completed.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Premature Withdrawal"
        },
        {
            "text": "In the case of a fatal outcome, all relevant information (including cause of death, concomitant medication, and relationship to study treatment or underlying disease) will be collected.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Premature Withdrawal"
        },
        {
            "text": "Any participant who withdraws consent will not have any further data collected after consent has been withdrawn. However, data and samples that were collected prior to a participant's withdrawal of consent will be included in the data analysis, unless otherwise specified by the participant.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Premature Withdrawal"
        },
        {
            "text": "All potential participants will be given a formal briefing at the WRAIR CTC by an investigator. This briefing, which generally lasts about an hour, will describe the rationale for and key features of the study, the nature and extent of participant participation, inclusion/exclusion criteria, and potential risks and/or benefits to the participant and allow opportunity for potential participants to ask and have addressed any questions or concerns they might have regarding the study. This briefing will involve a combination of standardized presentation materials (e.g. briefing slides) and spontaneous interaction between investigator and potential participants. Any standardized materials will have been approved by the WRAIR IRB prior to their use.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "Following the formal briefing and prior to undertaking any study procedure, signed informed consent for study participation and use of some collected blood for future research will be obtained from each potential participant in accordance with applicable US Army and federal regulations, utilizing IRB-approved materials. A specific State of Maryland consent for HIV testing and consent for photographs will be obtained at the same time. Participants will also be required to sign a copy of the \"Information Sheet Regarding Compensation to Federal Personnel When They Participate GLS-5300 GeneOne Life Science, Inc. Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "Date:13Nov2017 v10.0 -40-in Research as Human Subjects\" to attest that they understand the compensation policies for federal employees as research participants. Potential participants will have the opportunity to ask and have answered any questions they might have about the study prior to giving consent.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "The original signed informed consent forms for each participant will be kept on file in a secure location by the investigator. Each potential participant will receive a copy of their signed and dated written informed consent document and any other written information provided to the participants.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "After completing informed consent, participants will provide a medical history and undergo physical examination, to include both ECG, and routine standard laboratory screening tests to include: complete blood count (CBC), serum basic metabolic panel (glucose, electrolytes, blood urea nitrogen [BUN] , creatinine [Cr], alanine aminotransferase [ALT], aspartate aminotransferase [AST]), , serum pregnancy screen (beta-human chorionic gonadotropin; females only), and viral serologies for hepatitis B and C, HIV, as well as for the viruses under study. Screening history, physical examination, and laboratory findings for all participants will be recorded on appropriate source documents. Participants found to be seropositive for HIV-1 or hepatitis B or C will be counseled and referred to their regular health care provider or public health clinic for further evaluation.",
            "cite_spans": [
                {
                    "start": 294,
                    "end": 299,
                    "text": "[BUN]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "If deemed appropriate by an investigator, any or all of the screening laboratories may be repeated once as necessary to allow an accurate determination of a potential participant's eligibility if the investigator feels that there may be a reason that the screening laboratories are abnormal due to lab error or normal physiologic variance. Individuals who have minor laboratory abnormalities (considered to be no more than a Grade 1 abnormality using the FDA toxicity scales), that are deemed to be clinically insignificant by the physician investigator, AND do not meet exclusion criteria otherwise defined, may be enrolled in the study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "Participants will be excluded from participation if they fail to meet any of the inclusion or exclusion criteria or have any other finding that in the opinion of an investigator would increase the risk of having an adverse outcome during the trial.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "Military participants will also need to submit a signed statement of supervisor's approval.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "All participants enrolled in the trial will receive an emergency contact ID card which can be used to contact the PI or AI in the event of an emergency, or to contact study staff for any other needs.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "Each participant must meet all inclusion and no exclusion criteria. The PI or designee will make the final decision of the eligibility. Only eligible participants will be given the investigational product. The participant will be informed that a description of this clinical trial will be available on http://www..gov, as required by US law.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "If participants are illiterate, administrators of the consent will read the IRB-approved informed consent to the subject in English. The participant can either provide a signature or personal marking (such as a thumb print). The administrators of the consent will then sign and date the form. A copy of the consent form will be filed in the participant's chart and a signed copy will be provided to the participant.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "As part of the ICF, participants will be asked to consent to be contacted at a later date for separate enrollment into a possible follow-on trial to determine whether an additional dose of vaccine can boost immune reactivity to 2-5 years post the completion of the initial vaccine series. Participant consent to be contacted for a later trial does not affect participation in the primary protocol nor does GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "Date:13Nov2017 v10.0 -41-it constitute consent for participation in any potential subsequent trial as a separate consent must be obtained. If they consent and there is a follow-on trial then participants will be contacted using the contact information they have provided during study enrollment, the same contact information that is used to contact participants during phone call visits. Participants will also be asked make every effort to update their contact information should it change.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent and Screening"
        },
        {
            "text": "Participants will be recruited sequentially and assigned to the three treatment groups based on when they screen. Recruitment will begin for the lowest dose group first and then proceed to the higher dose groups as each group is filled.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Participant Identification Number and Group Assignments"
        },
        {
            "text": "Participants will be enrolled sequentially at the lowest dose (Group 1), with continuous enrollment through the first week. At the start of the second week, safety labs will be reviewed for the first five participants from Group 1. Once those safety labs have been cleared, then the second dose level will be opened. The next five participants who meet eligibility criteria and consent to the study will be enrolled into Group 2. Additionally Group 1 enrollment will be completed to a total of 25 participants. When the first five participants in Group 2 have reached one week, safety labs will be reviewed as above. Once the safety assessment has been cleared, then Group 3 will be opened. The next five participants who meet eligibility criteria will be enrolled into Group 3. Then Group 2 enrollment will be completed followed by Group 3.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Participant Identification Number and Group Assignments"
        },
        {
            "text": "Each participant who consents will be assigned a unique participant identification designation number (PID#), which identifies the participant for all study-related procedures. Screening numbers are a combination of protocol designation plus a 4-digit subject number starting with 1001. Once assigned, PID numbers cannot be reused for any reason. A copy of the signed and dated consent form will be given to the participant. Information regarding the participant's PID# and screening date will be documented on a screening log.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Participant Identification Number and Group Assignments"
        },
        {
            "text": "When a participant has been deemed eligible by criteria listed in protocol Section 4 -Selection and Enrollment of Participants, the clinical site will contact the Sponsor to register the participant and provide the required eligibility information.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Participant Identification Number and Group Assignments"
        },
        {
            "text": "Investigators should document all significant illnesses that the participant has experienced as Medical History. Illnesses' first occurring or detected during the study and/or worsening of an existing illness that occurs after the first vaccination is to be documented as an AE on the CRF. Prior treatments, defined as administered up to 8 weeks prior to the time of informed consent, will be recorded in the CRF as prior medications. Concomitant treatments, defined as continuing or new treatments taken at or after the signing of the informed consent, will be recorded in the CRF as concomitant medications.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical History"
        },
        {
            "text": "The following participant evaluations for safety will be performed.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety Assessments"
        },
        {
            "text": "Participants will record any post treatment reactions (local and systemic) and enter this information in a post-vaccination memory aid (shown in Appendix A) on the evening of each dose and for 7 days post each dose. Local administration site reactions will be recorded using the supplied ruler (Appendix B). The study staff will review the memory aid; the reported events will be assessed for clinical significance and recorded on the CRFs as appropriate. Although the memory aids may be GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Participant self-evaluations"
        },
        {
            "text": "Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Participant self-evaluations"
        },
        {
            "text": "Date:13Nov2017 v10.0 -42-collected from participants and the conclusion of that study visit, they do not necessarily have to be collected as they are not diaries to be used as source documents.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Participant self-evaluations"
        },
        {
            "text": "Study staff should evaluate each unique memory aid entry according to \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\", issued in September 2007 (Appendix B). Any reminder diary entry determined to meet the criteria for a Grade 1 or higher adverse event must be documented as an adverse event. If the reminder diary entry does not meet the criteria of a Grade 1 or higher AE as per the toxicity grading scale, clinical judgment can be used to determine whether the entry should be recorded as an AE. For cases where the reminder diary entry and final AE reporting (i.e., grading) do not agree, the reasoning must be recorded in the source documents.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Participant self-evaluations"
        },
        {
            "text": "A full physical examination will be conducted at screening. A targeted physical assessment will be performed at other visits as determined by the Investigator or directed per participant complaints. The injection site is to be assessed by the study personnel a minimum of 30 minutes after EP, as well as at the follow up visits.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Physical Assessments and Targeted Physical Assessment"
        },
        {
            "text": "Vital signs including oral temperature, respiration rate, blood pressure and heart rate will be measured at specified visits.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vital Signs"
        },
        {
            "text": "Weight (lb) and height (in) will be collected at specified visits.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Weight and Height"
        },
        {
            "text": "An ECG will be performed at screening for all participants to determine eligibility. The ECG should include measurements of ventricular rate, PR, QRS, QT, QTc with assessment as to whether the ECG is normal or abnormal. Abnormal ECGs will be interpreted as clinically significant or not clinically significant. Dosing will be delayed in the event of a clinically significant abnormal predose ECG until it has been reviewed by the PI, qualified PI designee, Medical Monitor or Sponsor consultant cardiologist and deemed safe to proceed.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "12-Lead ECGs"
        },
        {
            "text": "At screening, Week 1, Week 6, and Week 14 blood samples will be taken to be tested for serum chemistry and hematology. Approximately 771 mL of blood will be drawn from each participant during the entire duration of the study. For female participants of reproductive potential, a serum pregnancy test will be obtained at screening. A negative result for urine \u03b2-HCG (test must have a sensitivity of at least 25 mIU/mL) must be available prior to each administration of vaccine. If the \u03b2-HCG test is positive indicating that the participant is pregnant prior to completing the prescribed regimen then additional doses of vaccine must not be given. Every attempt should be made to follow pregnant participants for the remainder of the study and to determine the outcome of the pregnancy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Laboratory Evaluations"
        },
        {
            "text": "Participants will be asked to participate in a substudy for which leukapheresis may be performed at selected time points in lieu of collection of blood for immune analysis. Participants will be asked to provide consent for this trial; participation and consent does not affect participation in the main study. Up to 5 participants may be selected for participation. Leukapheresis will be performed as per WRAIR protocol in lieu of collection of blood for immune assessment at weeks 14 and 24. This procedure will take approximately 1-3 hours for each participant.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MERS-001 substudy"
        },
        {
            "text": "Participants will be asked to participate in the substudy based on an interim analysis which will be conducted in a subset of volunteers (10 per dose group) at the week 6 visit to determine the five highest immune responders (as measured by neutralization antibody titers). The five individuals will then be recruited for the leukapheresis substudy. The next five highest responders will be recruited if the first five decline.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MERS-001 substudy"
        },
        {
            "text": "A total of 3 cohorts of participants will receive a 3-vaccination series.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Injection of Investigational Product followed by Electroporation"
        },
        {
            "text": "\u2022 Group 1 (n=25) will receive 0.67mg GLS-5300 given by IM injection followed by EP with CELLECTRA \u00ae -5P",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Injection of Investigational Product followed by Electroporation"
        },
        {
            "text": "\u2022 Group 2 (n=25) will receive 2mg GLS-5300 given by IM injection followed by EP with CELLECTRA \u00ae -5P",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Injection of Investigational Product followed by Electroporation"
        },
        {
            "text": "\u2022 Group 3 (n=25) will receive 6 mg GLS-5300 given by IM injection followed by EP with CELLECTRA \u00ae -5P",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Injection of Investigational Product followed by Electroporation"
        },
        {
            "text": "Vaccinations will be delivered IM into the deltoid followed immediately by EP. If the deltoid is not a suitable location, the IM injection should be in the lateral quadriceps followed immediately by EP (see Section 5.9 -Use of CELLECTRA \u00ae Electroporation Device). Vaccinations must not be given within 2 cm of a tattoo, scar, or active lesion/rash. The timing of the initial dose will be designated Day 0 with the subsequent doses scheduled for administration as per the Schedule of Events (Table S2 ). Within 48 hours following each Study Treatment, data should be downloaded from the EP device and the data file that is created should be sent to the Sponsor (GeneOne Life Science, Inc.) or designee by email.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 490,
                    "end": 499,
                    "text": "(Table S2",
                    "ref_id": "TABREF2"
                }
            ],
            "section": "Injection of Investigational Product followed by Electroporation"
        },
        {
            "text": "Management of anxiety and pain due to EP procedure Participants will be offered an analgesic (e.g. ibuprofen, acetaminophen, and EMLA cream) before and/or after injection/EP.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Injection of Investigational Product followed by Electroporation"
        },
        {
            "text": "Participants who are allergic to or have contraindications ibuprofen or acetaminophen may be offered a suitable alternative.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Injection of Investigational Product followed by Electroporation"
        },
        {
            "text": "Blood will be drawn for serum chemistries and hematology assessments at the visits listed in the Schedule of Events, (Table S2 ) and as listed in Section 6.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 117,
                    "end": 126,
                    "text": "(Table S2",
                    "ref_id": "TABREF2"
                }
            ],
            "section": "Assessment of Laboratory Abnormalities"
        },
        {
            "text": "Laboratory AEs will be assessed and graded. See Section 7.1.8 for details. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Assessment of Laboratory Abnormalities"
        },
        {
            "text": "The injection site will be assessed by study personnel prior to and within a minimum of 30 minutes after injection/EP. Participants will be given an oral thermometer and instructed to take and record their oral temperature daily (at the same time each day). They will also be advised to record local and systemic events for 6 days after vaccination in a Post Vaccination Diary (Appendix A).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Assessment of Clinical Adverse Events"
        },
        {
            "text": "Participants will also be queried regarding the occurrence of any adverse events, concomitant medications and new onset chronic disease during their clinic visits. Participants will be reminded to contact study personnel and immediately report any event that may happen for the duration of the study up to and including the final study visit. These events will be recorded on the participant's CRF.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Assessment of Clinical Adverse Events"
        },
        {
            "text": "The Study Treatment procedure consists of insertion of the CELLECTRA \uf6da electroporation array needles (electrodes) through the skin and into the underlying muscle, and intramuscular of the study drug(s) followed by delivery of the electroporation pulses. This procedure is broadly described as administration because it involves more than the injection of a drug. Attributing any reaction (e.g. pain, erythema, and swelling) that is observed at or near the site of the Study Treatment procedure to injection of the study drug(s) versus administration of the electroporation pulses will be difficult and is not necessary. Consequently, reactions arising from the Study Treatment procedure may be reported as administration site or injection site reactions. When evaluating administration (injection) site reactions throughout the study, it is most important to be as specific as possible by selecting the most appropriate term (see components below) and use the grading scale as outlined in Appendix B. The following observations, including grade of severity, will be recorded on the CRF:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Assessment of Injection Site Reactions"
        },
        {
            "text": "\u2022 Time of occurrence relative to dose (e.g., immediately after, 1 day after dose, etc.) \u2022 Resolution date",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Assessment of Injection Site Reactions"
        },
        {
            "text": "Currently, the correlate of immunity for MERS CoV is not entirely defined. It is clear that most neutralizing antibodies are directed against the surface Spike glycoprotein with particular immunologic focus at the receptor-binding domain in the S1 subunit. However, additional targets of humoral and cellular immunity are still to be defined. Thus immunogenicity assessments will not only measure known correlates (S neutralizing antibodies) but evaluate other potential mechanisms of immune response as well.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Laboratory Assays"
        },
        {
            "text": "All blood specimens will be collected at the WRAIR CTC and processed by the US Military HIV Research Program (MHRP) in the laboratories of Dr. Mark Manak and Dr. Sheila Peel. Specimens for analysis of primary and secondary immunologic endpoints will be shipped to a specimen repository at the ACTG laboratory at the University of Pennsylvania. Additional specimens for exploratory endpoints will be retained at the MHRP. Specimens at the University of Pennsylvania GLS-5300 GeneOne Life Science, Inc. Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Laboratory Assays"
        },
        {
            "text": "Date:13Nov2017 v10.0 -45-will be sent in batched shipments to the laboratory of Dr. Gary Kobinger, in Quebec, Canada where they will undergo analysis for primary and secondary endpoints. A division of labor for the laboratory assays is provided in the table below. All specimens for primary and secondary analysis will be destroyed after these analyses have been completed. Specimens for exploratory endpoint analysis will be retained at the MHRP indefinitely.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Laboratory Assays"
        },
        {
            "text": "Dr. Gordon Joyce, Dr. Shelly Krebsand their laboratories will be isolating and characterizing monoclonal antibodies from vaccinees who had high virus neutralizing and antigen binding antibody responses. They will also screen serum from vaccinees to in competition binding studies to better characterize the epitopes to which vaccine-elicited antibodies are directed against. Dr. Joyce's and Dr. Krebs's laboratorieswill carry out structural studies on isolated antibodies to resolve, at an atomic scale, the antigen-antibody complexes and how their structural relationship correlates to functional responses. ). Samples will be scored as positive if the average OD is greater than 0.15 absorbance units and greater than the average OD before immunization plus 2.5 times the standard deviation (SD) of the OD before immunization at the same dilution. Results will be presented as end-point titer, i.e. the last dilution where the OD value of a sample meets the above criteria.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Laboratory Assays"
        },
        {
            "text": "A second ELISA platform will be used as a comparator on volunteer serum and will be performed in the laboratory of David Weiner at the Wistar Institute. Briefly, plates are coated with 1ug/ml of full length MERS spike protein. After blocking and washing, pre-and post-immunization sera from each individual is diluted to a single dilution and incubated at 37 o C for 1hr. Positive controls GLS-5300 GeneOne Life Science, Inc. Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Laboratory Assays"
        },
        {
            "text": "Date:13Nov2017 v10.0 -46-consisting of vaccinated non-human primate sera and a negative control are included in each run and each sample is run in triplicate. After washing, an HRP-conjugated anti-human-IgG secondary antibody are incubated at room temperature for 1hr. After washing, signal is developed with SigmaFast OPD substrate, then stopped with 1N H2SO4. OD450 values are read on a Synergy 2 microplate reader. Positive post-immunization samples will be identified as those with an OD450 above the corresponding cut-off value determined from seronegative samples, and must be at least 2.5 SD above the OD450 of pre-immunization baseline samples and 2.5 SD above the background control wells. The cut-off value is set as the upper 95% confidence interval of the OD450 of pooled seronegative sera.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Laboratory Assays"
        },
        {
            "text": "The serum samples tested on the above ELISA platform at the Wistar Insitute will also be evaluated for quantitative endpoint binding titers. In brief, OD450 values are read on a Synergy 2 microplate reader. An endpoint dilution for each individual is identified as the reciprocal of the highest dilution where the OD450 is above the corresponding cut-off value determined from seronegative samples, and must be at least 2.5 SD above the OD450 of pre-immunization baseline samples and 2.5 SD above the background control wells.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Laboratory Assays"
        },
        {
            "text": "All samples tested by ELISA at the Wistar Institute will also be evaluated qualitatively for MERS CoV S protein binding by Western Blot. Positive post-immunization samples are identified by the presence of an antigen specific band of the expected 160 kDa size.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Research Laboratory Assays"
        },
        {
            "text": "Neutralizing antibodies against MERS CoV will be performed in the laboratory of Dr. Gary Kobinger as previously described to determine TCID50 (Muthumanni 2015 Sci Trans Med). Sera from immunized participants will be mixed with 100 infectious particles MERS CoV EMC/2012 and overlaid onto a monolayer of Vero cells. The titer of neutralizing antibody is reported as the reciprocal of the highest dilution for which less than 50% of the cells show cytopathic effects. Pseudovirus assays will be used to determine the breadth of response as described previously (Muthumanni 2015 Sci Transl Med)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Neutralizing Antibodies"
        },
        {
            "text": "The number of antigen-specific IFN-\u03b3 secreting spot forming units (SFU) will be determined in the laboratory of Dr. David Weiner by IFN-\u03b3 ELISpot assays in response to stimulation with MERS CoV peptides using 15-mer peptides overlapping by 11 amino acids spanning the entire S protein (GenScript) as described (Muthumanni 2015 Science). Briefly, PBMCs will be thawed and plated at 200,000 cells/well. Cells will be incubated with MERS CoV peptides, incubated overnight, and IFN-\u03b3 release detected using standard procedures. The average number of SFU counted in media control wells will be subtracted from the average in individual MERS CoV peptide wells and then adjusted to 1x10 6 PBMCs for each MERS CoV peptide pool.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "ELISpot"
        },
        {
            "text": "Flow cytometric assays will include an examination of the influence of vaccination on the ability of participant T cells to exhibit phenotypic markers associated with cytolytic potential after shortterm stimulation by MERS CoV (hereafter referred to as \"CTL Phenotyping\"), the ability of participant T cells to remain active in the presence of long-term antigen exposure and efficiently synthesize proteins used in lytic activity (hereafter referred to as \"Lytic Granule Loading\"), and the ability of participant T cells to effectively employ Granzyme B for the purposes of lytic GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Flow Cytometry"
        },
        {
            "text": "Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Flow Cytometry"
        },
        {
            "text": "Date:13Nov2017 v10.0 -47-degranulation and killing of target cells expressing the S antigen (hereafter referred to as \"Killing\"). These panels may vary as new information becomes available. CTL Phenotyping will be prioritized while Lytic Granule Loading and Killing will only be run if sufficient participant samples are present.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Flow Cytometry"
        },
        {
            "text": "(i)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Flow Cytometry"
        },
        {
            "text": "The assay for CTL Phenotyping will employ a 6-hour in vitro stimulation of unfractionated participant PBMCs using peptides spanning the S glycoprotein as described above along with a positive control (Staphylococcal enterotoxin B or a combination of phorbol 12myristate 13-acetate and Ionomycin). The CTL Phenotyping assay will examine the following external cellular markers: CD3, CD4, CD8 (T-cell identification); CD45RO, CCR7 (memory subset identification); CD107a (marker of lytic degranulation). The CTL Phenotyping assay will additionally analyze the following intracellular markers: interferon gamma (IFN-\u03b3, Th1 biasing cytokine), tumor necrosis factor alpha (TNF-\u03b1), Granzyme A, Granzyme B, and perforin (proteins involved in lytic degranulation and cytotoxic potential). The markers evaluated in this assay may change as new relevant data become available.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Flow Cytometry"
        },
        {
            "text": "(ii) The Lytic Granule Loading assay will employ a 120-hour in vitro stimulation of unfractionated participant PMBCs using peptides spanning the MERS S protein, an irrelevant peptide control (OVA), and a positive control (concanavalin A). The Lytic Granule Loading assay will examine the following external cellular markers: CD3, CD4, CD8 (T cell identification); and CD137 (also known as 41BB, marker of T cell activation). The Lytic Granule Loading assay will additionally analyze the following intracellular markers: Granzyme A, Granzyme B, Granulysin, and Perforin (proteins involved in cytotoxic potential). The markers evaluated in this assay may change as new relevant data become available.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Flow Cytometry"
        },
        {
            "text": "(iii)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Flow Cytometry"
        },
        {
            "text": "The Killing assay will employ 120-hour in vitro stimulation of unfractionated PBMC using peptides spanning the MERS S protein. Stimulated whole PBMC or CD8 + T-cells isolated after 120-hours will be co-incubated for 60 minutes with target cells that have received a stain that differentiates them from participant PBMC/CD8 + T-cells and have additionally been pulsed with a reagent which is activated upon cleavage of terminal caspases. Target cells are identified using a stain and analyzed for the presence of cleaved caspase activity in targets as a measure of functional cytolytic degranulation and killing. Employment of this assay may change pending readouts from the Lytic Granule Loading assay. The markers evaluated in this assay may change as new relevant data become available.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Flow Cytometry"
        },
        {
            "text": "Leukapheresis provides a mechanism for collecting large numbers of leukocytes for better characterization of host immunity without drawing off other essential fractions of participants' blood (i.e. red blood cells, clotting factors). Leukapheresis is essentially a special type of plasmapheresis in which the component of plasma that are being drawn off from the blood for processing and storage are white blood cells with single nuclei circulating in the peripheral blood (peripheral blood mononuclear cells). Because these collected cells of interest are leukocytes, the procedure is termed leukapheresis. The purpose of collecting additional leukocytes is to better understand T and B cell immunity, through phenotyping DNA and RNA sequencing and transcriptomics, and array analysis, in response to vaccination. This additional analysis would be limited by small volume blood draws.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Leukapheresis"
        },
        {
            "text": "At the week 14 and 24 visits, in lieu of peripheral blood phlebotomy, a subset of volunteers (5) will have the option of undergoing apheresis to collect plasma and PBMCs and plasma. Leukocytes GLS-5300 GeneOne Life Science, Inc. Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Leukapheresis"
        },
        {
            "text": "Date:13Nov2017 v10.0 -48-and plasma will be obtained using automated apheresis techniques conducted by a qualified apheresis nurse/technician. During apheresis, whole blood is withdrawn through a catheter placed in an antecubital vein and channeled into a cell separator where cellular and plasma fractions are separated by centrifugation. The component to be harvested (i.e. leukocytes) will be directed into a collection bag while the erythrocytes, platelets, and plasma components not of interest (e.g. immunoglobulins, clotting factors, albumin) are returned to the donor. The return is accomplished through a second needle placed at another site, usually in the other antecubital vein. Approximately 120-150ml of peripheral blood mononuclear cells will be targeted for collection. Approximately 50 mL of red blood cell volume may be lost as residual loss in the machine during the procedure. Those volunteers who undergo leukapheresis will be exempted from the storage and additional testing blood draw scheduled at the same visit. Leukapheresis will not be performed on participants with platelet counts <150,000 or with hemoglobin < 12.0 mg/dL.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Leukapheresis"
        },
        {
            "text": "As part of potential exploratory objectives, B lymphocytes specific for epitopes on the MERS CoV spike protein will be sorted by flow cytometry. Neutralizing and non-neutralizing antibodies will be screened and expressed. Resolution of antibody structures in complex with the S protein may be resolved. Non-neutralizing antibody functional assays may include antibody-dependent cellmediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), antibody-dependent cell-mediated viral inhibition (ADCVI), and viral capture.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Antibody Characterization"
        },
        {
            "text": "Host immune-genotyping will be performed as resources are made available. Investigators will perform targeted analyses of genetic polymorphisms within host genes that may influence immune response to vaccination. Targeted genes involved in humoral and cell-mediated immune responses will include Fc\u03b3 receptors, capable of binding diverse immunoglobulin isotypes; and the alleles comprising Class I HLA-A, -B, and -C loci, respectively. HLA typing procedures that will be used in this study have yet to be validated for clinical use but represent essential research tools for the analyses of adaptive immune responses to vaccination. HLA typing data will be unlinked from personal identifiers, and reported in aggregate for the populations studied.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Host Genetics"
        },
        {
            "text": "Biological samples such as serum, plasma, PBMCs, whole blood, will be stored in a qualitycontrolled environment. Transport and storage of these biological samples will be handled according to GLP standards. Any future use of these biological samples that are not specified in the protocol will require additional IRB review and approval. Future use will be for any type of research. Biological samples such as serum, plasma, PBMCs, whole blood, remaining after all assays described in this protocol have been completed will be bar coded and archived using electronic specimen storage and tracking system. PBMCs will be stored at -125C or lower and plasma/sera will be stored at -70C or lower. Samples will be archived in the MHRP Specimen Processing Lab and Repository (SPL) in Rockville, Maryland and the University of Pennsylvania Specimen Processing Laboratory in Philadelphia Pennsylvania indefinitely. The Principal Investigator and the Sponsor and authorized regulatory bodies may have access to the data regarding the archived specimens.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Future Use of Specimens"
        },
        {
            "text": "Participants will not be considered eligible to participate unless they consent to have their specimens stored for future use. Although the results of this research, including donated specimens, may be patentable or have commercial value, Participants will have no legal or financial interest in any commercial development resulting from the research Within 48 hours following each Study Treatment, data will be downloaded from the EP device onto a USB Storage Device and the device forwarded by Courier or Express mail to the Sponsor (GeneOne Life Science, Inc.) or designee by email. Instructions on how to download the data and Sponsor contact information will be provided under a separate cover. Training will also be provided. Data contained in the download will be coded and unidentifiable. Data from the EP device will be downloaded to monitor and assess the function and any errors that may occur during use. Information will include impedance measurements and voltages generated and will be used for quality control and improvement of the device.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Future Use of Specimens"
        },
        {
            "text": "All medications taken or medical procedures performed within 8 weeks prior to enrollment and during the study that do not affect a participant's eligibility for participation (see Section 4.3 -Exclusion Criteria) must be recorded on the case report forms (CRFs). Dosage and frequency of immunosuppressive medications will also be recorded.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Concomitant Medications and Medical Procedures"
        },
        {
            "text": "Participants must not be vaccinated (e.g. influenza vaccine) or have had received polyclonal or monoclonal antibodies within 4 weeks of the first dose or 2 weeks before a subsequent dose of investigational product. Participants must not receive a course of systemic corticosteroids (\u226520 mg/day of prednisone or equivalent for 5 days) within 2 weeks before or after any dose of investigational product.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Restrictions"
        },
        {
            "text": "The safety of GLS-5300 will be measured and graded as outlined in Appendix B.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety Parameters"
        },
        {
            "text": "Throughout the course of the study, all AEs will be monitored and reported on an AE CRF, including the event's seriousness, severity, action taken, and relationship to study drug. If AEs occur, the first concern will be the safety of the study participants. AEs must be followed until resolution or stable and the outcome will be documented on the appropriate CRF. All AEs must be recorded in standard medical terminology rather than the participant's own words.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety Parameters"
        },
        {
            "text": "An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, or worsening of a pre-existing condition, temporally associated with the use of a product whether or not considered related to the use of the product. In this study, such changes will be monitored, classified, and summarized, as Clinical or Laboratory AEs. Medical condition/diseases present before starting the investigational drug will be considered adverse events only if they worsen after starting study treatment. An unexpected AE is one not identified in the Clinical Investigator's Brochure (CIB) or otherwise not expected from the characteristics of the clinical material.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse Events (AEs)"
        },
        {
            "text": "Study related AEs include the following:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse Events (AEs)"
        },
        {
            "text": "\u2022 Pre-or post-treatment complications that occur as a result of protocol mandated procedure during or after Screening (before the administration of study drug) \u2022 Any pre-existing condition that increases in severity, or changes in nature during or as a consequence of the study drug phase of a human clinical trial, will also be considered an AE \u2022 Complications and termination of pregnancy; see Section 7.1.9 for additional information \u2022 All AEs that occur from the study Day 0 visit onwards and throughout the duration of the study, including the follow-up off study drug period will be recorded as an AE performed; the condition that leads to the procedure is an AE \u2022 Pre-existing diseases or conditions or laboratory abnormalities present or detected before the first vaccination that do not worsen \u2022 Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for elective surgery, social and/or convenience admissions). \u2022 Overdose without clinical sequelae \u2022 Any medical condition or clinically significant laboratory abnormality with an onset date before the first vaccination and not related to a protocol associated procedure is not an AE. It is considered to be pre-existing and will be documented on the medical history CRF \u2022 Uncomplicated pregnancy \u2022 An induced elective abortion to terminate a pregnancy without medical reason",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse Events (AEs)"
        },
        {
            "text": "A serious adverse event (SAE) is any AE that meets one of the following conditions:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious Adverse Events (SAEs)"
        },
        {
            "text": "\u2022 Death during the period of surveillance defined by the protocol;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious Adverse Events (SAEs)"
        },
        {
            "text": "\u2022 Is immediately life-threatening (e.g., participant was, in the view of the Investigator, at immediate risk of death from the event as it occurred). This does not include an AE that, had it occurred in a more serious form, might have caused death; \u2022 An event requiring in participant hospitalization or prolongation of existing hospitalization during the period of protocol defined surveillance (including any overnight stay in the hospital, regardless of the length of stay, even if the hospitalization is only a precautionary measure to allow continued observation. However, hospitalization (including hospitalization for an elective procedure) for continued treatment or assessment of a pre-existing condition that has not worsened does not constitute an SAE. Evaluation in a non-admitted status such as overnight or overday observation, emergency department or urgent care setting, or in an office setting does not constitute an SAE; \u2022 Results in congenital anomaly or birth defect; \u2022 Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; \u2022 Is an important medical event that may not result in death, be life threatening, or require hospitalization, but based upon appropriate medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in in participant hospitalization, or the development of drug dependency or drug abuse; development of malignancies; \u2022 Is medically significant or requires intervention to prevent one or other of the outcomes listed above.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious Adverse Events (SAEs)"
        },
        {
            "text": "\u2022 Death is an outcome of an AE, and not an adverse event in itself",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Clarification of Serious Adverse Events"
        },
        {
            "text": "\u2022 The participant may not have been on investigational medicinal product at the occurrence of the event. Dosing may have been given as treatment cycles or interrupted temporarily before the onset of the SAE, but may have contributed to the event. \u2022 Inpatient hospitalization means that the participant has been formally admitted to a hospital for medical reasons, for any length of time. This may or may not be overnight. Observation status or evaluation in an emergency department, urgent care setting, or out-patient office does not constitute an SAE.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Clarification of Serious Adverse Events"
        },
        {
            "text": "\u2022 The investigator will attempt to establish a diagnosis of the event on the basis of signs, symptoms, and/or other clinical information. In such cases, the diagnosis will be documented as the AE and/or SAE and not the individual signs/symptoms.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Clarification of Serious Adverse Events"
        },
        {
            "text": "Serious adverse events that are ongoing should be followed until resolution. The reporting period for SAEs is described in Section 9.7.2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Clarification of Serious Adverse Events"
        },
        {
            "text": "A medically attended adverse event (MAAE) is defined as an adverse event that leads to an unplanned contact with a health care provider.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medically Attended Adverse Events (MAAE)"
        },
        {
            "text": "An unexpected adverse drug reaction (ADR) is a reaction for which the nature or severity is not consistent with the applicable product information (Investigator's Brochure). Until product information is amended, expedited reporting is required for additional occurrences of the reaction.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unexpected Adverse Drug Reactions"
        },
        {
            "text": "Reports that add significant information on specificity or severity of a known, already documented SAE constitute unexpected events. For example, an event more specific or more severe than described in the Investigator's Brochure would be considered \"unexpected.\" Specific examples would be (a) acute renal failure as a labeled ADR with a subsequent new report of interstitial nephritis and (b) hepatitis with a first report of fulminant hepatitis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unexpected Adverse Drug Reactions"
        },
        {
            "text": "An unexpected adverse device event (UADE) is any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application, or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unanticipated Adverse Device Events"
        },
        {
            "text": "Reports of UADEs will be sent to the Sponsor within 10 working days of becoming aware of the event. UADEs will be reported to the WRAIR IRB as expedited reports, as noted in Section 7.4, below.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unanticipated Adverse Device Events"
        },
        {
            "text": "The investigator will grade laboratory AEs and clinical AEs (based on discussions with study participants) as outlined in Appendix B.:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Assessing Severity (Intensity)"
        },
        {
            "text": "\u2022 Mild (Grade 1) Adverse events will be captured on the CRF at the maximum severity reported.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Assessing Severity (Intensity)"
        },
        {
            "text": "A causally related AE is one judged to have a suspected relationship to the administration of the clinical material (GLS-5300), and the investigational CELLECTRA \u00ae device. An AE may also be assessed as not related to the investigational product. The Principal Investigator, with the assistance of the DoD Research Monitor as needed, is responsible for reporting adverse events and judging the relationship between the administration of the clinical material and a subsequent AE because the investigator is knowledgeable about the participant (e.g., medical history, concomitant medications), administers the investigational product, and monitors the participant's response to the investigational product. The Investigator is aware of the participant's clinical state and thus may be sensitive to distinctions between events due to the underlying disease process versus events that may be product related and may have observed the event. The Sponsor will assess the overall safety of the investigational product and determine whether to report expeditiously to the regulatory agencies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Causal Relationship of Clinical Material to Adverse Events"
        },
        {
            "text": "The investigator must assign a relationship of each AE to the receipt of the investigational product. The investigator will use clinical judgment in conjunction with the assessment of a plausible biologic mechanism, a temporal relationship between the onset of the event in relation to receipt of the investigational product, and identification of possible alternate etiologies including underlying disease, concurrent illness or concomitant medications. The following guidelines should be used by investigators to assess the relationship of an AE to study product administration. ONLY A PHYSICIAN CAN MAKE THIS DETERMINATION.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Relationship to Investigational Product"
        },
        {
            "text": "No relationship to investigational product. Applies to those events for which evidence exists that there is an alternate etiology. Unlikely:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Not related:"
        },
        {
            "text": "Likely unrelated to the investigational product. Likely to be related to factors other than investigational product, but cannot be ruled out with certainty. Possible:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Not related:"
        },
        {
            "text": "An association between the event and the administration of investigational product cannot be ruled out. There is a reasonable temporal association, but there may also be an alternative etiology such as the subject's clinical status or underlying factors including other therapy. Probable:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Not related:"
        },
        {
            "text": "There is a high degree of certainty that a relationship to the investigational product exists. There is a reasonable temporal association, and the event cannot be explained by known characteristics of the subject's clinical state or factors including other therapy. Definite:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Not related:"
        },
        {
            "text": "An association exists between the receipt of investigational product and the event. An association to other factors has been ruled out.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Not related:"
        },
        {
            "text": "Laboratory, physical exam, or EKG abnormalities are usually not recorded as AEs or SAEs. However, clinical, EKG or laboratory abnormalities (e.g., serum chemistry, CBC, CPK) independent of the underlying medical condition that require medical or surgical intervention or lead to investigational medicinal product interruption or discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, laboratory or other abnormal assessments (e.g., electrocardiogram, x-rays, vital signs) that are associated with signs and/or symptoms must be GLS-5300 GeneOne Life Science, Inc. Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abnormal Evaluation or Laboratory Value"
        },
        {
            "text": "Date:13Nov2017 v10.0 -53-recorded as an AE or SAE if they meet the definition of an AE (or SAE) as described in Sections 7.1.1 and 7.1.2. If the laboratory abnormality is part of a syndrome, record the syndrome or diagnosis (e.g., anemia) not the laboratory result (e.g., decreased hemoglobin).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abnormal Evaluation or Laboratory Value"
        },
        {
            "text": "Any laboratory abnormality that is new in onset or worsened in severity or frequency from the baseline condition and meets one of the following criteria will be recorded as an AE:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abnormal Evaluation or Laboratory Value"
        },
        {
            "text": "\u2022 Requires therapeutic intervention or diagnostic tests \u2022 Leads to discontinuation of study treatment \u2022 Has accompanying or inducing symptoms or signs \u2022 Is judged by the investigator as clinically significant Severity will be assessed as detailed in Section 7.1.6. If abnormalities are deemed by the principal investigator to not be clinically significant and stable then they will not be followed thereafter.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abnormal Evaluation or Laboratory Value"
        },
        {
            "text": "Participants who are pregnant or expect to become pregnant during the course of the study will be excluded from participation in the study. Should a participant become pregnant after enrolling in the study, she will not be given any further treatments with GLS-5300. The principal investigator will report this event to the study team and medical monitor, or its designee, and to the IRB. Site must request the participant's permission to query pregnancy outcome and follow each participant to determine the outcome of the pregnancy. Results will be summarized in the clinical study report (CSR).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedures for Documenting Pregnancy During Study"
        },
        {
            "text": "Participants who become pregnant at any point during the study will continue to be followed for safety assessments without receiving further investigational product. Data and samples that were collected prior to a participant's withdrawal of consent will be included in the data analysis, unless otherwise specified by the participant. Procedures that are contraindicated during pregnancy, including additional treatments, must not be performed. Investigators should use clinical judgment regarding subsequent study-related blood collection based on the presence or absence of anemia in each participant. Participants who are not withdrawn will continue to be followed for safety assessments to study discharge per protocol.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedures for Documenting Pregnancy During Study"
        },
        {
            "text": "All pregnancies that occur from the time of first screening procedure through the follow up visits must be reported. Monitoring of the participant and the outcome of the pregnancy will be followed by the investigator. If the end of the pregnancy occurs after the study has been completed, the outcome will be reported directly to the study team and the medical monitor.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedures for Documenting Pregnancy During Study"
        },
        {
            "text": "Male participants will be instructed through the Informed Consent Form to immediately inform the investigator if their partner becomes pregnant until the end of follow-up period. A Pregnancy Form will be completed by the investigator and submitted to the sponsor within 24 hours after learning of the pregnancy. Attempts will be made to collect and report details of the course and outcome of any pregnancy in the partner of a male participant exposed to Study Treatment. The pregnant partner will need to sign an Authorization for Use and Disclosure of Pregnancy Health Information to allow for follow-up on her pregnancy. Once the authorization has been signed, the investigator will update the Pregnancy Form with additional information on the course and outcome of the pregnancy. An investigator who is contacted by the male participant or his pregnant partner may provide information on the risks of the pregnancy and the possible effects on the fetus, to support an informed decision in cooperation with the treating physician and/or obstetrician. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedures for Documenting Pregnancy During Study"
        },
        {
            "text": "All AEs and SAEs including deaths, regardless of cause or relationship, must be reported for participants on study (including any protocol-required post-treatment follow-up).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Post-Study Reporting Requirements"
        },
        {
            "text": "Investigators are not obligated to actively seek AEs or SAEs beyond the follow up period for participants. However, if the investigator learns of an AE or SAE that occurs after the completion or termination visit and the event is deemed by the investigator to be probably or possibly related to the study treatment, he/she should promptly document and report the event to the study team and medical monitor.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Post-Study Reporting Requirements"
        },
        {
            "text": "0-6 days after each dose: Study participants will be directly observed by study personnel for a minimum of 30 minutes after injection of GLS-5300 and contacted by study personnel on Day 1 post vaccination for immediate reactions. The occurrence and severity of any AE during this period or the lack of same will be recorded on the appropriate CRF. After that, participants will be given an oral thermometer and a Participant Reminder Diary. They will be asked to take and record their oral temperature daily at the same time and to note and characterize in their own words any local or systemic AEs they experience, during this 7 day period after each injection/EP procedure.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Methods and Timing for Collection and Recording of Safety Data"
        },
        {
            "text": "Throughout the Study: In addition to the daily record of oral temperature, injection site reactions, and systemic complaints recorded for 7 days after injection of clinical material, study participants will be queried at each clinic visit regarding the occurrence of any SAE or other unexpected AE that may have occurred since the last visit. They will be reminded to contact study personnel and immediately report any such event that happens during the course of the study. These events will be recorded on the CRFs.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Methods and Timing for Collection and Recording of Safety Data"
        },
        {
            "text": "All AEs, regardless of severity, seriousness, or presumed relationship to study treatment, must be recorded using medical terminology in source documents and on the CRF. Whenever possible, a diagnosis will be documented, in lieu of symptoms. The source document and the CRF must contain the investigator's opinion concerning the relationship of the AE to study treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Methods and Timing for Collection and Recording of Safety Data"
        },
        {
            "text": "AEs should be described with the following attributes:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Methods and Timing for Collection and Recording of Safety Data"
        },
        {
            "text": "\u2022 Duration (start and end dates) \u2022 Seriousness \u2022 Severity \u2022 Causality \u2022 Action(s) taken \u2022 Outcome",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Methods and Timing for Collection and Recording of Safety Data"
        },
        {
            "text": "The Medical Monitor will be responsible for the overall safety monitoring of the study. The site PI and DoD safety monitor will be responsible locally for safety..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety and Toxicity Management"
        },
        {
            "text": "\u2022 Incidence of all adverse events classified by system organ class (SOC), preferred term, severity, and relationship to study treatment \u2022 Changes in safety laboratory parameters (e.g., hematology, serum chemistry, and urinalysis) \u2022 Local and systemic injection site review; special attention will be paid to the examination of the injection site. Administration site reactions and the participant's complaints will be documented.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety assessments include the following:"
        },
        {
            "text": "Date:13Nov2017 v10.0 -55-",
            "cite_spans": [],
            "ref_spans": [],
            "section": "GLS-5300"
        },
        {
            "text": "Events requiring expedited reporting (ERER) will be defined as any Adverse Event of Special Interest (see section 7.1.3) regardless of intensity or relationship to Study Treatment or any Study Treatment-related adverse events that follow:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Events Requiring Expedited Reporting"
        },
        {
            "text": "\u2022 Grade 3 or greater administration site erythema, and/or induration recorded \u2265 2 hours after Study Treatment; \u2022 Grade 4 or greater administration site pain, tenderness recorded \u2265 2 hours after Study Treatment; \u2022 Grade 3 or greater fever; \u2022 Grade 3 or greater systemic symptoms, including generalized pruritus;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Events Requiring Expedited Reporting"
        },
        {
            "text": "\u2022 Grade 3 or greater laboratory abnormalities \u2022 Unexpected adverse device events: all As per the Toxicity Grade for Healthy Adults (Appendix B). The most severe grade for that particular event is to be documented in the CRFs.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Events Requiring Expedited Reporting"
        },
        {
            "text": "The site will inform the Sponsor of any ERER within 24 hours to discuss whether dosing to the participant should continue.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Events Requiring Expedited Reporting"
        },
        {
            "text": "If any of the following situations occur then further enrollment and Study Treatments will be halted immediately until a thorough investigation has been conducted by the DoD Research Monitor or Principal Investigator and the IRB/EC (if applicable):",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Stopping Rules (Criteria for Pausing of Study)"
        },
        {
            "text": "\u2022 Three or more participants (per dose level) experience an ERER assessed as related to Study Treatment; \u2022 Three or more participants in the same treatment arm discontinue due to an AE related to the Study Treatment; This does not include participants who discontinue due to pain related to the EP Procedure. \u2022 Any participant experiences an SAE (e.g., potentially life threatening AE. Grade 4 AE or death) assessed as related to Study Treatment; \u2022 Two or more participants within a treatment arm experience the same or similar grade 3 or 4 adverse event, assessed as related to Study Treatment; \u2022 Seven or more participants across all treatment arms experience the same or similar grade 3 or 4 adverse event, assessed as related to Study Treatment; \u2022 Any report of anaphylaxis assessed as related to Study Treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Stopping Rules (Criteria for Pausing of Study)"
        },
        {
            "text": "Relatedness to Study Treatment will be considered Possibly, Probably, or Definitely, as determined by the PI. *Immediate pain from IP will not be considered stopping criteria Upon conclusion, the sponsor or designee will notify all investigators and IRBs/EC (if required) regarding the outcome of any investigation stemming from a Study Pause.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Stopping Rules (Criteria for Pausing of Study)"
        },
        {
            "text": "Any SAE or death assessed as related to Study Treatment will lead to an immediate halt of study enrollment and Study Treatments.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Stopping Rules (Criteria for Pausing of Study)"
        },
        {
            "text": "Guidelines for assessing relatedness are detailed in Section 7.1.6.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Stopping Rules (Criteria for Pausing of Study)"
        },
        {
            "text": "Date:13Nov2017 v10.0 -56-Data management will be carried out by WRAIR or one of its representatives. Data collection will be conducted on tablets or computers with daily upload to a central database. Access to the data collection software is limited by individual username and password. Data is stored in encrypted fashion on the local computer. After the data is uploaded to the central database it is deleted from the local tablet or computer.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "GLS-5300"
        },
        {
            "text": "Data obtained in the conduct of this study are housed in a secure database maintained by the WRAIR and/or its representative. All research data will be entered in a secure database with standardized quality assurance review procedures in accordance with Good Clinical Practices (GCP). Data will be entered into and maintained in a password-protected database. Data are accessible only to clinical, data management, Sponsor and information technology staff authorized to work on the protocol. The database will be located at the WRAIR CTC and/or its representative and protected by a firewall.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "GLS-5300"
        },
        {
            "text": "This data does not contain participant names or Social Security or other national identification number, but is referenced only by the study specific identification code. All subjects consented will be assigned a 7-digit participant identification number (PID). The first three digits are the protocol number (2274), followed by a 3-digit number which, will be assigned sequentially.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "GLS-5300"
        },
        {
            "text": "Every attempt must be made to follow the protocol and to obtain and record all data requested for each subject at the specified times. However, ethical considerations or other events may result in the failure to obtain and record certain data, or to record data at the times specified. If this occurs, the events and, the reasons for the event must be clearly documented on the case report form for deviations and reported as described above.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "GLS-5300"
        },
        {
            "text": "Analysis files are created on a periodic basis and made available to the Principal Investigators, Associate Investigators (AIs) and Medical Monitor at the direction of the Principal Investigator. Other collaborators may be given access to these analysis files, or data gathered from them, at the direction of the Principal Investigator. Data may be made available as a listing, external file, or through a query program.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "GLS-5300"
        },
        {
            "text": "The statistical analysis of the data will be performed by WRAIR or its representative. Descriptive statistics will be presented from the data collected in this Phase I study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "GLS-5300"
        },
        {
            "text": "Per-protocol (PP) analysis to comprise participants who receive all vaccine doses, have no protocol deviations as defined below, and have primary endpoint data available. Participants in this sample will be grouped to treatment arms as assigned. The modified intention to treat (mITT) analysis includes all participants who receive at least one Study Treatment. Participants in this ample will be grouped to treatment arms as assigned. Analyses on the mITT sample will be considered supportive of the corresponding PP analyses. The safety analysis set includes all participants who receive at least one Study Treatment and for whom post-dose safety data are available. Participants will be analyzed as to the treatment they received.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Analysis populations will include:"
        },
        {
            "text": "Participants who do not complete the study will not be replaced. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Analysis populations will include:"
        },
        {
            "text": "Demographic and baseline data, vital signs, medical history, concomitant illnesses, and current medications/treatments will be summarized by means of descriptive statistics: mean standard deviation, minimum, median, and maximum values for continuous variables, and percentages for categorical variables, stratified by treatment arm. All data from enrolled participants will be analyzed according to the initial assignment regardless of how many vaccinations they received. The analysis is a modified intent-to-treat analysis in that individuals who are screened but not enrolled do not contribute data and hence are excluded.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Demographic and Other Baseline Characteristics"
        },
        {
            "text": "All solicited and unsolicited AEs will be summarized by frequency per treatment arm. These frequencies will be presented separately by dose and overall, i.e. based on pooled doses, and will depict overall, by system organ class and by preferred term, the number and percentage of participants affected. Percentages, along with associated 95% Clopper-Pearson confidence intervals, will be based on the number of participants who were treated. Additional frequencies will be presented with respect to maximum severity and to strongest relationship to Study Treatment. Multiple occurrences of the same AE will be counted only once following a worst-case approach with respect to severity and relationship to Study Treatment. All serious AEs and administration site events will also be summarized as above.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse events"
        },
        {
            "text": "The main summary of safety data will be based on events occurring within 28 days of administration of Study Treatment (as specified in Section 9.6.1).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse events"
        },
        {
            "text": "Continuous response variables per time point and changes from baseline will be summarized with mean, median, minimum, and maximum values. Categorical response variables will be summarized per time point with percentages. These will be calculated according to treatment arm.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Laboratory Data and Vital Signs"
        },
        {
            "text": "Data classified as positive/negative or responder/non-responder will be analyzed as the frequency of response for each assay within treatment arm at each time point at which an assessment is performed. Proportions of responders will be presented with their corresponding 95% CI estimates, based on Clopper-Pearson methodology. Continuous variables (e.g., neutralizing and binding antibody titer) will be analyzed by assay within treatment arm with mean values and corresponding 95% CI estimates, based on t distributions.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunogenicity analysis"
        },
        {
            "text": "No formal power analysis is applicable to this study, as descriptive statistics will be used to summarize the data.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sample Size"
        },
        {
            "text": "With 25 participants per treatment arm, the study provides 95% confidence that the true incidence of SAEs is <20% if no SAEs are observed in the treatment arm. Overall, with 75 treated participants, the study provides 95% confidence that the true incidence of SAEs is <5%, if no SAEs are observed.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sample Size"
        },
        {
            "text": "Missing data will not be replaced, and calculations will be done on reported values.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Missing Values"
        },
        {
            "text": "An interim analysis will be carried out prior to the database lock but on monitored data according to a formal statistical analysis plan being developed by the Principal Investigator and the data GLS-5300 GeneOne Life Science, Inc. Clinical Protocol Date:13Nov2017 v10.0 -58-management and analysis team. In brief, this interim analysis will be carried out on all enrolled study participants and focus primarily on safety, reactogenicity, and immunogenicity data. The primary analysis will evaluate baseline demographics and adverse event outcomes in aggregate and across the three different dose groups. Both reactogenicity and longer term adverse event endpoints will be compared across groups. The primary immunogenicity endpoint to be evaluated will be a comparison, across the three dose groups, of endpoint antibody binding titers to the Spike protein and virus neutralization antibody titers at the Week 14 visit. In the interim analysis, there will also be comparisons carried out on neutralizing and binding antibody titer curves across all time points up to Week 14. Cellular immunologic outcomes will be assessed in the final analysis. No individual data will be released and these analyses will not impact the course of this study, though they may be published or used in the planning of future studies. Safety analyses may include enrollment and demographic information, medical history, concomitant medications, physical assessments, protocol adherence, clinical laboratory values, and solicited and unsolicited adverse events.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Interim analyses"
        },
        {
            "text": "Information about study participants will be kept confidential to the best of the study site's ability.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidentiality"
        },
        {
            "text": "In the event that a participant revokes authorization to collect or use PHI, the sponsor retains the ability to use all information collected prior to the revocation of participant authorization. For participants that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e., that the participant is alive) at the end of their scheduled study period.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidentiality"
        },
        {
            "text": "All non-exempt research involving human subjects shall, at a minimum, meet the requirement of 32 CFR 219.116(a)(6).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical Care for Research-Related Injury"
        },
        {
            "text": "If a participant is injured because of participation in this research and is a DoD healthcare beneficiary (eg, active duty in the military, military spouse or dependent), the participant is entitled to medical care for that injury within the DoD healthcare system, as long as the participant remains a DoD healthcare beneficiary. This care includes, but is not limited to, free medical care at military hospitals or clinics.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical Care for Research-Related Injury"
        },
        {
            "text": "If a participant is injured because of participation in this research and is not a DoD healthcare beneficiary, the participant entitled to medical care for that injury at an military hospital or clinic; medical care charges for care at an military hospital or clinic will be waived. It cannot be determined in advance which military hospital or clinic will provide care. If the participant obtains care for research-related injuries outside of a military hospital or clinic, the participant or the participant's insurance will be responsible for medical expenses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical Care for Research-Related Injury"
        },
        {
            "text": "For all participants: Transportation to and from DoD hospitals or clinics will not be provided, except in emergencies or situations where a non-DoD health care beneficiary requires a military escort for access to said hospitals or clinics. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Medical Care for Research-Related Injury"
        },
        {
            "text": "Source data is all information, original records or clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in original source documents. Examples of these original documents, and data records include: hospital records, clinical and office charts, laboratory notes, memoranda, participant's diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, participant files, and records kept at the pharmacy, at the laboratories, and at medical records and within information technology systems that are involved in the clinical trial.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Source Documents"
        },
        {
            "text": "Monitoring of the clinical trial will be performed by experienced monitors, who will report to the Sponsor or the Sponsor designee. Records for all clinical participants in this trial will be monitored. The following clinical site monitoring tasks will be performed at all site.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Source Documents"
        },
        {
            "text": "CRFs will be provided for each study participant. Participants must not be identified by name on any CRF. Participants will be identified by their participant identification number (PID).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Records to be kept"
        },
        {
            "text": "It is the Sponsor's responsibility to retain study essential documents for at least 2 years after the last approval of a marketing application in their country and until there are no pending or contemplated marketing applications in their country or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. The sponsor will inform the investigator/institution as to when these documents are no longer needed to be retained.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Records Retention"
        },
        {
            "text": "Monitoring Monitoring of the clinical trial will be performed by experienced monitors, who will report to the Sponsor or the Sponsor designee. Records for all clinical participants in this trial will be monitored. The following clinical site monitoring tasks will be performed at all site:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety and Quality Monitoring and Record Availability"
        },
        {
            "text": "\u2022 Prior to trial initiation, a site visit will be conducted to review all relevant forms and documentation, to ensure compliance with all applicable requirements \u2022 All clinical site monitoring visits will be documented \u2022 Periodic site visits will be performed throughout the study \u2022 The site monitor will be responsible for addressing and documenting the following study conduct activities and obligations and will: \u2022 Assure that the study is being conducted in accordance with the protocol, applicable regulatory agency regulations, and IRB/EC policies \u2022 Discuss study conduct issues and incidents of noncompliance with the Investigator and/or study personnel and document them on the resolution trip report. Report any significant unresolved problems immediately to the sponsor \u2022 Remind the Investigator as necessary of the obligation to immediately report all serious adverse events (SAE) and provide subsequent follow-up report of the final outcome to the IRB/EC \u2022 Inspect all Case Report Form (CRF) pages for completeness, logic, and internal consistency throughout the study \u2022 Assure that the study facilities continue to be acceptable \u2022 Compare the study CRFs with source documents to assure that the data are accurate and complete and that the protocol is being followed \u2022 Assure that test article accountability and reconciliation records are complete and accurate GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety and Quality Monitoring and Record Availability"
        },
        {
            "text": "Clinical Protocol Date:13Nov2017 v10.0 -60-\u2022 Assure that all participant specimens are being stored and forwarded properly for testing Record availability and auditing The investigator will make study documents (e.g., ICFs, drug accountability forms, CRFs) and pertinent hospital or clinic records readily available for inspection by the local IRB/EC, representatives of the Department of Defense, the site monitors, regulatory agencies, GeneOne Life Science, Inc. or its designee for confirmation of the study data.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety and Quality Monitoring and Record Availability"
        },
        {
            "text": "Participation as an investigator in this study implies acceptance of potential inspection by regulatory authorities and applicable compliance and quality assurance offices.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety and Quality Monitoring and Record Availability"
        },
        {
            "text": "To assure the safety of the participants, information about all AEs (see Section 7.1 Safety Parameters for definitions), whether volunteered by the participant, discovered by investigator or study staff questioning, or detected through physical examination, laboratory test or other means, will be collected and recorded in the participant's source documents and followed as appropriate.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse Experience (AE) Reporting"
        },
        {
            "text": "In addition to AE reporting, a summary of the study's overall progress will be forwarded to regulatory agencies according to the local requirements (e.g., every 6 months, annual).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse Experience (AE) Reporting"
        },
        {
            "text": "All solicited and unsolicited adverse events will be collected throughout the study and recorded on the CRFs. The Study Report will analyze and summarize all adverse events throughout the study. Unsolicited AEs will be summarized for the 28 day period following each administration of Study Treatment. See next section for SAEs. All Adverse Events will be summarized at the time of continuing review.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Reporting Period of Adverse Events"
        },
        {
            "text": "The reporting period for SAEs (without regard to causality) is the entire period following the signing of the informed consent form until the end of the study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Reporting Period of Serious Adverse Events"
        },
        {
            "text": "Each AE will be assessed to determine whether it meets seriousness criteria. If the AE is considered serious, the investigator should record this event to GeneOne Life Science within 24 hours of becoming aware of the event. The investigator may also directly report this event to the WRAIR IRB per standard operating procedures within 24 hours.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Reporting Period of Serious Adverse Events"
        },
        {
            "text": "Expectedness of SAEs will be determined by GeneOne Life Science using reference safety information specified in the Investigator's Brochure. An event may qualify for expedited reporting to regulatory authorities if it is an SAE, unexpected per reference safety information and considered related following the guidelines in Section 7.1.7 (Serious Unexpected Suspected Adverse Reaction, SUSAR) in line with relevant legislation. All investigators will receive a safety letter notifying them of relevant SUSAR reports. The investigator should notify the Ethics Committee as soon as is practical, of serious events in writing where this is required by local regulatory authorities, and in accordance with the local institutional policy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Reporting Period of Serious Adverse Events"
        },
        {
            "text": "At any time after completion of the SAE reporting period, if an investigator becomes aware of an SAE that is suspected by the investigator to be related to the study drug, the event will be reported to the Sponsor or its designee. The report should contain as much clinical safety information as possible, but at minimum, the initial report must include the following information:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Reporting Period of Serious Adverse Events"
        },
        {
            "text": "\u2022 Event \u2022 Study code \u2022 Participant number and date of birth \u2022 Investigational study product \u2022 Reporter name and contact information",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAE TELEPHONE AND CONTACT INFORMATION"
        },
        {
            "text": "In the case of a \"minimum report\" (one that is solely comprised of the information bulleted above), a more detailed follow-up report will be sent as soon as more information becomes available but no later than 7 calendar days after the date of the initial report. Each SAE must be followed up until resolution or stabilization and for a reported death, the investigator will supply GeneOne Life Science and the Ethics Committee with any additional requested information (e.g., autopsy reports and terminal medical reports). Additionally, reporting of all deaths will occur in real-time.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAE TELEPHONE AND CONTACT INFORMATION"
        },
        {
            "text": "The original SAE form must be kept at the study site. GeneOne Life Science or its representative will be responsible for determining and in turn, reporting SAEs to regulatory authorities according to the applicable regulatory requirements.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAE TELEPHONE AND CONTACT INFORMATION"
        },
        {
            "text": "SAEs must be followed by the investigator until resolution, even if this extends beyond the studyreporting period. Resolution of an SAE is defined as the return to baseline status or stabilization of the condition with the expectation that it will remain chronic.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAE TELEPHONE AND CONTACT INFORMATION"
        },
        {
            "text": "In accordance with local regulations, the Sponsor shall notify the appropriate regulatory authorities, and all participating investigators in a written safety report of any adverse experience associated with the use of the product that is both serious and unexpected (e.g., FDA Form 3500A in the US). Reports of serious adverse events shall be made as soon as possible and in no event later than 15 calendar days after the Sponsor's initial receipt of the information. Written notification may be submitted on the form described above or equivalent or in a narrative format and shall bear prominent identification of its contents. Each written notification to regulatory agencies shall be transmitted to the division that has responsibility for review. In each written safety report, the Sponsor shall identify all safety reports previously filed concerning a similar adverse experience, and shall analyze the significance of the adverse experience in light of the previous, similar reports. The Sponsor shall also notify the relevant regulatory authorities by telephone or by facsimile transmission of all deaths regardless of causality and any unexpected fatal or life-threatening experience associated with the use of the drug as soon as possible but in no event later than 7 calendar days after the sponsor's initial receipt of the information. Each telephone call or facsimile transmission to regulatory agencies shall be transmitted to the division that has responsibility for review.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Notifications of Serious Adverse Events"
        },
        {
            "text": "Follow up information to a safety report shall be submitted as soon as the relevant information is available. If the results of a Sponsor's event investigation show that an adverse drug experience not initially determined to be reportable is, in fact, reportable, the Sponsor shall report such experience in a written safety report as soon as possible, but in no event later than 15 calendar days after the GLS-5300 GeneOne Life Science, Inc. Clinical Protocol Date:13Nov2017 v10.0 -62-determination is made. Results of investigations of other safety information shall be submitted, as appropriate, in an information amendment or annual report.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Notifications of Serious Adverse Events"
        },
        {
            "text": "In addition to the reporting period for SAEs specified in Section 9.7.2, should the Investigator become aware of an SAE (assessed as related to the investigational product following the guidelines in Section 7.1.7) that occurs within 28 days after stopping the investigational product, the SAE must be reported in accordance with procedures specified in this protocol.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Notifications of Serious Adverse Events"
        },
        {
            "text": "In the event of death, if an autopsy is performed, a copy of the report will be sent to GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Notifications of Serious Adverse Events"
        },
        {
            "text": "MAAE will be collected during the entire study through one year following the last Study Treatment. As such, the reporting period for MAAE is the entire period following the signing of the informed consent form until study discharge.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Reporting of Medically Attended Adverse Events"
        },
        {
            "text": "A tabulation of all MAAE and their assessed relationship to Study Treatment will be included in all required periodic reports to regulatory agencies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Reporting of Medically Attended Adverse Events"
        },
        {
            "text": "Any problems experienced during the treatment procedure including potential malfunctions of the CELLECTRA \u00ae device, error messages displayed on the device screen following treatment or errors that occur during the treatment procedure must be reported to the Sponsor or designee immediately for evaluation. The error reporting form provided in Appendix D must be completed and emailed to the Sponsor at error@GeneOneLS-US.com, and Inovio Pharmaceuticals at EPerror@inovio.com.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Reporting of Device Related Complaints"
        },
        {
            "text": "GeneOne Life Science reserves the right to discontinue the study at this site or at multiple sites for safety or administrative reasons at any time. In particular, a site that does not recruit at a reasonable rate may be discontinued. Should the study be terminated and/or the site closed for whatever reason, all documentation and study product pertaining to the study must be returned to GeneOne Life Science or its representative.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Discontinuation"
        },
        {
            "text": "A protocol deviation is defined as an isolated occurrence involving a procedure that did not follow the study protocol. The timeline for reporting protocol deviations to the Division of Human Subjects Protection/ WRAIR IRB is determined by the categorization of the deviation: (1) emergent/significant or (2) non-emergent/minor. Unanticipated problems should be reported in the appropriate timeframe according to the seriousness of the event as a significant deviation or a minor deviation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol Deviations"
        },
        {
            "text": "Emergent/significant deviations are departures from protocol that have a significant impact on the welfare or safety of a volunteer or on the integrity of the study data. Examples: providing the wrong lab result to a volunteer or failure to obtain a scheduled blood draw for multiple participants. Changes in protocol procedures may be initiated without prior IRB/ethical review committee approval,only in cases where the change (s) is /are necessary to eliminate an immediate apparent hazard.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol Deviations"
        },
        {
            "text": "Non-emergent/minor deviations are routine departures that typically involve a volunteer's failure to comply with the protocol. Examples include missing scheduled visits and failing to complete a required questionnaire. Minor deviations will be reported to the sponsor and the Division of GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol Deviations"
        },
        {
            "text": "Clinical Protocol Date:13Nov2017 v10.0 -63-Human Subjects Protection/IRB in a summary report with the annual continuing review report. A cumulative deviation report will be submitted to the HSPB/WRAIR IRB with each protocol continuing review report or with the closeout report, whichever comes first.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol Deviations"
        },
        {
            "text": "All major protocol deviations that adversely affect the safety or rights of a participant or scientific integrity of the study, will be reported to the WRAIR HSPB within 48 hours and a written report should be submitted within 10 working days. The contact information for the WRAIR HSPB is as follows:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol Deviations"
        },
        {
            "text": "Director, Human Subjects Protection Branch 503 Robert Grant Avenue Silver Spring, MD 20910 Telephone: 301-319-9940 Fax: 301-319-9961 E-mail: usarmy.detrick.medcom-wrair.mbx.hspb@mail.mil All protocol deviations occurring within the reporting period should be summarized in the continuing review reports that are submitted to the WRAIR HSPB.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol Deviations"
        },
        {
            "text": "All modifications to the protocol and supporting documents (informed consent, SSPs, SOPs, recruitment materials, etc) must be reviewed and approved prior to implementation. Any protocol amendment will be agreed upon and approved by the sponsor's representative prior to submission to the WRAIR IRB and prior to implementation of said change or modification. The informed consent document must be revised to concur with any amendment as appropriate and must be reviewed and approved with the amendment. Any subject already enrolled in the study will be informed about the revision and asked to sign the revised informed consent document if the modification directly affects the individual's participation in the study. A copy of the revised, signed, and dated informed consent document will be given to the subject. All original versions of the informed consent document will be retained in the protocol regulatory file.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol Modifications"
        },
        {
            "text": "Any modification that could potentially increase risk to subjects must be submitted to the ORP HRPO and the FDA for approval prior to implementation. Documentation that the WRAIR IRB reviewed and approved the modifications also will be submitted.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol Modifications"
        },
        {
            "text": "It is the policy of the USAMRMC that data sheets are to be completed for all participants participating in research (Form 60-R, Volunteer Registry Data Sheet). The data sheets will be entered into this Command's Volunteer Registry Database. The information to be entered into this confidential data base includes the participant's name, address, and Social Security Number; study title; and dates of participation. The intent of this data base is twofold: first, to readily answer questions concerning an individual's participation in research sponsored by USAMRMC; and second, to ensure that USAMRMC can exercise its obligation to ensure research participants are adequately warned (duty to warn) of risks and to provide new information as it becomes available. The information will be stored at USAMRMC for a minimum of 75 years. The Volunteer Registry Database is a separate entity and is not linked to the study database. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Volunteer Registry Data Sheets"
        },
        {
            "text": "Publication of the results of this trial will be allowed. The proposed presentation, abstract and/or manuscript must be made available to GeneOne Life Science, Inc. 60 days prior to submission for publication. GeneOne Life Science, Inc. shall have thirty (30) days after receipt of the copies to object to the proposed presentation or publication because there is patentable participant matter that needs protection. In the event that GeneOne Life Science, Inc. makes such objection, the researcher(s) shall refrain from making such publication or presentation for a maximum of three (3) months from the date of receipt of such objection in order for patent application(s) directed to the patentable participant matter contained in the proposed publication or presentation to be filed with the United States Patent and Trademark Office and/or foreign patent office(s).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Publication Of Research Findings"
        },
        {
            "text": "All data collected during this study will be used to support this IND. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Publication Of Research Findings"
        },
        {
            "text": "Serum and Whole Blood The following information must be included on the label for each of the immunologic samples drawn to allow accurate processing and analysis of samples: The Research monitor will function as an independent safety advocate for participants per AR70-25 and DoD Instruction 3216.02.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Appendix C: Collection and Shipping of Immunologic Samples"
        },
        {
            "text": "The Research Monitor is required to review all unanticipated problems involving risks to participants or others, serious adverse event (SAE) reports, and all participant deaths. The Research Monitor will provide an unbiased written report of all unanticipated problems involving risks to participants or others, and related SAEs and deaths, within 10 working days to the WRAIR IRB by email (Usarmy.detrick.medcom-wrair.mbx.hspb@mail.mil), or by mail at the following address: Walter Reed Army Institute of Research, ATTN: Human Subjects Protection Branch, 503 Robert Grant Ave, Silver Spring, MD 20910. In addition to submission of the DOD Research Monitor reports to the WRAIR IRB, a copy of the same report will be sent to the Sponsor team. All Research Monitor reports for unrelated SAEs and deaths should be kept with the corresponding SAE reports at the study site. The WRAIR HSPB will submit copies of these reports to the USAMRMC ORP HRPO as per SOP UWZ-C-636. The DoD Research Monitor at a minimum must comment on the outcomes of the event or problem and in case of a serious adverse event or death, comment on the relationship to participation in the study. The Monitor must also indicate whether he/she concurs with the details of the report provided by the principal investigator. The DoD Research Monitor should review all initial reports for SAEs, unanticipated problems involving risks to participants or others, and all participant deaths in a timely manner, and provide their own independent report. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specifics as to timing and amounts of serum and whole blood required at each blood draw is included in the Laboratory"
        },
        {
            "text": "Unanticipated problems involving risks to participants or others encompass a broader category of events than SAEs and may include issues such as problems with loss of control of participant data or the investigational product; adverse psychological reactions; or breach of confidentiality. Risks to others (e.g., program personnel) must also be reported.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unanticipated Problems Involving Risks To Participants Or Others"
        },
        {
            "text": "Unanticipated problems involving risks to participants or others are any incident, experience, or outcome that meets all of the following criteria:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unanticipated Problems Involving Risks To Participants Or Others"
        },
        {
            "text": "\u2022 Unexpected (in terms of nature, severity, or frequency) given (a) the procedures that are described in the protocol, investigators brochure or informed consent document; and (b) the characteristics of the participant population;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unanticipated Problems Involving Risks To Participants Or Others"
        },
        {
            "text": "\u2022 Related or possibly related to a participant's participation in the study; and",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unanticipated Problems Involving Risks To Participants Or Others"
        },
        {
            "text": "\u2022 Suggests that the study places participants or others at a greater risk of harm than was previously known or recognized.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unanticipated Problems Involving Risks To Participants Or Others"
        },
        {
            "text": "Unanticipated problems involving risk to participants or others, should be promptly reported (48 hours) by telephone, email, or fax to the WRAIR HSPB. A complete written report should follow the initial notification within 10 working days. All unanticipated problems occurring within the reporting period should also be summarized in the continuing review reports submitted to the WRAIR HSPB. The contact information for the WRAIR HSPB is as follows:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unanticipated Problems Involving Risks To Participants Or Others"
        },
        {
            "text": "Director, Human Subjects Protection Branch 503 Robert Grant Avenue Silver Spring, MD 20910 Telephone: 301-319-9940 Fax: 301-319-9961 E-mail: usarmy.detrick.medcom-wrair.mbx.hspb@mail.mil",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unanticipated Problems Involving Risks To Participants Or Others"
        },
        {
            "text": "All related serious adverse events (SAEs) and deaths should be reported to the WRAIR HSPB within 48 hours by telephone, email, or fax. A complete written report should follow the initial notification within 10 working days. All SAEs occurring within the reporting period should also be summarized in the continuing review reports submitted to the WRAIR HSPB. The contact information for the WRAIR HSPB is as follows: ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious Adverse Events"
        },
        {
            "text": "All amendments/modifications to the protocol and supporting documents (informed consent, SSPs, SOPs, recruitment materials, etc.) must be reviewed by the WRAIR HSPB and a WRAIR Commander Authorization Approval issued prior to WRAIR participation on the amended/modified protocol.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol Modifications/Amendments"
        },
        {
            "text": "The WRAIR Point of Contact will be responsible for preparing and submitting continuing review reports as per UWZ-C-618 and a closeout report as per WRAIR Policy 12-2. The WRAIR HSPB will review and acknowledge the reports in order for WRAIR personnel to continue their participation on the study. Once all study activities have been completed, to include data analysis, a closeout report will need to be submitted to the WRAIR HSPB to close the study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Continuing Reviews and Closeout Report"
        },
        {
            "text": "The knowledge of any pending compliance inspection/visit by the FDA, Office for Human Research Protections (Department of Health and Human Services), or other government agency concerning clinical investigation or research, the issuance of Inspection Reports, FDA Form 483, warning letters, or actions taken by any regulatory agency including legal or medical actions and any instances of serious or continuing noncompliance with the regulations or requirements will be reported immediately to the WRAIR HSPB. \u2022 Reviews all severe adverse events, serious adverse events, protocol violations, and annual reports \u2022 May perform oversight functions (e.g., observe recruitment, enrollment procedures, and the consent process for individuals, groups or units; oversee study interventions and interactions; review monitoring plans and UPIRTSO reports; and oversee data matching, data collection, and analysis)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pending Inspections/Issuance of Reports"
        },
        {
            "text": "\u2022 May discuss the research protocol with the investigators, interview human subjects, and consult with others outside of the study about the research \u2022 Have authority to stop a research protocol in progress, remove individual human subjects from a research protocol, and take whatever steps are necessary to protect the safety and well-being of human subjects until the IRB can assess the monitor's report GLS-5300 GeneOne Life Science, Inc.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pending Inspections/Issuance of Reports"
        },
        {
            "text": "Clinical Protocol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pending Inspections/Issuance of Reports"
        },
        {
            "text": "Date:13Nov2017 v10.0 -80-\u2022 Acts as an independent party and can be available to help answer any questions from an impartial standpoint",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pending Inspections/Issuance of Reports"
        },
        {
            "text": "\u2022 Complies with GCP and Belmont Principles \u2022 Qualified through training, education and experience \u2022 Ensures the accuracy, quality, and integrity of the data \u2022 Performs MedDRA and WHO coding \u2022 Reviews electronic case report forms (eCRF) for consistency and clarity, generates and resolves data queries and provides analysis and feedback to PIs, protocol nurse coordinators, and protocol team \u2022 Runs discrepancy report and quality control check reports and distributes to the protocol nurse coordinator to review for data accuracy against the eCRF \u2022 Oversees the data entry process for the study ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data Manager"
        },
        {
            "text": "Participants will receive financial compensation at each visit for the time and effort involved in participating in this study. They will be compensated as follows:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Appendix H Compensation for Participation:"
        },
        {
            "text": "\u2022 $25 for the screening visit (1 visit) \u2022 $25 for the follow up phone calls (3) \u2022 $300 per vaccination (3) plus $130 per scheduled Follow Up study visit (6) \u2022 $220 bonus for completing all injections and scheduled visits through Week 60 \u2022 $150 for completing the last scheduled study visit \u2022 If chosen for leukapheresis compensation for those visits will be $350 for those visits in addition to the $130 follow up By regulation, active duty personnel and federal employees can be compensated only for visits in which blood draws occur, and then only $50 per visit, unless the visits occur during off-duty hours or when they are on leave. If the volunteer is off-duty or on leave, he or she will be paid the same as non-military/non-federal personnel.",
            "cite_spans": [
                {
                    "start": 30,
                    "end": 39,
                    "text": "(1 visit)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Appendix H Compensation for Participation:"
        },
        {
            "text": "The total amount of compensation may vary depending on the number of visits completed. Civilian (non-Federal employee) volunteers who undergo injection may receive approximately $2,000 in compensation. Participants who are on active duty or federal employees who are part of a vaccine group are expected to receive approximately $425 in compensation, unless they are on approved leave or participating outside of normal duty hours. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Appendix H Compensation for Participation:"
        },
        {
            "text": "The Statistical Analysis Plan (SAP) for \"Phase I, open-label, dose-ranging study to evaluate the safety, tolerability, and immunogenicity of GLS-5300, administered intramuscularly (IM) and followed by electroporation (EP) in healthy volunteers\" describes and expands upon the statistical information presented in the protocol.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "PREFACE"
        },
        {
            "text": "This document describes all planned analyses and provides reasons and justifications for these analyses. It also includes sample tables, listings, and figures planned for the final analyses. Regarding the final analyses and Clinical Study Report (CSR), this SAP follows the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidelines, as indicated in Topic E3 (Structure and Content of Clinical Study Reports), and more generally is consistent with Topic E8 (General Considerations for Clinical Trials) and Topic E9 (Statistical Principles for Clinical Trials). The structure and content of the SAP provides sufficient detail to meet the requirements identified by the FDA and ICH, while all work planned and reported for this SAP will follow internationally accepted guidelines published by the American Statistical Association and the Royal Statistical Society for statistical practice.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "PREFACE"
        },
        {
            "text": "This document contains four sections: (1) a review of the study design, (2) general statistical considerations, (3) comprehensive statistical analysis methods for immunogenicity and safety outcomes, and (4) a list of proposed tables and figures. Any deviation from this SAP will be described and justified in protocol amendments and/or in the CSR, as appropriate. The reader of this SAP is encouraged to also review the study protocol for details on conduct of the study and the operational aspects of clinical assessments INTRODUCTION This is a Phase I open-label dose ranging study to evaluate the safety, tolerability, and immunogenicity of GLS-5300. GLS-5300 contains plasmid pGX9101 that encodes for a consensus sequence of the spike (S) protein of the Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV). Currently there are no approved treatments or prophylactic vaccines for MERS CoV, although a number of products are poised to be advanced into human trials. 2 T-cell responses following each vaccination will determine the effectiveness of vaccination. Follow-up will determine the longevity of immunogenicity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "PREFACE"
        },
        {
            "text": "These analyses will assess the safety, tolerability, and immunogenicity of GLS-5300 and will be included in the clinical study report. Note, not all analyses for endpoints included in the protocol are detailed in this plan. See Section 8.2 for details regarding which exploratory endpoint analyses are included in this SAP. Furthermore, the interim safety monitoring assessment which is required before enrollment to the next dose level that is conducted throughout the study is not included in this SAP. In addition, the analysis for the leukapheresis substudy is also not included in this SAP. The interim analyses assessing safety and immunogenicity up to the Week 14 visit is also included in this SAP.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Purpose of the Analyses"
        },
        {
            "text": "\u2022 Evaluate the safety and tolerability of GLS-5300 when administered by IM injection followed by EP in healthy adult participants",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Objectives Primary Objectives"
        },
        {
            "text": "\u2022 Evaluate the cellular and humoral response of GLS-5300 when delivered IM followed by EP \u2022 Evaluate the dose response for cellular and humoral reactivity of GLS-5300 when delivered IM followed by EP",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "\u2022 Explore whether end point antibody titers to MERS CoV S protein are dose related \u2022 Explore the time to onset of antibody production and longevity of serologic response \u2022 Explore if increasing dose levels of GLS-5300 more rapidly induce cellular immunity \u2022 Explore the time to onset of T cell responsiveness and longevity of cell mediated immunity \u2022 Evaluate the kinetics of antigen expression in the peripheral blood compartment \u2022 Evaluate host genetics as a potential predictor of vaccine immune response \u2022 Evaluate additional cellular immune responses \u2022 Neutralizing and non-neutralizing antibody repertoire analysis \u2022 Explore innate immune responses to the MERS CoV S protein \u2022 Assess cross-neutralization activity against other human coronaviruses ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "\u2022 Incidence of adverse events classified by system organ class (SOC), preferred term (PT) severity, and relationship to study treatment and schedule \u2022 Administration (injection) site reactions (described by frequency and severity grade) and administration site pain \u2022 Changes in safety laboratory parameters described by frequency and severity grade (e.g., liver panel tests, vital signs)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Endpoints Primary Safety Endpoints"
        },
        {
            "text": "\u2022 Quantitative binding antibody titers to the full length MERS CoV Spike (S) glycoprotein \u2022 Qualitative and quantitative levels of neutralizing antibodies against MERS CoV \u2022 Antigen specific cellular immune responses to MERS CoV as determined by: ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Immunologic Endpoints"
        },
        {
            "text": "The Study Treatment procedure consists of insertion of the CELLECTRA \uf6da electroporation array needles (electrodes) through the skin and into the underlying muscle, and intramuscular of the study vaccine followed by delivery of the electroporation pulses. This procedure is broadly described as administration because it involves more than the injection of a drug. For purposes of defining the analysis populations and compliance measures, treatment administration for this protocol includes both the vaccine dose (IM injection) as well as the following EP administration. A successful treatment administration requires that the vaccine dose and the EP were administered successfully. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Definitions and Derived Variables"
        },
        {
            "text": "The endpoint pertaining to the quantitative binding antibody titers to the MERS CoV Spike (S) glycoprotein includes the ELISA antibody responses. ELISA antibody response results will be presented as end-point titer. The positive response for the ELISA antibody response will be defined using a specific threshold. Titer responses greater than X dilution will be defined as having a positive response. The lowest dilution (1:100) to be tested will be used as the lower limit of detection. Observations below the lower limit of detection will be imputed to 1/2 the lowest observable value (i.e. 50).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunologic Endpoints:"
        },
        {
            "text": "The endpoint pertaining to the qualitative and quantitative levels of neutralizing antibodies against MERS CoV will be defined using the titer of the neutralizing antibody which will be reported as the reciprocal of the highest dilution for which less than 50% of the cells show cytopathic effects. The lowest dilution (1:10) to be tested will be used as the lower limit of detection. Observations below the lower limit of detection will be imputed to 1/2 the lowest observable value (i.e., 5). The positive response for the neutralizing antibody titer will be defined using a specific threshold. Neutralizing antibody titer responses greater than X dilution will be defined as having a positive response.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunologic Endpoints:"
        },
        {
            "text": "One of the endpoints pertaining to the antigen-specific cellular immune responses to MERS CoV is determined by the interferon-gamma (IFN-\u03b3) ELISpot. The IFN-\u03b3 ELISpot will be derived by subtracting the average number of spot forming units (SFU) counted in media control wells and the average in individual MERS CoV peptide wells and then adjusted to 1x10 6 PBMCs for each MERS CoV peptide pool. To obtain these values, PBMCs will be thawed and plated at 200,000 cells/well. Cells will be incubated with MERS CoV peptides, incubated overnight, and IFN-\u03b3 release detected using standard procedures. If the media control wells value is greater than the MERS CoV peptide wells value, an imputed value of half of the smallest positive adjusted value is used for the analysis. For values of the MERS CoV peptide wells that are tabulated as too numerous to count (TNTC), the largest MERS CoV peptide well value is imputed.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunologic Endpoints:"
        },
        {
            "text": "The other endpoint pertaining to the antigen-specific cellular immune responses to MERS CoV is determined by the ICS (cytotoxic T lymphocyte phenotype, lytic granule loading, granzyme B killing of target cells).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunologic Endpoints:"
        },
        {
            "text": "This is a Phase I open-label dose ranging study to evaluate the safety, tolerability, and immunogenicity of GLS-5300. GLS-5300 contains plasmid pGX9101 that encodes for a consensus sequence of the spike (S) protein of the Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV). Currently there are no approved treatments or prophylactic vaccines for MERS CoV, although a number of products are poised to be advanced into human trials.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "This clinical trial will evaluate whether GLS-5300 administered via intramuscular (IM) injection and followed by electroporation (EP is able to generate protective immunity against MERS CoV and whether there is an immune reactivity follows a pattern of vaccine dose response. Injections will be given in the deltoid or lateral quadriceps muscle followed immediately by EP with the CELLECTRA \u00ae -5P device.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Healthy adult volunteers, male and female, military and civilian, will be recruited by non-coercive means through WRAIR CTC according to applicable U.S. Army regulations. A total of 75 participants aged 18 to 50 divided into 3 groups will be enrolled for this study and followed for 60 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Group I Participants (n=25) assigned to receive GLS-5300 will be administered 0.67 mg DNA/dose given as a 1 ml IM injection followed by EP with the CELLECTRA \u00ae -5P device. Participants will receive a 3-dose series with immunizations at 0, 4 and 12 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Group II Participants (n=25) assigned to receive GLS-5300 will be administered 2 mg DNA/dose given as a 1 ml IM injection followed by EP with the CELLECTRA \u00ae -5P device. Participants will receive a 3-dose series with immunizations at 0, 4 and 12 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Group III Participants (n=25) assigned to receive GLS-5300 will be administered 6 mg DNA/dose given as a 1 ml IM injection followed by EP with the CELLECTRA \u00ae -5P device. Participants will receive a 3-dose series with immunizations at 0, 4 and 12 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Participants will be enrolled at the lowest dose (Group I) with continuous enrollment through the 1st week of enrollment. At the start of week 2, clinical laboratory data for the first five participants from Group I will be reviewed as part of the safety review. Once safety labs have been reviewed and cleared for the first five participants in Group 1 , the second dose level will be opened. The next five participants who have met eligibility criteria will then be enrolled into Group II. Then enrollment for Group I will be completed.",
            "cite_spans": [
                {
                    "start": 346,
                    "end": 353,
                    "text": "Group 1",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Once group 1 has completed enrollment of 25 participants, then Group 2 will be populated sequentially.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "When the first five participants in Group 2 have reached one week post vaccination then safety labs will be reviewed as above. Once this safety assessment is cleared, then Group III will be opened for enrollment of the next five participants. Then enrollment will be completed for Group 2 and afterwards Group 3.",
            "cite_spans": [
                {
                    "start": 36,
                    "end": 43,
                    "text": "Group 2",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Review of safety labs will be conducted by a safety monitoring committee consisting of the study PI, medical monitor and the DoD Research Monitor. Safety reviews can be by teleconference or electronically such as email. Enrollment to the next dose level will require approval of all review members. The IRB will be provided a summary statement of each safety review.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Safety assessments: All participants will be monitored for \uf0d8 Local and systemic adverse events (AE's) at each study visit.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "\uf0d8 Laboratory related AE's following the first, second, and third vaccination.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "\uf0d8 Injection site reactions for up to one month following each vaccination.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Immunogenicity assessments: The study will explore humoral and cell mediated immune responses in blood samples collected at the following times: b. Able to provide consent to participate and having signed an Informed Consent Form.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "c. Able and willing to comply with all study procedures. d. Women of child-bearing potential agree to remain sexually abstinent, use medically effective contraception (oral contraception, barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 3 months following the last injection, or have a partner who is unable to induce pregnancy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "e. Sexually active men who are considered sexually fertile must agree to use either a barrier method of contraception during the study, and agree to continue the use for at least 3 months following the last injection, or have a partner who is permanently sterile or unable to become pregnant;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "f. Normal screening ECG or screening ECG with no clinically significant findings; q. Prior major surgery or any radiation therapy within 4 weeks of group assignment;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "r. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "s. Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator (AICD);",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "t. Metal implants within 20 cm of the planned site(s) of injection;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "u. Presence of keloid scar formation or hypertrophic scar as a clinically significant medical condition at the planned site(s) of injection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "v. Prisoner or participants who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness; w. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "x. Tattoos covering the injection site area y. Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint. A participant will be considered to have completed the study when he/she completes all scheduled study treatments and follow-up visits. If a participant discontinues the study at any time after dosing, the investigator will make every effort to have the participant complete all assessments. The investigator will make every effort to have all scheduled immune assessment blood samples collected. Unless a participant refuses to continue participation, all follow-up visits and procedures should be completed as indicated, following the last dose whether or not the participant has completed all doses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "All data collected up to the time of withdrawal, including any final evaluation and lab results that may be pending at the time of withdrawal will be reported. Likewise, any specimens collected up to the time of withdrawal, including any blood collected for storage and use in future research, will be kept and utilized as outlined in the protocol and consent form. The study termination eCRF will be completed, with the reason for withdrawal specified.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "The reason for any discontinuation of investigational product will be discussed with the Sponsor's Medical Monitor and indicated on the study forms. The primary reason for a participant discontinuing further dosing or withdrawal from the study itself is to be selected from the following standard categories:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Adverse Event (Adverse Reaction): Clinical or laboratory events occurred that, in the medical judgment of the investigator, are grounds for discontinuation for the best interest of the participant. This includes serious and non-serious adverse events regardless of relation to study drug.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Death: The participant died.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Withdrawal of Consent: The participant desired to withdraw from further participation in the study in the absence of an investigator-determined medical need to withdraw. If the participant gave a reason for withdrawal, it must be recorded on the CRF. This reason does not allow for further data collection or later study related procedures.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Protocol Violation: The participant failed to meet the protocol entry criteria or failed to adhere to the protocol requirements (e.g., treatment noncompliance, failure to return for defined number of visits). The violation should be discussed with the Sponsor's Medical Monitor prior to discontinuation of either study treatments or study withdrawal.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Lost to Follow-up: The participant fails to attend study visits and study personnel are unable to contact the participant after repeated attempts including letter sent by certified mail or its equivalent.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Physician Decision: The participant was terminated for a reason other than those listed above by the physician caring for the participant.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "Incarceration: Participation of prisoners is not planned and any volunteer will be suspended from study visits while incarcerated. The IRB will be notified of the period of incarceration. If possible, site teams will coordinate with correctional authorities to ensure that relevant medical information for the safety and care of the patient is communicated promptly. Other: The participant was terminated for a reason other than those listed above, such as termination of study by the Sponsor.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Overall Study Design and Plan"
        },
        {
            "text": "GLS-5300, the investigational product to be used in this study contains a DNA plasmid encoding for the S protein of MERS CoV. Each product will be provided at a concentration of approximately 6 mg/ml to be diluted and mixed on site to the needed dose such that a standard 1 ml volume will be administered to all study participants. Because of this the concentration of the final plasmid will vary based on the dosage administered. GLS-5300 is a solution in sterile water for injection (sWFI). Therefore, sWFI will be used for dilution of the biologic products during clinical site formulation. The vaccine product will be shipped from manufacturer at VGXI in Houston, Texas on dry ice. The lot number for the vaccine to be used is GLS-5300 15L019.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatments"
        },
        {
            "text": "A total of 75 participants divided into 3 groups will be enrolled for this study. It is estimated that approximately 225 participants will need to be screened to fill the desired enrollment of 75 participants.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatments"
        },
        {
            "text": "Group I Participants (n=25) assigned to receive GLS-5300 will be administered 0.67 mg DNA/dose given as a 1 ml IM injection followed by EP with the CELLECTRA \u00ae -5P device. Participants will receive a 3-dose series with immunizations at 0, 4 and 12 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatments"
        },
        {
            "text": "Group II Participants (n=25) assigned to receive GLS-5300 will be administered 2 mg DNA/dose given as a 1 ml IM injection followed by EP with the CELLECTRA \u00ae -5P device. Participants will receive a 3-dose series with immunizations at 0, 4 and 12 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatments"
        },
        {
            "text": "Group III Participants (n=25) assigned to receive GLS-5300 will be administered 6 mg DNA/dose given as a 1 ml IM injection followed by EP with the CELLECTRA \u00ae -5P device. Participants will receive a 3-dose series with immunizations at 0, 4 and 12 weeks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatments"
        },
        {
            "text": "Participants will be enrolled at the lowest dose (Group I) with continuous enrollment through the 1st week of enrollment. At the start of week 2, clinical laboratory data for the first five participants from Group I will be reviewed as part of the safety review. Once safety labs have been reviewed and cleared for the first five participants in Group 1 , the second dose level will be opened. The next five participants who have met eligibility criteria will then be enrolled into Group II. Then enrollment for Group I will be completed.",
            "cite_spans": [
                {
                    "start": 346,
                    "end": 353,
                    "text": "Group 1",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Method of Assigning Subjects to Treatment Groups (Randomization)"
        },
        {
            "text": "Once group 1 has completed enrollment of 25 participants, then Group 2 will be populated sequentially.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Method of Assigning Subjects to Treatment Groups (Randomization)"
        },
        {
            "text": "When the first five participants in Group 2 have reached one week post vaccination then safety labs will be reviewed as above. Once this safety assessment is cleared, then Group III will be opened for enrollment of the next five participants. Then enrollment will be completed for Group 2 and afterwards Group 3. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Method of Assigning Subjects to Treatment Groups (Randomization)"
        },
        {
            "text": "Safety Assessments:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunogenicity and Safety Variables"
        },
        {
            "text": "Participant self-evaluations are used to record any post treatment reactions (local and systemic). Participants enter the information in a post-vaccination memory aid on the evening of each dose and for 7 days post each dose. Any memory aid entry determined to meet the criteria for a Grade 1 or higher adverse event will be documented as an adverse event.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunogenicity and Safety Variables"
        },
        {
            "text": "Additional safety assessments include unsolicited adverse events and laboratory safety assessments.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunogenicity and Safety Variables"
        },
        {
            "text": "Unsolicited adverse events will be collected for the duration of the study. Details for these events will be collected either during on-site visits or via telephone. Laboratory safety assessments are collected at Screening, Week 1, Week 6 and Week 14. If a laboratory safety assessment is clinically significant, then an adverse event will be entered.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunogenicity and Safety Variables"
        },
        {
            "text": "Currently, the correlate of immunity for MERS CoV is not defined. It is clear that most neutralizing antibodies are directed against the surface Spike glycoprotein with particular immunologic focus at the receptor-binding domain in the S1 subunit. However, additional targets of humoral and cellular immunity are still to be defined. Thus immunogenicity assessments will not only measure known correlates (S neutralizing antibodies) but evaluate other potential mechanisms of immune response as well.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Immunologic Assessments:"
        },
        {
            "text": "All blood specimens will be collected at the WRAIR CTC and processed by the US Military HIV Research Program (MHRP) in the laboratories of Dr. Mark Manak and Dr. Sheila Peel. Specimens for analysis of primary and secondary immunologic endpoints will be shipped to a specimen repository at the ACTG laboratory at the University of Pennsylvania. Additional specimens for exploratory endpoints will be retained at the MHRP. Serum specimens at the University of Pennsylvania will be sent in batched shipments to the laboratory of Dr. Gary Kobinger at the National Microbiology Laboratory (NML) in Winnipeg, Canada where they will undergo ELISA and Neutralization analysis for secondary immunogenicity endpoints. PBMC specimens at the University of Pennsylvania will be sent in batched shipments to the laboratory of Dr. David Weiner at the Wistar Institute in Philadelphia, PA, USA where they will undergo ELISpot and ICS analysis for secondary immunogenicity endpoints. A division of labor for the laboratory assays is provided in the table below. Specimens for exploratory endpoint analysis will be retained at the UPENN or MHRP repositories for a period of 10 years. Whole blood in ACD (yellow top) tubes for PBMC isolation and serum will be collected on all participants at Baseline (Day 0), and Weeks 1, 2 or 3, 4, 6, 12, 14, 24, 36, and 60. ",
            "cite_spans": [
                {
                    "start": 1296,
                    "end": 1304,
                    "text": "Weeks 1,",
                    "ref_id": null
                },
                {
                    "start": 1305,
                    "end": 1312,
                    "text": "2 or 3,",
                    "ref_id": null
                },
                {
                    "start": 1313,
                    "end": 1315,
                    "text": "4,",
                    "ref_id": null
                },
                {
                    "start": 1316,
                    "end": 1318,
                    "text": "6,",
                    "ref_id": null
                },
                {
                    "start": 1319,
                    "end": 1322,
                    "text": "12,",
                    "ref_id": null
                },
                {
                    "start": 1323,
                    "end": 1326,
                    "text": "14,",
                    "ref_id": null
                },
                {
                    "start": 1327,
                    "end": 1330,
                    "text": "24,",
                    "ref_id": null
                },
                {
                    "start": 1331,
                    "end": 1334,
                    "text": "36,",
                    "ref_id": null
                },
                {
                    "start": 1335,
                    "end": 1342,
                    "text": "and 60.",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Immunologic Assessments:"
        },
        {
            "text": "No formal power analysis is applicable to this study, as descriptive statistics will be used to summarize the data. With 25 participants per treatment arm, the study provides 95% confidence that the true incidence of SAEs is <20% if no SAEs are observed in the treatment arm. Overall, with 75 treated participants, the study provides 95% confidence that the true incidence of SAEs is <5%, if no SAEs are observed.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAMPLE SIZE CONSIDERATIONS"
        },
        {
            "text": "All continuous variables will be summarized using the following descriptive statistics: n (non-missing sample size), mean, standard deviation, median, maximum and minimum. The frequency and percentages (based on the non-missing sample size) of observed levels will be reported for all categorical measures. In general, all data will be listed, sorted by dose level and subject, and when appropriate by visit number",
            "cite_spans": [],
            "ref_spans": [],
            "section": "General Principles"
        },
        {
            "text": "The Emmes Corporation Version 1.0 Statistical Analysis Plan -Protocol: WRAIR #2274 07 June 2017 12 within subject. All summary tables will be structured with a column for each dose level in the order (Group 1, 2, 3) and will be annotated with the total population size relevant to that table/treatment, including any missing observations.",
            "cite_spans": [
                {
                    "start": 200,
                    "end": 209,
                    "text": "(Group 1,",
                    "ref_id": null
                },
                {
                    "start": 210,
                    "end": 212,
                    "text": "2,",
                    "ref_id": null
                },
                {
                    "start": 213,
                    "end": 215,
                    "text": "3)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "General Principles"
        },
        {
            "text": "The interim analyses will be performed after the immunology assays for samples up to the Week 14 visits are completed. The final analysis described in this SAP will be performed after the main immunology assays are completed. The main immunology assays are defined in Section 4.4.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Timing of Analyses"
        },
        {
            "text": "A tabular listing of all subjects, visits, and observations excluded from the various analysis populations will be provided in the CSR (Appendix 16.2.3).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Analysis Populations"
        },
        {
            "text": "The modified intention to treat (mITT) analysis includes all participants who receive at least one study treatment administration (IM injection with EP). Participants in this sample will be grouped based dose assigned. Analyses on the mITT sample will be considered supportive of the corresponding PP analyses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Modified Intention-to-Treat (mITT) Population"
        },
        {
            "text": "Per-protocol (PP) analysis to comprise participants who receive all treatment administrations, have no major protocol deviations, and have primary endpoint data available. A participant will be defined as having primary endpoint data available if they have not terminated from the protocol earlier than the active treatment administration period. The active treatment administration period will be defined as prior to Week 14 as this would ensure participants did not terminate prior to the third treatment administration. Participants in this sample will be grouped for purposes of the tables, figures and listings based on dose assigned.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Per Protocol (PP) Population"
        },
        {
            "text": "The safety analysis set includes all participants who receive at least one study treatment and for whom post-dose safety data are available. A participant will be considered to have post-dose safety data available if he/she attends at least one post treatment study visit. Participants will be analyzed according to the dose of GLS-5300 they received.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Safety Population"
        },
        {
            "text": "The protocol does not define any formal subgroup analyses, and the study is not adequately powered to perform subgroup analyses. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Covariates and Subgroups"
        },
        {
            "text": "Missing data will not be replaced, and calculations will be done on reported values.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Missing Data"
        },
        {
            "text": "An interim analysis of immunogenicity data will take place after week 14 visits have been completed. This will not be used to make any decisions concerning the conduct of the trial. Since this early look at the data is not intended to impact the conduct of the trial, alpha-spending adjustments are not needed to control the overall Type I error. Tables, figures and listings included in the interim analyses are indicated with an A superscript in the Appendix and will only include data up to and including the Week 14 visit.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Interim Analyses and Data Monitoring"
        },
        {
            "text": "In general, descriptive statistics will be used to summarize the data pertaining to the non-immunological endpoints with the exception of some of the safety data being analyzed using Fisher's exact tests and ttests as noted in Section 9. Immunological endpoints will be analyzed as denoted in Section 8. No adjustments for multiple testing are planned. The disposition of subjects in the study will be tabulated by group (Table 14. 1.3, Appendix I). The table shows the total number of subjects screened, enrolled, receiving at least 1 dose, receiving at least 2 doses, discontinued dosing and the number completing the study. A listing of subjects who discontinued dosing and the reason will be included in Listing 16.2.1 (Appendix III).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 421,
                    "end": 431,
                    "text": "(Table 14.",
                    "ref_id": "TABREF13"
                }
            ],
            "section": "Multiple Comparisons/Multiplicity"
        },
        {
            "text": "A flowchart showing the disposition of study subjects, adapted from the Consort Statement will be included (Figure 14 .1.1, Appendix II). This figure will present the number of subjects screened, enrolled, lost to follow-up, and analyzed, by group.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 107,
                    "end": 117,
                    "text": "(Figure 14",
                    "ref_id": null
                }
            ],
            "section": "Subject Disposition"
        },
        {
            "text": "A summary of subject-specific protocol deviations will be presented by the reason for the deviation, the deviation category, and treatment group for all subjects ( ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Protocol Deviations"
        },
        {
            "text": "All immunogenicity variables will be listed by group, subject and visit. Data will be summarized by group.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "IMMUNOGENICITY EVALUATION"
        },
        {
            "text": "The primary objective and endpoints are summarized in Section 9 since they pertain to the safety and tolerability of GLS-5300.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "IMMUNOGENICITY EVALUATION"
        },
        {
            "text": "The secondary objectives of the study include evaluating the cellular and humoral response of GLS-5300 when delivered IM followed by EP as well as evaluating the dose response for cellular and humoral reactivity of GLS-5300 when delivered IM followed by EP. To compare the ELISA titer responses across the three groups by study day to determine whether the responses differ by dose will be analyzed using the Kruskal-Wallis test. This test is a non-parametric test and is an extension to more than two groups of the Wilcoxon rank sum test for two groups. Since sample sizes are not large enough to assume asymptotic normality and the analyses endpoints are likely skewed (titer responses), non-parametric tests are employed as they do not require distributional assumptions. The null hypothesis of the Kruskal-Wallis test is that the three different dose groups have the same distribution of the ELISA responses for a particular study visit. If a significant difference is determined using the Kruskal-Wallis test, pairwise comparisons will be evaluated. Identical statistical analyses to compare the neutralizing antibody titer response across the three groups by study day as noted for the ELISA endpoint will be used. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Endpoint Analyses"
        },
        {
            "text": "As described above, immunological endpoints will be summarized graphically to display trends over time for different dose groups. Comparison of these trends will allow for qualitative assessment of exploratory endpoints, including:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Endpoint Analyses"
        },
        {
            "text": "\u2022 Comparison of S binding antibody and MERS CoV neutralizing antibody titers \u2022 Kinetics and durability of S binding antibody and MERS CoV neutralizing antibody titers \u2022 Comparison of IFN-\u03b3 ELISpot, and ICS responses across different vaccine doses \u2022 Kinetics and durability of IFN-\u03b3 ELISpot, and ICS responses across different vaccine doses",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Endpoint Analyses"
        },
        {
            "text": "The primary objective of the study is to evaluate the safety and tolerability of GLS-5300 when administered by IM injection followed by EP in healthy adult participants. Safety assessments including the primary safety endpoints are defined in the following subsections. All safety outcomes will be assessed by dose group ordered from lowest to highest (0.67 mg/dose, 2 mg/dose, 6 mg/dose) and overall which includes all dose groups.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAFETY EVALUATION"
        },
        {
            "text": "Demographic and baseline data, vital signs, medical history, concomitant illnesses, and current medications/treatments will be summarized by means of descriptive statistics: mean standard deviation, minimum, median, and maximum values for continuous variables, and percentages for categorical variables, stratified by treatment group. The analysis is a modified intent-to-treat analysis in that individuals who are screened but not enrolled do not contribute data and hence are excluded.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Demographic and Other Baseline Characteristics"
        },
        {
            "text": "Summaries of age, baseline temperature, baseline respiration rate, baseline blood pressure, baseline heart rate, gender, ethnicity, and race will be presented by group (Tables 14.1 .5.1-14.1.5.2, Appendix I).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 168,
                    "end": 180,
                    "text": "(Tables 14.1",
                    "ref_id": "TABREF13"
                }
            ],
            "section": "Demographic and Other Baseline Characteristics"
        },
        {
            "text": "Ethnicity is categorized as Hispanic or Latino, or not Hispanic and not Latino. In accordance with NIH reporting policy, subjects may self-designate as belonging to more than one race or may refuse to identify a race, the latter reflected in the CRF as \"No\" to each racial option. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Demographic and Other Baseline Characteristics"
        },
        {
            "text": "All current illnesses and past pre-existing medical conditions will be MedDRA coded using MedDRA dictionary version 18.1 or higher. Summaries of subjects' pre-existing medical conditions will be presented by group (Table 14. 1.6, Appendix I).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 214,
                    "end": 224,
                    "text": "(Table 14.",
                    "ref_id": "TABREF13"
                }
            ],
            "section": "Concurrent Illnesses and Medical Conditions"
        },
        {
            "text": "Individual subject listings will be presented for all medical conditions (Listing 16.2.4.2, Appendix III).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Concurrent Illnesses and Medical Conditions"
        },
        {
            "text": "All subjects were to receive three treatment administrations in the clinic. The number of treatment administrations to subjects will be presented by treatment group site as part of the subject disposition table (Table 14. 1.3, Appendix I). In addition, the listing of treatment administration compliance data is provided in Listing 16.2.5, Appendix III, including whether reflux/leakage occurred at the injection site during administration.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 211,
                    "end": 221,
                    "text": "(Table 14.",
                    "ref_id": "TABREF13"
                }
            ],
            "section": "Measurements of Treatment Compliance"
        },
        {
            "text": "When calculating the incidence of adverse events (i.e., on a per subject basis), each subject will only be counted once and any repetitions of adverse events within a subject will be ignored; the denominator will be the total number of subjects. All adverse events reported will be included in the summaries and analyses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse Events"
        },
        {
            "text": "One of the primary endpoints of interest is the administration (injection) site reactions. These local solicited events pertaining to administration (injection) site reactions include tenderness, pruritus, erythema, induration/swelling and bruising. The systemic solicited events include fever, malaise/fatigue, myalgia, headache, arthalgia and nausea. Both local and systemic events are recorded in the tables summarized. The proportion of subjects reporting at least one solicited adverse event will be summarized for each solicited adverse event, any systemic symptom, any local symptom, and any symptoms. The 95% CI calculated using Clopper-Pearson methodology from a binomial distribution (SAS Proc Freq with a binomial option) will be presented and a Fisher's exact test will be performed to test for the difference in the proportion of subjects reporting a solicited adverse event (Table 14. 3.1.1, Appendix I). ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 888,
                    "end": 898,
                    "text": "(Table 14.",
                    "ref_id": "TABREF13"
                }
            ],
            "section": "Solicited Events and Symptoms"
        },
        {
            "text": "Unsolicited AEs will be summarized for the 28 day period following each administration of Study Treatment. The proportion of subjects reporting at least one unsolicited adverse event will be summarized by MedDRA system organ class and preferred term for each vaccination and over all vaccinations. Denominators for percentages are the number of subjects who received the vaccination being summarized. A 95% CI will be presented along with a Fisher's exact test comparing the treatment groups and testing the difference in the proportion of subjects reporting an unsolicited adverse event for each MedDRA system organ class and preferred term.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unsolicited Adverse Events"
        },
        {
            "text": "Adverse events by subject will be presented in Listing 16.2.7.2, Appendix III.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unsolicited Adverse Events"
        },
        {
            "text": "The following summaries for unsolicited adverse events will be presented by MedDRA system organ class, preferred term, dose and group:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Unsolicited Adverse Events"
        },
        {
            "text": "\u2022 Subject level summary (Tables 14.3 The frequency and incidence of non-serious adverse events are displayed in bar charts by severity and MedDRA system organ class for each group (Figure 14.3.1.1 and 14. 3.1.2, Appendix II, respectively). The overall frequency and incidence of adverse events by severity and group is displayed in Figures  14.3.1.3 and 14. 3.1.4 respectively. The frequency and incidence of non-serious adverse events are displayed in bar charts by relationship to treatment and MedDRA system organ class for each group (Figure 14 .3.1.5 and 14.3.1.6, Appendix II, respectively). The overall frequency and incidence of adverse events by relationship to treatment and group is displayed in Figures 14.3.1.7 and 14. 3.1.8 respectively.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 24,
                    "end": 36,
                    "text": "(Tables 14.3",
                    "ref_id": "TABREF13"
                },
                {
                    "start": 180,
                    "end": 204,
                    "text": "(Figure 14.3.1.1 and 14.",
                    "ref_id": null
                },
                {
                    "start": 332,
                    "end": 357,
                    "text": "Figures  14.3.1.3 and 14.",
                    "ref_id": null
                },
                {
                    "start": 538,
                    "end": 548,
                    "text": "(Figure 14",
                    "ref_id": null
                },
                {
                    "start": 707,
                    "end": 731,
                    "text": "Figures 14.3.1.7 and 14.",
                    "ref_id": null
                }
            ],
            "section": "Unsolicited Adverse Events"
        },
        {
            "text": "The reporting period for SAEs (without regard to causality) is the entire period following the signing of the informed consent form until the end of the study. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Deaths, Serious Adverse Events and other Significant Adverse Events"
        },
        {
            "text": "For any subjects in the Safety population who became pregnant or pregnancy in the partner of a male participant exposed to study treatment during the study, every attempt was made to follow these subjects to completion of pregnancy to document the outcome, including information regarding any complications with pregnancy and/or delivery. A listing of pregnancies and outcomes will be presented (Listing 16.2.11, Appendix III).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pregnancies"
        },
        {
            "text": "Descriptive statistics including mean, standard deviation, median, minimum and maximum values by study day, for each laboratory parameter, will be summarized in Table 14 .3.4.1, Appendix I. Changes in laboratory values will be presented in Figure 14 .4, Appendix II. ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 161,
                    "end": 169,
                    "text": "Table 14",
                    "ref_id": "TABREF13"
                },
                {
                    "start": 240,
                    "end": 249,
                    "text": "Figure 14",
                    "ref_id": null
                }
            ],
            "section": "Clinical Laboratory Evaluations"
        },
        {
            "text": "Vital sign measurements including oral temperature, respiration rate, blood pressure and heart rate will be measured at specified visits. Baseline vital signs are summarized in ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Vital Signs and Physical Evaluations"
        },
        {
            "text": "All medications taken or medical procedures performed within 8 weeks prior to enrollment and during the study must be recorded on the case report forms. A by-subject listing of concomitant medication use will be presented in Listing 16.2.10, Appendix III.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Concomitant Medications"
        },
        {
            "text": "An ECG will be performed at screening for all participants to determine eligibility. The ECG should include measurements of ventricular rate, PR, QRS, QT, QTc with assessment as to whether the ECG is normal or abnormal. Abnormal ECGs will be interpreted as clinically significant or not clinically significant. Dosing will be delayed in the event of a clinically significant abnormal pre-dose ECG until it has been reviewed by the PI, qualified PI designee, Medical Monitor or Sponsor consultant cardiologist and deemed safe to proceed.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Other Safety Measures"
        },
        {
            "text": "P-values \u22650.001 and \u22640.999 will be reported to 3 decimal places; p-values less than 0.001 will be reported as \"<0.001\"; p-values greater than 0.999 will be reported as \"> 0.999\". The mean, standard deviation, and any other statistics other than quantiles, will be reported to one decimal place greater than the original data. Quantiles, such as median, or minimum and maximum will use the same number of decimal places as the original data. Proportions will be presented as two decimal places; values <0.01 will be presented as \"<0.01\". Percentages will be reported to the nearest whole number; values < 1% will be presented as \"<1\". Estimated parameters, not on the same scale as raw observations (e.g. regression coefficients) will be reported to 3 significant figures.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "REPORTING CONVENTIONS"
        },
        {
            "text": "SAS version 9.3 or above will be used to generate all tables, figures and listings.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TECHNICAL DETAILS"
        },
        {
            "text": "The protocol references summarizing the current medications/treatments via descriptive statistics. Rather than descriptive statistics, current medications will be summarized via a line listing. Week 2/3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SUMMARY OF CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED ANALYSES"
        },
        {
            "text": "Week 3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 4",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 12",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 14",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 24",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 36",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 60 N= Number of subjects in the mITT population Day 0 x",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x (x.xx)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x (x.x,",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x (x.xx)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x (x.x,",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x (x.xx)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x (x.x,",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x (x.xx)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x (x.x,",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "x.x) (x.x, x.x)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 2 Week 3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 4",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 12",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 14",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 24",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 36",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 60",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Protocol: WRAIR #2274 07 June 2017 Statistical Analysis Plan: Appendix I - Week 1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 2 Week 3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 4",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 12",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 14",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 24",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 36",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Week 60",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        },
        {
            "text": "Protocol: WRAIR #2274 07 June 2017 Statistical Analysis Plan: Appendix I - ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "LISTING OF TABLES, FIGURES, AND LISTINGS"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Morrow",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Tebas",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Mol Ther",
            "volume": "23",
            "issn": "3",
            "pages": "591--601",
            "other_ids": {
                "DOI": [
                    "10.1038/mt.2014.245"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological survey",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "M\u00fcller",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Meyer",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "M"
                    ],
                    "last": "Corman",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Lancet Infect Dis",
            "volume": "15",
            "issn": "5",
            "pages": "559--64",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "A synthetic consensus anti-Spike protein DNA vaccine induces protective immunity against Middle East Respiratory Syndrome Coronavirus in non-human primates",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Muthumani",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Falzarano",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "L"
                    ],
                    "last": "Reuschel",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Sci Transl Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "J"
                    ],
                    "last": "Prud&apos;homme",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Glinka",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Khan",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Draghia-Akli",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Curr Gene Ther",
            "volume": "6",
            "issn": "",
            "pages": "243--73",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Safety profile of the Merck human immunodefiency virus-1 clade B gagDNA plasmid vaccine with and without adjuvants",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "K"
                    ],
                    "last": "Quirk",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "L"
                    ],
                    "last": "Brown",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "Y"
                    ],
                    "last": "Leavitt",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Open Forum Infect Dis",
            "volume": "1",
            "issn": "1",
            "pages": "1--3",
            "other_ids": {
                "DOI": [
                    "10.1093/ofid/ofu016"
                ]
            }
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Rosati",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Valentin",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Jalah",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Vaccine",
            "volume": "26",
            "issn": "",
            "pages": "5223--5232",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Saad",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Omrani",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Baig",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Int J Infect Dis",
            "volume": "29",
            "issn": "",
            "pages": "301--306",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a Phase I clinical trial",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "N"
                    ],
                    "last": "Sarwar",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Costner",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Enama",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "J Infect Dis",
            "volume": "211",
            "issn": "4",
            "pages": "549--57",
            "other_ids": {
                "DOI": [
                    "10.1093/infdis/jiu511"
                ]
            }
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomized, double-blind, placebo-controlled phase 2b trial",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "L"
                    ],
                    "last": "Trimble",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Morrow",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Kraynyak",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Lancet",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(15)00239-1"
                ]
            }
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "E"
                    ],
                    "last": "Ugen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Kutzler",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Marrero",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Westover",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Coppola",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Weiner",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Heller",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Cancer Gene Ther",
            "volume": "13",
            "issn": "",
            "pages": "969--74",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Evaluation of candidate vaccine approaches for MERS CoV",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Joyce",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Nature Commun",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/ncomms8712"
                ]
            }
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 iii PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION TABLE 14.3.4.1: Laboratory Summary Statistics by Parameter, Study Day",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        ".......... ."
                    ],
                    "last": "Group",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Chemistry Results: ALT",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        ". ."
                    ],
                    "last": "/L)",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Chemistry Results: AST",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        ". ."
                    ],
                    "last": "/L)",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Chemistry Results: Creatinine (mg/dL)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Chemistry Results: Sodium",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        ". ."
                    ],
                    "last": "/L)",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Chemistry Results: Glucose (mg/dL)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Chemistry Results: Bicarbonate (mmol/L)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Chemistry Results: Blood Urea Nitrogen (mg/dL)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Chemistry Results: Creatine Kinase",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        ". ."
                    ],
                    "last": "Iu/L)",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Chemistry Results: Chloride",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        ". ."
                    ],
                    "last": "/L)",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Chemistry Results: Potassium",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        ". ."
                    ],
                    "last": "/L)",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Hematology Results: Hemoglobin (g/dL)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Hematology Results: Neutrophils (cells/ L)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Hematology Results: Eosinophils (cells/ L)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Hematology Results: Lymphocytes (cells/ L)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Hematology Results: Monocytes (cells/ L)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Protocol: WRAIR #2274",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Note: N = Number of subjects in the Safety Analysis Population",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "For severity, a subject is counted once per preferred term and is summarized according to their highest severity",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "For relationship, a subject is only counted once per preferred term and is summarized according to their closest relationship",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Note: N = Number of subjects in the Safety Analysis Population",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "For severity, a subject is counted once per preferred term and is summarized according to their highest severity",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "For relationship, a subject is only counted once per preferred term and is summarized according to their closest relationship",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Note: N = Number of subjects in the Safety Analysis Population",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "For severity, a subject is counted once per preferred term and is summarized according to their highest severity",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "For relationship, a subject is only counted once per preferred term and is summarized according to their closest relationship",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Note: N = Number of subjects in the Safety Analysis Population",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "For severity, a subject is counted once per preferred term and is summarized according to their highest severity",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "For relationship, a subject is only counted once per preferred term and is summarized according to their closest relationship. Protocol: WRAIR #2274 FIGURE 14.3.1.1: Frequency of Adverse Events by MedDRA\u00ae System Organ Class and Severity",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Group I: 0.67 mg/dose (N=X)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Group II: 2 mg/dose (N=X)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Group III: 6 mg/dose",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        ". ."
                    ],
                    "last": "N=x)",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Group I: 0.67 mg/dose (N=X)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "Group II: 2 mg/dose (N=X)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "3.1.3: Frequency of Adverse Events by Severity",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        ". ."
                    ],
                    "last": "N=x)",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Group III: 6 mg/dose",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "3.1.5: Frequency of Adverse Events by MedDRA \u00ae System Organ Class and Relationship to Treatment",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "Group I: 0.67 mg/dose (N=X)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "Group II: 2 mg/dose (N=X)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "Statistical Analysis Plan: Appendix II -Figure Mock-ups Version 1.0 ii PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "3.1.6: Incidence of Adverse Events by MedDRA \u00ae System Organ Class and Relationship to Treatment",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        "........ ."
                    ],
                    "last": "N=x)",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Group III: 6 mg/dose",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Group I: 0.67 mg/dose (N=X)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Group II: 2 mg/dose (N=X)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "3.4: Laboratory Results by Scheduled Visits: Mean Changes from Screening by Laboratory Parameter, and Group",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        "................ ."
                    ],
                    "last": "N=x)",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Group III: 6 mg/dose",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "were incubated for five hours with a single pool of all MERS-CoV S 15-mer peptides (see IFN\u03b3-ELISPOT) in the presence of Brefeldin A. Cells were washed and incubated with live-dead violet stain (Invitrogen) followed by a cocktail of anti-CD4-BV510 and anti-CD8-AP Cy7 antibodies. Cells were washed, fixed and permeabilized, and then incubated with a cocktail of anti-IFN\u03b3-PE, anti-TNF\u03b1-AF700, anti-IL-2-APC, anti-IL4-PE D594, anti-CD3-BV650 antibodies (antibodies from BioLegend except anti-IL-2 from BD). Samples were analyzed on FACS LSRII (BD) equipped with four lasers (violet, blue, green and red) and band pass filters to capture 18 colors. Data was analyzed using FloJo v.10 software. Gating strategy: FSC-A/FSC-H singlets-> FSC-A/SSC-A lymphocytes-> Live, CD3+ cells-> [CD8+CD4-cells -> IFN\u03b3+, TNF\u03b1+, IL-2+, and IL-4+ populations] or [CD8-CD4+ cells -> IFN\u03b3+, TNF\u03b1+, IL-2+, and IL-",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "OF CONTENTS .....................................................................................................4 CLINICAL PROTOCOL SYNOPSIS .................................................................................9 Table S1: Dosing Arms and Regimens ....................................................................... 9 Table S2. Schedule of Events .................................................................................... 13 1. INTRODUCTION .................................................................................15 Background and Rationale .................................................................15 MERS CoV Epidemiology and Clinical Illness ................................... 15 Current Treatment ................................................................................ 15 1.1.3 Military Relevance ............................................................................... 16 Pre-clinical experience with GLS-5300 ............................................... 17 Human experience with DNA plasmids for gene expression ............... 17 Administration of similar DNA plasmids by Electroporation ............. 18",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "j. Willing to allow storage and future use of samples for MERS CoV related research of an investigational compound either currently or within 30 days of first dose; b. Previous receipt of an investigational product for the treatment or prevention of MERS CoV except if participant is verified to have received placebo;",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "virus 1 R region for translational enhancement (Martin 2006 Clin Vaccine Immunol, Martin 2007 Vaccine). The GLS-5300 to be used in this study is based on the pGX0001 plasmid backbone and does not contain lentiviral components and has been safely used in numerous clinical trials (MacGregor 1998 JID, Bagarazzi 2012 Sci Trans Med, Morrow 2015 Mol Ther).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Enrollment Leukapheresis in lieu of immunology testing may be performed for up to 5 participants at week 14 and 24, based on enrollment into a dedicated substudy",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Leukapheresis in lieu of collection of blood for immune assessment if enrolled (weeks 14 and 24 only) \u2022 Review Participant Reminder Diary (Weeks 6 and 14);",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Hematology CBC: White blood cell (WBC) count and differential count, Red blood cell (RBC) count, Hemoglobin, Hematocrit, Platelet count; Serum Chemistry Serum electrolytes, blood urea nitrogen (BUN), creatinine (Cr), glucose, ALT, AST, CPK; Serology (screening only): Antibody to HIV (human immunodeficiency virus), Hepatitis B surface antigen (HBsAg), and Hepatitis C antibody (HCV Ab)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Components of administration (injection) site reactions: o Tenderness (present or absent and severity) o Pruritus (present or absent and severity) o Erythema (diameter in cm) o Induration/Swelling (diameter in cm) o Bruising (diameter in cm)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "Moderate",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "Shipping specifications are included the Laboratory Manual 3. Serum and whole blood not used for above analyses to be shipped overnight to:",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": "Manages and maintains the database Statistician \u2022 Complies with GCP and Belmont Principles \u2022 Qualified through training, education and experience \u2022 Statistically analyzes the verified data according to the protocol, statistical analysis plan and any amendments in place \u2022 Provides documentation of statistical findings to the principal investigator for incorporation into required reports Clinical Monitors \u2022 Complies with GCP and Belmont Principles \u2022 Qualified through training, education and experience \u2022 Reviews study procedures, staff training and study documentation to ensure safety and accuracy in accordance with internal procedures Regulated Studies Laboratory Staff and Research Investigators \u2022 Complies with GCP, Good Laboratory Practices and Belmont Principles \u2022 Qualified through training, education and experience \u2022 Analyzes study participants sera for immune response to vaccines Clinical Laboratory Staff \u2022 Complies with GCP and Belmont Principles \u2022 Qualified through training, education and experience",
            "latex": null,
            "type": "figure"
        },
        "FIGREF11": {
            "text": "............................................................................................................................................ 1 2 INTRODUCTION ............................................................................................................................... 1 2.1 Purpose of the Analyses ................................................................................................................ 2 3 STUDY OBJECTIVES AND ENDPOINTS ................................................................................................................................................................................................................. 2 3.2 Endpoints .....................................................................................................................................and Derived Variables ..................................................................................... 3 4 INVESTIGATIONAL PLAN .............................................................................................................Design and Plan ....................................................................................................Study Population ....................................................................................................... 6 4.3 Treatments ....................................................................................................................................Assigning Subjects to Treatment Groups (Randomization) .............................. 9 4.4 Immunogenicity and Safety Variables ........................................................................................ 10 5 SAMPLE SIZE CONSIDERATIONS .............................................................................................. 11 6 GENERAL STATISTICAL CONSIDERATIONS ........................................................................... 11 6.1 General Principles ....................................................................................................................... 11 6.2 Timing of Analyses ..................................................................................................................... 12 6.3 Analysis Populations ................................................................................................................... 12 6.3.1 Modified Intention-to-Treat (mITT) Population ............................................................... 12 6.3.2 Per Protocol (PP) Population ............................................................................................. 12 6.3.3 Safety Population .............................................................................................................. 12 6.4 Covariates and Subgroups ........................................................................................................... 12 6.5 Missing Data ............................................................................................................................... 13 6.6 Interim Analyses and Data Monitoring ....................................................................................... 13 6.7 Multiple Comparisons/Multiplicity ............................................................................................. 13 7 STUDY SUBJECTS .......................................................................................................................... 13 7.1 Subject Disposition ..................................................................................................................... 13 7.2 Protocol Deviations ..................................................................................................................... 13 8 IMMUNOGENICITY EVALUATION ............................................................................................ 14 8.1 Secondary Endpoint Analyses .................................................................................................... 14 Immunologic Endpoint: ELISA ............................................................................................................. 14 8.2 Exploratory Endpoint Analyses .................................................................................................................................................................................................................. 15 9.1 Demographic and Other Baseline Characteristics ....................................................................... 15 9.1.1 Concurrent Illnesses and Medical Conditions ................................................................... 16 9.2 Measurements of Treatment Compliance ................................................................................... 16 9.3 Adverse Events .........................................................................................................................and Symptoms ......................................................................................Events .............................................................................................. 17 9.4 Deaths, Serious Adverse Events and other Significant Adverse Events ..................................... 17 9.5 Pregnancies ................................................................................................................................. 18 9.6 Clinical Laboratory Evaluations ................................................................................................. 18 9.7 Vital Signs and Physical Evaluations .......................................................................................... 18 9.8 Concomitant Medications ........................................................................................................... 18 9.9 Other Safety Measures ................................................................................................................ 18 10 REPORTING CONVENTIONS ....................................................................................................... 19 11 TECHNICAL DETAILS ................................................................................................................... 19 12 SUMMARY OF CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED ANALYSES . ......................................................................................................................................................... 19 13 REFERENCES .................................................................................................................................. 19 14 LISTING OF TABLES, FIGURES, AND LISTINGS ...................................................................... 19 APPENDICES: APPENDIX I -TABLE MOCK-UPS -See separate document APPENDIX II -FIGURE MOCK-UPS -See separate document APPENDIX III -DATA LISTING MOCK-UPS -See separate document",
            "latex": null,
            "type": "figure"
        },
        "FIGREF12": {
            "text": "Based on prior experience with treatment of HIV infection, a dose of 2 mg of GLS-5300 corresponds to a vaccine dose of approximately 30 \u00b5g/kg. Preclinical studies in rhesus macaques assessed high (2 mg/vaccination) and low (0.5 mg/vaccination) doses of pGX9001. Robust T-cell immune responses in humans were elicited with a dose of 2 mg/vaccination with a similar DNA construct in a Phase I doseranging study for the treatment of cervical dysplasia related to HPV cervical infection (Bagarazzi 2012 Sci Transl Med, Trimble 2015 Lancet). Preliminary analysis of the human response to VGX-6150 for the treatment of Hepatitis C shows minimal immunologic benefit since when the dose is increased from 2 mg to 6 mg, there is only a small increase in immune response. Notably, both the HPV product and VGX-6150 are based on the same expression system used to construct GLS-5300. Assessment of antibody and",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": "Interferon-gamma (IFN-\u03b3) ELISpot \u2022 Intracellular cytokine staining (ICS) (cytotoxic T lymphocyte phenotype, lytic granule loading, granzyme B killing of target cells) Exploratory Endpoints \u2022 Comparison of S binding antibody and MERS CoV neutralizing antibody titers \u2022 Kinetics and durability of S binding antibody and MERS CoV neutralizing antibody titers \u2022 Comparison of IFN-\u03b3 ELISpot, and ICS responses across different vaccine doses \u2022 Kinetics and durability of IFN-\u03b3 ELISpot, and ICS responses across different vaccine doses \u2022 Expression of the full length MERS CoV S protein in the peripheral blood over time \u2022 Host immune-genotyping as resources are available \u2022 Epitope mapping of CD4+ and CD8+ T lymphocyte responses \u2022 Immunophenotyping and functional characterization of cellular subsets of interest, including natural killer (NK) cells \u2022 Isolate, express and characterize monoclonal antibodies against the MERS CoV S protein and assess their neutralizing and non-neutralizing functional activity",
            "latex": null,
            "type": "figure"
        },
        "FIGREF14": {
            "text": "Enrollment (pre 1 st dose of vaccine) \uf0d8 Week 1 Week 2 or week 3 post 1 st vaccination ) Age 18-50 years; military, civilian, male and female.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF15": {
            "text": "Box Plots of ICS Results Over Time by Group (% of cells expressing the cytokine under evaluation) ...................................................................................................................................AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION Excluded from safety analyses (n=x) Did not attend at least one post-treatment study visit (x) Excluded from safety analyses (n=x) Did not attend at least one post-treatment study visit (x) Allocated to Group III: (n=x) \u2666 (mITT population ) Received at least one treatment administration (n=x) \u2666 Did not receive one treatment administration Excluded from safety analyses (n=x) Did not attend at least one post-treatment study visit (x) AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "CD8+ and CD4+ T-cell TNF\u03b1 and IFN\u03b3 Responses 5 S5: Immune responses of patients recovered from MERS-CoV infection. 6 S6: Comparison of fl-S-ELISA between Convalescent and Vaccine Samples 8 Tables S1: Descriptions of methods for immunology assays 9 S2: Reasons for screen failure or non-inclusion into the WRAIR-2274 study 10 S3: Unsolicited adverse events by MedDRA System organ class by severity and relationship to study vaccine 11 S4: P-values for Fisher's Exact Tests Comparing MERS S1 ELISA Positive Response between Groups by S6: Kruskal-Wallis Test p-values by Time Point for the ELISA S1 Titer Results 14 S7: T-test Results Comparing Total IFN-\u03b3 Means between Groups by Study Day, mITT Population 15 S8: One Way Anova -Tukey's Group Comparison Test for between Naturally Infected vs. Vaccinated Groups 16 Clinical Trial Documents WRAIR-2274 Clinical Study Protocol 17",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Method Descriptions for MERS-CoV Immunology Assays",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Reasons for screen failure or non-inclusion into the WRAIR-2274 study",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Unsolicited adverse events by MedDRA System organ class by severity and relationship to study vaccine",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "P-values for Fisher's Exact Tests Comparing MERS S1 ELISA Positive Response between Groups by Study Day, mITT Population",
            "latex": null,
            "type": "table"
        },
        "TABREF6": {
            "text": "MERS S1 ELISA Geometric Mean Titer (GMT) Results with 95% Confidence Intervals (CI) by Study Day and Group, mITT population",
            "latex": null,
            "type": "table"
        },
        "TABREF7": {
            "text": "Kruskal-Wallis Test p-values by Time Point for the ELISA S1 Titer Results",
            "latex": null,
            "type": "table"
        },
        "TABREF8": {
            "text": "T-test Results Comparing Total IFN-\u03b3 Means between Groups by Study Day, mITT Population",
            "latex": null,
            "type": "table"
        },
        "TABREF9": {
            "text": "One Way Anova -Tukey's Group Comparison Test between Naturally Infected and Vaccinated Groups",
            "latex": null,
            "type": "table"
        },
        "TABREF11": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF12": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF13": {
            "text": "1: Total Participants and Total DNA Doses Administered with IM and ID EP with the CELLECTRA \u00ae Device ......................................................... 19 CLINICAL PROTOCOL SYNOPSIS Title of Study: Phase I, open-label, dose-ranging study to evaluate the safety, tolerability, and immunogenicity of GLS-5300, administered IM and followed by electroporation in healthy volunteers Estimated Number of Study Centers and Countries/Regions: 1 site, US",
            "latex": null,
            "type": "table"
        },
        "TABREF14": {
            "text": "Dosing Arms and Regimens",
            "latex": null,
            "type": "table"
        },
        "TABREF15": {
            "text": "Nat Comm), a micelle expressing the full length post-fusion S trimer, and modified vaccinia Ankara virus and adenovirus expression systems containing the spike (S) protein, as well as the S protein DNA plasmid vaccine to be administered in this clinical trial (Muthumani 2015 Sci Transl Med). Multiple small molecule and biologic therapeutic candidates are being assessed that include immunomodulators, polymerase and fusion protein inhibitors, as well as monoclonal antibodies against the S protein.",
            "latex": null,
            "type": "table"
        },
        "TABREF16": {
            "text": "Pacific Command (CENTCOM, PACOM) areas of responsibility (AOR) where recent outbreaks have occurred (i.e. Republic of Korea, Kingdom of Saudi Arabia). The potential for high personto-person transmissibility and the continued transmission in the CENTCOM AOR underscore the need for the US military to advance the development of effective countermeasures to mitigate the risk of MERS CoV exposure and transmission to US military personnel.",
            "latex": null,
            "type": "table"
        },
        "TABREF17": {
            "text": "Jin 2015 Vaccine, Quirk 2014 Open Forum Infect Dis). Other published Phase I trials of DNA plasmid vaccines include studies evaluating vaccines against Ebola virus (Martin 2006, Sarwar 2015, Kibuuka 2014), HPV, HIV, and influenza (Bagarazzi 2013, Kalams 2012 PLoS ONE, Ledgerwood 2015 PLoS One). Phase II clinical trial data from the Inovio HPV DNA vaccine is currently in press.Experience with DNA vaccines using modified pVAX1 plasmid backbone by Inovio Pharmaceuticals and GeneOne Life Science is extensive. Ongoing collaborative clinical trials between Inovio Pharmaceuticals and GeneOne Life Science include a prophylactic vaccine against the Zaire strain of Ebola virus (NCT02464670) and a therapeutic vaccine against genotype 1 hepatitis C virus (NCT02027116). Prior studies have examined a DNA plasmid based vaccine",
            "latex": null,
            "type": "table"
        },
        "TABREF19": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF20": {
            "text": "Common name: pGX9001Chemical name: pGX9001 is a circular, double stranded, deoxyribonucleic acid plasmid consisting of 7025 base pairs.",
            "latex": null,
            "type": "table"
        },
        "TABREF21": {
            "text": "\u2022 Severe localized administration site reaction, such as sterile abscess or secondary bacterial infection \u2022 Allergic reaction, including urticaria, angioedema, bronchospasm, or anaphylaxis \u2022 Chills, flu-like syndrome \u2022 Muscle damage at the administration site \u2022 Autoimmune disease \u2022 Electrical injury \u2022 Disruption of function of implanted electronic medical devices \u2022 Exacerbation of cardiac arrhythmia \u2022 Effects on the fetus and on pregnancyThe full safety monitoring plan is described in detail in the Evaluation of Safety and Management of Toxicity section below (Section 7).",
            "latex": null,
            "type": "table"
        },
        "TABREF26": {
            "text": "participant. This includes serious and non-serious adverse events regardless of relation to study drug. \u2022 Death: The participant died.",
            "latex": null,
            "type": "table"
        },
        "TABREF27": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF29": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF32": {
            "text": "ELISAAntibody Responses A standardized binding ELISA will be performed at the laboratory of Dr. Gary Kobinger to measure the anti-MERS S protein binding antibody responses. Briefly, 96-well enzyme immunoassay plates will be coated with purified recombinant human betacoronavirus spike protein from MERS CoV strain 2c EMC/2012 (Clade A) (Sino Biological, Inc.",
            "latex": null,
            "type": "table"
        },
        "TABREF34": {
            "text": "Unrelated AEs include the following: \u2022 Medical or surgical procedures (e.g., surgery, endoscopy, tooth extraction, transfusion)",
            "latex": null,
            "type": "table"
        },
        "TABREF35": {
            "text": "\u2022 \"Life-threatening\" means that the participant was at immediate risk of death from the event as it occurred. This does not include an event that might have led to death if it had occurred with greater severity\u2022 Complications that occur during hospitalizations are AEs. If a complication prolongs the hospitalization, it is an SAE",
            "latex": null,
            "type": "table"
        },
        "TABREF38": {
            "text": "No reimbursement is available if the participant incurs medical expenses to treat research-related injuries. No compensation is available for research-related injuries. The participant is not waiving any legal rights. The participant should contact the PI if the participant believes he or she has sustained a research-related injury. The participant should contact the PI for any questions.",
            "latex": null,
            "type": "table"
        },
        "TABREF41": {
            "text": "Appendix B: Toxicity Grading ScaleToxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007",
            "latex": null,
            "type": "table"
        },
        "TABREF42": {
            "text": "Appendix D: Reporting of Device Related ComplaintsCELLECTRA\u00ae Error Reporting FormPlease complete the form and fax to (267) 440-4242 or scan the form to EPerror@inovio.com 5P ONLY, was the EP Guide used? \u2610 YES \u2610 NO IM-5P ONLY: If EP Guide was used, please provide reason and include subject's BMI. NO If NO, please provide reason and include needle gauge and syringe volume used.Did the display on the device read EP successful? \u2610 YES\u2610 NO If NO, please check all complications that led to failure and describe complication below \u2610 IM-5P ONLY: Impedance Test Error message displayed, fill out Impedance Test Error section below \u2610 Electroporation Error message displayed, fill out Electroporation Error section below \u2610 EP aborted by trigger or keypad error message displayed \u2610 Battery level too low for electroporation message displayed \u2610 Difficulty inserting array into muscle or skin \u2610 Other, please specify below Describe device complication below (continue on back if necessary): NO Were all attempts performed on the same day? \u2610 YES \u2610 NO Was a different location used for each attempt? \u2610 YES \u2610 NO Was a new array used for each attempt?\u2610 YES \u2610 NO Please provide any additional information below (continue on back if necessary): Was the array fully inserted in the subject's arm?\u2610 YES \u2610 NO Was the array inserted perpendicular to the subject's arm? \u2610 YES \u2610 NO Did the needles of the array appear damaged in any way? \u2610 YES \u2610 NO If you were provided a sharps shuttle, please eject the array into a shuttle and ship to Inovio.Appendix E RESEARCH MONITORResearch Monitor: Jason W. Bennett, MD, MSPH, LTC, MC, USA Infectious Diseases Division Uniformed Services University of the Health Sciences Room A3060",
            "latex": null,
            "type": "table"
        },
        "TABREF45": {
            "text": "APPENDIX G: Research Team Roles, Responsibilities and Study Team ListingPrincipal Investigator\u2022 Complies with protocol and all Federal and local regulations and policies and has ultimate responsibility for the conduct of the study and submission of the study report. Complies with GCP and Belmont Principles\u2022 Qualified through training, education and experience \u2022 Supervises sub-investigators and protocol nurse coordinator \u2022 Trains study staff \u2022 Screens individuals and reviews all of the screening tests to determine eligibility of person to participate in the study. Investigator or designee makes final eligibility decision. \u2022 Permits auditing, institutional monitoring (US Army Medical Materiel Development Activity), and inspection by the US Food and Drug Administration \u2022 Assures adequate resources, time, and participant population to meet study requirements \u2022 Provides medical care for adverse events \u2022 Documents protocol deviations \u2022 Reports all serious adverse events to the regulatory bodies (i.e., WRAIR IRB or UMB HRPP) and sponsor's representative (US Army Medical Materiel Development Activity) \u2022 Delegates investigational product accountability and administration \u2022 Evaluates AEs for diagnosis, relationship, and severity. Ensures documentation and safety reporting \u2022 Ensures that he/she has sufficient time to conduct and complete the study \u2022 Ensures he/she has adequate staff and appropriate facilities that are available for the duration of the study and to ensure that other studies do not divert essential participants or facilities away from the study at hand \u2022 Submits an up-to-date curriculum vitae and other credentials (e.g. medical license number in the United States) to the sponsor and, where required, to relevant authorities \u2022 Acquires the normal ranges for laboratory tests performed locally and, if required by local regulations, obtains the laboratory licenses or certifications \u2022 Informs the IRB of any non-protocol specified laboratory testing that may occur on stored serum samples left over after protocol specified laboratory testing is completed (e.g., clinical tests performed in the evaluation of a participant's medical problem or additional specific immunologic evaluations as they become available) \u2022 Prepares and maintains adequate case histories designed to record observations and other data pertinent to the study \u2022 Conducts the study in compliance with the protocol and any amendments \u2022 Cooperates with representatives of USAMMDA in monitoring the study and in resolution of queries about the data Associate Investigators \u2022 Complies with GCP and Belmont Principles \u2022 Qualified by training, education and experience \u2022 Assists principal investigator in conduct of study \u2022 Assists in supervising study staff \u2022 Reviews all of the screening tests to determine eligibility of individual to participate in the study. Investigator or designee makes final eligibility decision. \u2022 Complies with GCP and Belmont Principles \u2022 Qualified by training, education and experience, and holds a current, unrestricted nursing license \u2022 Investigational vaccine accountability delegated to licensed nursing personnel. Reviews all of the screening tests \u2022 Schedules follow-up appointments \u2022 Collects information on adverse events \u2022 Accurate and timely completion of case report forms \u2022 Trains staff on protocols/protocol changes \u2022 Documents protocol deviations. Stores IND product in temperature controlled and monitored units \u2022 Signs out IND product to the investigational product preparer \u2022 Verifies and records administration of investigational products to study participants Other Study Staff \u2022 Complies with GCP and Belmont Principles \u2022 Qualified through training, education, and experience \u2022 Recruits study participants with IRB approved materials \u2022 Contacts study participants to collect adverse event data \u2022 Schedules follow-up appointments \u2022 Follows-up on non-compliant study participants \u2022 Ensures efficient clinic flow \u2022 Performs participant specific training Study Administrative Support \u2022 Complies with GCP and Belmont Principles \u2022 Qualified through training, education and experience \u2022 Maintains essential clinical trial documents \u2022 Hosts visits of auditors, monitors and inspectors \u2022 Coordinates routing of all protocol activity \u2022 Maintains and updates all study staff curriculum vitae and GCPs training certificates IND Product Support \u2022 Complies with GCP and Belmont Principles \u2022 Qualified through training, education and experience \u2022 Assists with vaccine accountability, storage and vial destruction \u2022 Issues vaccine to clinic Research Monitor/Ombudsman \u2022 Complies with GCP and Belmont Principles \u2022 Qualified through training, education and experience \u2022 Acts as safety advocate for study participants",
            "latex": null,
            "type": "table"
        },
        "TABREF46": {
            "text": "\u2022 Performs all phlebotomy for the study\u2022 Processes biochemistry, hematology, urinalysis, hepatitis panel, human immunodeficiency virus, and \u03b2-hCG samples on study participants Research Monitor/Ombudsman Jason W. Bennett, MD, MSPH, LTC, MC, USA Infectious Diseases Division Uniformed Services University of the Health Sciences Room A3060",
            "latex": null,
            "type": "table"
        },
        "TABREF48": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF58": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF60": {
            "text": "1.1 (Appendix I), will present a summary of the reasons that subjects were screened but not enrolled. The composition of analysis populations, including reasons for subject exclusion, by group, is presented inTable 14.1.2 (Appendix I).",
            "latex": null,
            "type": "table"
        },
        "TABREF61": {
            "text": "Table 14.1.4). All subject-specific protocol deviations and non subject-specific protocol deviations will be included in Appendix III as data listings (Listings 16.2.2.1 and 16.2.2.2, respectively). Subjects excluded from the analysis populations and reasons are provided in Listing 16.2.3.",
            "latex": null,
            "type": "table"
        },
        "TABREF62": {
            "text": "Immunologic Endpoint: ELISA Tables 14.2.1.1 and 14.2.1.4 summarize the geometric mean of the ELISA titer response with 95% confidence intervals by study day and group for the mITT and the PP populations respectively. Tables 14.2.1.2 and 14.2.1.5 summarize the proportions of positive response with 95% confidence intervals by study day and group for the mITT and the PP populations respectively. Table 14.2.1.3 displays p-values from Fisher's exact tests comparing proportions of positive response between treatment group at multiple time points.Listing 16.2.6.1 includes the individual immunogenicity titer response data which includes the ELISA and neutralizing antibody titer responses.Figure 14.2.1.1 illustrates the reverse cumulative distribution(Reed,  Meade and Steinhoff, 1995)  of ELISA by study day and group and will be used to evaluate the dose response. In addition,Figure 14.2.1.2 displays the ELISA geometric mean with 95% confidence intervals over time by group.",
            "latex": null,
            "type": "table"
        },
        "TABREF63": {
            "text": "2.2.1 summarizes the geometric mean of the neutralizing antibody (NT50) response with 95% confidence intervals by study day and group for the mITT population.Table 14.2.2.2 summarizes the NT50 positive response with 95% confidence intervals by study day and group for the mITT population. Figure 14.2.2.1 illustrates the reverse cumulative distribution of NT50 by study day and group and will be used to evaluate the dose response. In addition, Figure 14.2.2.2 displays the NT50 geometric mean with 95% confidence intervals over time by group. Tables 14.2.2.3 and 14.2.2.4 summarize the results for the PP population.",
            "latex": null,
            "type": "table"
        },
        "TABREF64": {
            "text": "Immunologic Endpoint: IFN-\u03b3 ELISpot Figure 14.2.3 summarizes the distributions of the IFN-\u03b3 ELISpot via box plots by group and study day. Tables 14.2.3.1 and 14.2.3.2 summarize the distributions if IFN-\u03b3 values by group and study day, reported in Spot Forming Units per million cells (SFU/10 6 cells), for the mITT population. Tables 14.2.3.3 and 14.2.3.4 present analogous summaries for the PP population. Results of t-tests comparing mean IFN\u03b3 values between groups are displayed in table 14.2.3.5. Immunologic Endpoint: ICS Figure 14.2.4 displays the ICS geometric mean by group (with 95% confidence intervals) over time. Figure 14.2.5 summarizes the distributions of the ICS via box plots by group and study day. Results of t-tests comparing mean ICS values between groups are displayed in table 14.2.3.6.",
            "latex": null,
            "type": "table"
        },
        "TABREF66": {
            "text": "Individual subject listings (Appendix III) will be presented for all demographics (Listing 16.2.4.1); preexisting medical conditions (Listing 16.2.4.2); vital signs and oral temperature (Listing 16.2.9.1); and concomitant medications (Listing 16.2.10).",
            "latex": null,
            "type": "table"
        },
        "TABREF68": {
            "text": "Table 14.3.1.2 summarizes the number and percentage of subjects experiencing solicited events by symptom, maximum severity, dose and group. Solicited adverse events by subject will be presented in Listing 16.2.7.1, Appendix III.",
            "latex": null,
            "type": "table"
        },
        "TABREF69": {
            "text": ".1.3, Appendix I) \u2022 Subject level summary of severity and relationship to study product (Tables 14.3.1.4, Appendix I); \u2022 Subject listing of non-serious adverse events of moderate or greater severity (Table 14.3.2.2, Appendix I);",
            "latex": null,
            "type": "table"
        },
        "TABREF70": {
            "text": "The following listings will be presented including Subject ID, Age(years) Adverse Event Description, Adverse Event Onset Date/End Date, Last Dose Received/Days Post Dose, Reason Reported as an SAE, Relationship to Treatment, Alternate Etiology if not Related, Outcome, and Duration of Event (days): \u2022 Deaths and Serious Adverse Events (Table 14.3.2.1, Appendix I); \u2022 Non-Serious, Unsolicited, Moderate or Severe Adverse Events (Table 14.3.2.2, Appendix I)",
            "latex": null,
            "type": "table"
        },
        "TABREF71": {
            "text": "Listings 16.2.8.1-16.2.8.2 presented  in Appendix III will provide a complete listing of individual clinical laboratory results for Hematology and Chemistry respectively.",
            "latex": null,
            "type": "table"
        },
        "TABREF72": {
            "text": "Table 14.1.5.2, Appendix I. A complete listing of the vital sign data is found in Listing 16.2.9.1, Appendix III.A full physical examination will be conducted at screening. A targeted physical assessment will be performed at other visits as determined by the Investigator or directed per participant complaints. The injection site is to be assessed by the study personnel within 30 to 45 minutes after EP, as well as at the follow up visits. Physical exam findings are listed in Appendix III, Listing 16.2.9.2.",
            "latex": null,
            "type": "table"
        },
        "TABREF74": {
            "text": "Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012 Oct 10;4(155):155ra138. 2. Reed GF, Meade BD, Steinhoff MC. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics. 1995 Sep;96(3 Pt 2) 600-603. PMID: 7659485.",
            "latex": null,
            "type": "table"
        },
        "TABREF75": {
            "text": "figure, and listing shells are presented in Appendices I, II, and III. PHASE I, OPEN-LABEL, DOSE RANGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF GLS-5300, ADMINISTERED IM FOLLOWED BY ELECTROPORATION IN HEALTHY VOLUNTEERS",
            "latex": null,
            "type": "table"
        },
        "TABREF76": {
            "text": "SECTION 14.1: DEMOGRAPHIC DATA ............................................................................................ 1 TABLE 14.1.1: Ineligibility Summary of Screen Failures ................................................................. 1 TABLE 14.1.2: Analysis Populations by Group ................................................................................ 2 TABLE 14.1.3: Subject Disposition by Group................................................................................... 3 TABLE 14.1.4: Distribution of Protocol Deviations by Category, Type, and Group ........................ 4 TABLE 14.1.5.1 A : Summary of Categorical Demographic and Baseline Characteristics byGroup . 6",
            "latex": null,
            "type": "table"
        },
        "TABREF77": {
            "text": "1.5.2 A : Summary of Continuous Demographic and Baseline Characteristic by Group... 7 TABLE 14.1.6: Summary of Subjects with Pre-Existing Medical Conditions by MedDRA\u00ae System Organ Class and Group .......................................................................................................... 9 SECTION 14.2: IMMUNOGENICITY DATA ................................................................................... 10TABLE 14.2.1.1 A : ELISA Geometric Mean Titer (GMT) Results with 95% Confidence Intervals by Study Day and Group, mITT population ..................................................................................... 10 TABLE 14.2.1.2: ELISA Positive Response Results by Study Day and Group, mITT Population. 12 TABLE 14.2.1.3: P-values for Fisher's Exact Tests Comparing ELISA Positive Response between Groups for each Study Day, mITT Population ................................................................................. 14 TABLE 14.2.1.4: ELISA Geometric Mean Titer (GMT) Results with 95% Confidence Intervals by Study Day and Group, PP population ............................................................................................... 15 TABLE 14.2.1.5: ELISA Positive Response Results by Study Day and Group, PP Population ..... 16 TABLE 14.2.2.1 A : Neutralizing Antibody (NT50) Geometric Mean Titer (GMT) Results with 95% Confidence Intervals by Study Day and Group, mITT population .................................................. 17 TABLE 14.2.2.2: Neutralizing Antibody (NT50) Positive Response a Results by Study Day and Group, mITT Population .................................................................................................................. 19 TABLE 14.2.2.3: Neutralizing Antibody (NT50)Geometric Mean Titer (GMT) Results with 95% Confidence Intervals by Study Day and Group, PP population ....................................................... 21 TABLE 14.2.2.4: Neutralizing Antibody (NT50)Positive Response Results by Study Day and Group, PP Population ....................................................................................................................... 22 TABLE 14.2.3.1: Summary of IFN-\u03b3 ELISpot Results (SFU/1,000,000 cells per well) by Group, mITT population ............................................................................................................................... 23 TABLE 14.2.3.2: Summary of IFN-\u03b3 ELISpot Results (1,000,000 cells per well) by Group, PP population ......................................................................................................................................... 24 TABLE 14.2.3.3: T-test Results Comparing IFN-\u03b3 Means between Groups for each Study Day, mITT Population .............................................................................................................................. 25 TABLE 14.2.3.4: T-test Results Comparing ICS Means between Groups for each Study Day, mITT Population .............................................................................................................................. 26 TABLE 14.3.1.3 A : Number and Percentage of Subjects Experiencing Unsolicited Adverse Events with 95% Confidence Intervals by MedDRA\u00ae System Organ Class and Preferred Term, and Group.......................................................................................................................................................... 51 TABLE 14.3.1.4: Number and Percentage of Subjects Experiencing Unsolicited Adverse Events by MedDRA\u00ae System Organ Class and Preferred Term, Maximum Severity, Relationship, and Group .......................................................................................................................................................... 52 Group I: 0.67 mg/dose (N=X) .................................................................................................... 52 Group II: 2 mg/dose (N=X) ........................................................................................................ 53 Group III: 6 mg/dose (N=X) ....................................................................................................... 54 All Subjects (N=X) ..................................................................................................................... 55TABLE 14.3.2.1: Listing of Serious Adverse Events ...................................................................... 56 TABLE 14.3.2.2: Listing of Non-Serious, Unsolicited, Moderate or Severe Adverse Events ........ 57 SECTION 14.3.3: NARRATIVES OF DEATHS, OTHER SERIOUS AND SIGNIFICANT ADVERSE EVENTS ....................................................................................................................... 58 Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION SECTION 14.1: DEMOGRAPHIC DATA",
            "latex": null,
            "type": "table"
        },
        "TABREF78": {
            "text": "1.1: Ineligibility Summary of Screen Failures*More than one criterion may be marked per subject. Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF79": {
            "text": "1.4: Distribution of Protocol Deviations by Category, Type, and GroupMet exclusion criterion ICF not signed prior to study procedures Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0",
            "latex": null,
            "type": "table"
        },
        "TABREF80": {
            "text": "1.4: Distribution of Protocol Deviations by Category, Type, and Group (continued) PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION N=Number of subjects in the mITT population Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF81": {
            "text": "1.5.2 A : Summary of Continuous Demographic and Baseline Characteristic by GroupThe interim analyses will not include the baseline vital signs. Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0",
            "latex": null,
            "type": "table"
        },
        "TABREF82": {
            "text": "1.5.2 A : Summary of Continuous Demographic and Baseline Characteristic by Group (continued) PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION N=Number of subjects in the mITT population Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION SECTION 14.2: IMMUNOGENICITY DATA TABLE 14.2.1.1 A : ELISA Geometric Mean Titer (GMT) Results with 95% Confidence Intervals by Study Day and Group, mITT population Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0",
            "latex": null,
            "type": "table"
        },
        "TABREF83": {
            "text": "2.1.1 A : ELISA Geometric Mean Titer (GMT) Results with 95% Confidence Intervals by Study Day and Group, mITT population (continued) PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF84": {
            "text": "2.1.2: ELISA Positive Response Results by Study Day and Group, mITT Population Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0",
            "latex": null,
            "type": "table"
        },
        "TABREF85": {
            "text": "2.1.2: ELISA Positive Response Results by Study Day and Group, mITT Population (continued) PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF86": {
            "text": "2.1.3: P-values for Fisher's Exact Tests Comparing ELISA Positive Response between Groups for each Study Day, mITT Population N = number of observations for each time point per group Fisher's Exact Test Results",
            "latex": null,
            "type": "table"
        },
        "TABREF87": {
            "text": "PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF88": {
            "text": "2.1.4: ELISA Geometric Mean Titer (GMT) Results with 95% Confidence Intervals by Study Day and Group, PP populationSame format asTable 14.2.1.1 Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF89": {
            "text": "2.1.5: ELISA Positive Response Results by Study Day and Group, PP Population Same format as Table 14.2.1.2 Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF90": {
            "text": "2.2.1 A : Neutralizing Antibody (NT50) Geometric Mean Titer (GMT) Results with 95%Confidence Intervals by Study Day and Group, mITT population Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0",
            "latex": null,
            "type": "table"
        },
        "TABREF91": {
            "text": "2.2.1 A : Neutralizing Antibody (NT50) Geometric Mean Titer (GMT) Results with 95% Confidence Intervals by Study Day and Group, mITT population (continued) PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF92": {
            "text": "2.2.2: Neutralizing Antibody (NT50) Positive Response a Results by Study Day and Group,mITT Population Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0",
            "latex": null,
            "type": "table"
        },
        "TABREF93": {
            "text": "2.2.2: Neutralizing Antibody (NT50) Positive Response a Results by Study Day and Group, mITT Population (continued) PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION N= Number of subjects in the mITT population a Positive response represents the percentage of subjects with an IC50 value more than a specified threshold. Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF94": {
            "text": "2.2.3: Neutralizing Antibody (NT50)Geometric Mean Titer (GMT) Results with 95% Confidence Intervals by Study Day and Group, PP populationSame format asTable 14.2.2.1 Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF95": {
            "text": "2.2.4: Neutralizing Antibody (NT50)Positive Response Results by Study Day and Group, PP PopulationSame format asTable 14.2.2.2 Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF96": {
            "text": "2.3.1: Summary of IFN-\u03b3 ELISpot Results (SFU/1,000,000 cells per well) by Group, mITT population",
            "latex": null,
            "type": "table"
        },
        "TABREF97": {
            "text": "Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF98": {
            "text": "2.3.2: Summary of IFN-\u03b3 ELISpot Results (1,000,000 cells per well) by Group, PP populationSame format asTable 14.2.3.1 Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATIONNOTE: The following table will be repeated seven times: once for each of the six separate S-protein based peptide pools and once for the result that is the sum of the six pools combined.",
            "latex": null,
            "type": "table"
        },
        "TABREF99": {
            "text": "2.3.3: T-test Results Comparing IFN-\u03b3 Means between Groups for each Study Day, mITT Population",
            "latex": null,
            "type": "table"
        },
        "TABREF100": {
            "text": "Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF101": {
            "text": "2.3.4: T-test Results Comparing ICS Means between Groups for each Study Day, mITT PopulationSame format asTable 14.2.3.3 Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION SECTION 14.3: SAFETY DATA TABLE 14.3.1.1 A : Number and Percentage of Subjects Experiencing Solicited Events with 95% Confidence Intervals by Symptom, Dose, and Group Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF102": {
            "text": "3.1.2: Number and Percentage of Subjects Experiencing Solicited Events by Symptom,Maximum Severity, Dose, and Group Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF103": {
            "text": "3.2.1: Listing of Serious Adverse Events PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF104": {
            "text": "3.2.2: Listing of Non-Serious, Unsolicited, Moderate or Severe Adverse Events PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION SECTION 14.3.3: NARRATIVES OF DEATHS, OTHER SERIOUS AND SIGNIFICANT ADVERSE EVENTS (Not included in SAP. This is a placeholder for the CSR) Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0 PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF105": {
            "text": "3.4.1: Laboratory Summary Statistics by Parameter, Study Day, and GroupChemistry Results: ALT (U/L) Statistical Analysis Plan: Appendix I -Table Mock-Ups Version 1.0",
            "latex": null,
            "type": "table"
        },
        "TABREF106": {
            "text": "3.4.1: Laboratory Summary Statistics by Parameter, Study Day, and Group (continued) PRIVILEGED AND CONFIDENTIAL COMMUNICATION PREPARED BY THE EMMES CORPORATION",
            "latex": null,
            "type": "table"
        },
        "TABREF107": {
            "text": "FIGURE 14.1.1: CONSORT Flow Diagram .......................................................................................... 1 FIGURE 14.2.1.1 A : Reverse Cumulative Distribution of ELISA by Study Day and Group ................. 2 FIGURE 14.2.1.2 A : ELISA Geometric Mean (95% Confidence Interval) Over Time by Group .......... 3 FIGURE 14.2.2.1 A : Reverse Cumulative Distribution of Neutralizing Antibody (NT50) by Study Day and Group ............................................................................................................................................... 4 FIGURE 14.2.2.2 A : Neutralizing Antibody (NT50) Geometric Mean (95% Confidence Interval) Over Time by Group ....................................................................................................................................... 4 FIGURE 14.2.3: Boxplots of IFN-\u03b3 ELISpot Results (Spot Forming Units per million cells), Background Subtracted by Group .......................................................................................................... 5 FIGURE 14.2.4: ICS Geometric Mean (95% Confidence Interval) Over Time by Group .................... 6",
            "latex": null,
            "type": "table"
        },
        "TABREF108": {
            "text": "LISTING 16.2.1: Discontinuation of Treatment Subjects ...................................................................... 1 LISTING 16.2.2.1: Subject-Specific Protocol Deviations ...................................................................... 2 LISTING 16.2.2.2: Non-Subject-Specific Protocol Deviations .............................................................. 3 LISTING 16.2.3: Subjects Excluded from Analysis Populations ........................................................... 4 LISTING 16.2.4.1: Demographics Data................................................................................................. 5 LISTING 16.2.4.2: Pre-Existing Medical Conditions ............................................................................ 6 LISTING 16.2.5: Treatment Administration Compliance Data .............................................................. 7 LISTING 16.2.6.1: Individual Immunogenicity Titer Response Data .................................................... 8 LISTING 16.2.6.2: Individual IFN-\u03b3 secreting spot forming units (SFU) ELISpot Response Data ...... 9 LISTING 16.2.6.3: Individual Flow Cytometry Response Data .......................................................... 10 LISTING 16.2.7.1: Solicited Events -Systemic Symptoms a ................................................................ 11 LISTING 16.2.7.1: Solicited Events -Injection/Administration Site Reaction a Symptoms ................. 12 LISTING 16.2.7.2: Unsolicited Adverse Events .................................................................................. 13 LISTING 16.2.8.1: Clinical Laboratory Results -Hematology ........................................................... 14 LISTING 16.2.8.2: Clinical Laboratory Results -Chemistry .............................................................. 15 LISTING 16.2.9.1: Vital Signs ............................................................................................................. 16 LISTING 16.2.9.2: Physical Exam Findings ........................................................................................ 17 LISTING 16.2.10: Concomitant Medications ....................................................................................... 18 LISTING 16.2.11.1: Pregnancy Reports -Maternal Information ......................................................... 19 LISTING 16.2.11.2: Pregnancy Reports -Gravida and Para ................................................................ 20 LISTING 16.2.11.3: Pregnancy Reports -Live Birth Outcomes .......................................................... 21 LISTING 16.2.11.4: Pregnancy Reports -Still Birth Outcomes .......................................................... 22 LISTING 16.2.11.5: Pregnancy Reports -Spontaneous, Elective, or Therapeutic Abortion Outcomes .. .............................................................................................................................................................. 23",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "Supplementary Appendix Statistical Analysis Plan: Appendix I - x, x.x Statistical Analysis Plan: Appendix I - x Statistical Analysis Plan: Appendix I - x Statistical Analysis Plan: Appendix I - x Statistical Analysis Plan: Appendix I - ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "annex"
        }
    ]
}